0·01, 0·69, 1-year, 10-cell, 10-week, 10-year, 12-lead, 12-week, 16-month, 1a, 1b, 1c, 2-fold, 2-vessel, 2-year, 20-week, 25mg, 25th-75th, 28-day, 2·9, 3-month, 3-vessel, 3-year, 30-day, 4-fold, 4-year, 41-year-old, 5-year, 52-year-old, 57-year-old, 57±22, 6-minute, 6-month, 6-mwt, 6-week, 60s, 66±3, 6mwt, 7-day, 7508t→a, 79·1, 8-fluo-camp, 90-day, aa, aa participants, aac, aas, aas with hf, abc, abc hf, abc hf model, abc hf risk, abc hf risk model, abc short physical, abc short physical performance, abc short physical performance battery, abcc2, abcd, abcd classification, abdominal, abdominal aortic, abdominal aortic constriction, abdominal problems, aberrant, aberrant reactivation, ability, ability of bnp, ability of cardiomyocytes, ability of gls, ablation, abnormal, abnormal body, abnormal body composition, abnormal cardiac, abnormal chamber, abnormal chamber patterning, abnormal exercise, abnormal in individuals, abnormal liver, abnormal liver texture, abnormal liver texture changes, abnormalities, abolished protein, abolished protein expression, abrogate pathological gene, abrogate pathological gene expression, absence, absence of changes, absolute, absolute change, absolute improvements, absolute increase, absolute risk, absolute risk of heart, absolute risk of heart failure, absolute value, absolute value of mdc, absorptiometry, absorption, absorption function, absorption function in patients, abstract, abundance, abundance during disease, academic, academic medical, academic medical center, acceptable, acceptable alternative, acceptable internal, acceptable to patients, accepted peak, accepted peak oxygen, accepted peak oxygen consumption, access, access programme, accessibility, accessory, accessory pathways, accompany heart, accompany heart failure, account, accountable, accumulating evidence, accumulation, accumulation of deficits, accurate, accurate recognition, accurate risk, accurate risk stratification, accurate risk stratification of patient, acetyl-lysine, acetyl-lysine reader, acetyl-lysine reader proteins, acetylcholinesterase, acetylcholinesterase inhibition, acetylcholinesterase inhibitor, acetylcholinesterase inhibitor pyridostigmine, acetyltransferase, acf, acf groups, acf ±, acf ± allopurinol, achieve guideline-recommended target, achieve guideline-recommended target doses, achieved bb, achieved bb dose, achieved study, achieved study drug, achieved study drug dose, achievement, acid, acids, acp, acquired cardiovascular risk, acquired cardiovascular risk factors, acquired heart, acquired heart failure, acr, acs, acs consultation, acs consultations, acs problems, acs problems in patients, acs procedures, actin, actin cytoskeleton, actin cytoskeleton pathways, actin dynamics, action, action on camp, action on camp production, action potential duration, action potentials, action through activation, actions, actions of rad, activated caspase, activated neurohormonal systems, activation, activation of vegf, activation of vegf pathway, activation sequence, activation therapy, activators, active, active individuals, active treatment, activities, activities of paf-ah, activity, activity controls, activity on qtv, activity status, activity status index, actrn12610001087044, acute, acute anthracycline-induced cardiotoxicity, acute autonomic, acute autonomic nervous, acute autonomic nervous system, acute autonomic nervous system modulation, acute autonomic nervous system modulation on qtv, acute care, acute care hospital, acute care hospital for hf, acute care hospitals, acute care surgery, acute care surgery in heart, acute care surgery in heart transplant, acute care surgery in heart transplant recipients, acute coronary, acute coronary syndrome, acute coronary syndromes, acute decompensated hf, acute dyspnea, acute heart, acute heart failure, acute heart failure in patients, acute heart failure trials, acute hf, acute hf diagnosis, acute hf trials, acute hospital, acute hospital facilities, acute ischemic, acute ischemic right, acute ischemic right heart, acute ischemic right heart failure, acute kidney, acute kidney injury, acute kidney injury during spironolactone, acute kidney injury during spironolactone use, acute myocardial, acute myocardial infarction, acute myocardial infarction in western australia, acute pulmonary, acute pulmonary embolism, acute right, acute right heart, acute right heart failure, acute right heart failure with therapy, acute right heart failure with therapy refractory, acute right ventricular, acute right ventricular pressure, acute right ventricular pressure overload, acute rv, acute rv decompensation, acute rv failure, acute treatment, acute treatment of heart, acute treatment of heart failure, acute β-adrenoceptor, acute β-adrenoceptor blockade, acute β-adrenoceptor blockade with esmolol, acute β-ar, acute β-ar stimulation, ad-c, ad-c rats, ad-flk, ad-flk rats, adamant, adaptation, adaptive, adaptive response, add-on, add-on diagnostic features, adding ctnt, addition, addition of gls, addition of habc, addition of habc battery, addition of habc battery scores, addition of salt, addition of salt loading, additional, additional benefit, additional models, additional prognostic, additional prognostic benefit, additional progress, additional prospective, additional risk, additional studies, additive, additive adverse, additive adverse impact, additive effect, addressing practice-level differences, adenine nucleotides, adenine nucleotides contents, adenosine, adenoviral, adenoviral vector, adenovirus, adenylyl, adenylyl cyclase, adequacy, adequate, adequate blood, adequate blood pressure, adequate blood pressure control, adequate self-management, adequate self-management training, adequate self-management training of patients, adherence, adherence to class, adherence to hf, adherence to hf cpgs, adherence to prescribed, adherence to prescribed therapy, adherence with exercise, adherence with exercise training, adhesion, adhesion genes, adipokines, adiponectin, adiponectin at baseline, adipose, adipose tissue, adjunctive, adjunctive treatment, adjunctive treatment for patients, adjusted, adjusted ankle-brachial, adjusted ankle-brachial index, adjusted carotid, adjusted carotid intima-media, adjusted carotid intima-media thickness, adjusted cox, adjusted cox models, adjusted hazard, adjusted hazard ratio, adjusted hazard ratios, adjusted median, adjusted median rate, adjusted median rate ratio, adjusted odds, adjusted odds ratio, adjustment, adjustment for age, adjustment for covariates, adjustment for differences, adjustment for patient, adjuvant, adjuvant setting, administration, administration of contrast, administration of contrast agent, administration of doxorubicin, administration of pyridostigmine, administrative, administrative databases, administrative health, administrative health data, admission, admission median bnp, admission median bnp levels, admission nt-probnp, admissions, admissions for individuals, admissions from baseline, admissions per patient, adolescence, adopting evidence-based practices, adoption, adoption of heart, adoption of heart failure, adoption of heart failure guidelines, adult, adult fontan, adult jehovah, adult male, adult male wistar, adult male wistar rats, adult medicine, adult mouse, adult mouse ventricular, adult mouse ventricular myocytes, adult patients, adult patients with heart, adult patients with heart disease, adult population, adults, adults versus controls, adults with anemia, adults with ejection, adults with ejection fraction, adults with ejection fraction ≤, adults with heart, adults with heart disease, adults with heart failure, adults with hf, advanced, advanced chronic, advanced chronic obstructive, advanced chronic obstructive pulmonary, advanced chronic obstructive pulmonary disease, advanced chronic organ, advanced chronic organ failure, advanced copd, advanced disease, advanced heart, advanced heart failure, advanced heart failure patients, advanced heart failure therapy, advanced hf, advanced human, advanced human hf, advanced management, advanced phase, advanced stages, advanced stages of heart, advanced stages of heart failure, advanced structural, advanced structural heart, advanced structural heart disease, advancement, advancement of science, advances, advances in treatment, advantage, adverse, adverse cardiovascular, adverse consequences, adverse event, adverse event profile, adverse event rates, adverse events, adverse events evaluation, adverse health, adverse health outcomes, adverse impact, adverse neurohormonal, adverse neurohormonal activation, adverse neurological, adverse outcome, adverse outcomes, advisors, advocate, advocate pre-participation, advocate pre-participation screening, aerobic, aerobic capacity, aerobic exercise, aerobic exercise per week, aerobic exercise training, aerobic exercise training on peak, aerobic exercise training on peak oxygen, aerobic exercise training on peak oxygen consumption, aerobic training, aerobic training period, aetiologies, af ablation, af at risk, af in patients, af patients, af type, af-free, af-free probability, af-free probability after catheter, af-free probability after catheter ablation, affairs, affairs hf, affairs hf clinic, affect electrolytes, affect outcomes, affect reclassification, african, african americans, afterload, afterload burden, afterload of patients, age, age categories, age group, age groups, age of participants, age of patients, age-by-lvef, age-by-lvef interaction, age-dependent, age-dependent effect, age-dependent increase, age-dependent increase in incidence, age-matched, age-specific, age-specific low, aged, agent, agent administration, agent therapy, agents, agents in adults, agents in combination, agents in patients, ages, aggravate cardiovascular health, aggressive, aggressive dose, aggressive dose uptitration, aggressive medical, aggressive medical treatment, aggressive medical treatment for heart, aggressive medical treatment for heart failure, aggressive medical treatment for hf, aggressive protocols, aging, agonist, agreement, aha, ahf, ai, aim, aims, air, air pollution, air pollution on heart, air pollution on heart failure, akt, akt→forkhead, akt→forkhead box, akt→forkhead box class, al with interest, alberta, albumin, albumin concentration, albumin level, albumin levels, albumin levels during lvad, albumin levels during lvad support, alcohol, aldactone, aldactone evaluation, aldactone evaluation study, aldosterone, aldosterone antagonism, aldosterone antagonism in heart, aldosterone antagonism in heart failure, aldosterone antagonist, aldosterone antagonist therapy, aldosterone blockade, aldosterone receptor, aldosterone receptor antagonists, alendronate, algorithms, algorithms for de, algorithms for de novo, alive, alive from hospital, all-cause, all-cause death, all-cause hospitalisations, all-cause hospitalisations for tm, all-cause hospitalisations for tm interventions, all-cause hospitalization, all-cause hospitalization in heart, all-cause hospitalization in heart failure, all-cause hospitalization in heart failure clinic, all-cause hospitalization in heart failure clinic outpatients, all-cause hospitalizations, all-cause hospitalizations in patients, all-cause medical, all-cause medical hospitalization, all-cause medical hospitalization in hf, all-cause medical hospitalization in hf clinic, all-cause medical hospitalization in hf clinic outpatients, all-cause mortality, all-cause mortality for sts, all-cause mortality for sts hh, all-cause mortality in patients, all-cause readmission, all-cause readmissions, alleviate symptoms, allocate specialized hf, allocate specialized hf resources, allocation, allocation ratio, allogeneic, allopurinol, allopurinol rats, allowed prediction, alphalisa, alphalisa immunoassays, alter chromatin structure, alterations, alterations by metoprolol, alterations in body, alterations in body composition, alterations in energy, alterations in energy metabolism, alterations in markers, alterations in skm, alterations in tac, altered, altered expression, altered protein, altered protein kinase, altered regulation, altered regulation of rad, altered ventricular structure, alternative, alternative mrna, alternative mrna splicing, alternative treatments, alternatives, ambient, ambient air, ambient air pollution, ambulatory, ambulatory heart, ambulatory heart failure, ambulatory heart failure trial, ambulatory hf, ambulatory hf patients, ambulatory icd, ambulatory icd patients, ambulatory patients, ambulatory patients with heart, ambulatory patients with heart failure, ambulatory patients with hf, ambulatory setting, ameliorates mitochondrial dysfunction, amelioration, amenable, america, american, american college, american college of cardiology, american college of physicians, american heart, american heart association, american heart association guidelines, american heart association guidelines on evaluation, americans, ami, ami admission, ami mortality, ami mortality rates, ami patient, amino-terminal, amino-terminal pro-b-type, amount, amount of malondialdehyde, amplitude, amyloidosis, amyloidotic, amyloidotic pattern, anabolic, anabolic imbalance, anaerobic, anaerobic metabolism, anaerobic threshold, anaerobic threshold in heart, anaerobic threshold in heart failure, anaesthesia, analyses, analyses of disease, analyses of disease management, analyses of disease management programs, analysis, analysis at baseline, analysis of doppler, analysis of microarray, analysis of microarray data, analysis of patient, analysis of patient management, analysis of patient management interventions, analysis of patients, analysis of rhythm-control, analysis of subgroups, analysis of twist, analyze bivp, analyze clinical outcomes, analyze interview, analyze interview data, analyzer, anand, anand et, anand et al, anastomosis, anecdotal, anecdotal evidence, anemia, anemia in adults, anemia in hf, anemia in patients, anemia treatment, anemia treatment in patients, anemic, anesthetized, anesthetized dogs, ang, ang ii, ang ii infusion, ang ii infusion mouse, ang ii infusion mouse model, angeli, angii, angina, angiogenesis, angiogenesis in heart, angiogenesis in heart failure, angiography, angioplasty, angiotensin, angiotensin ii, angiotensin ii infusion, angiotensin receptor, angiotensin receptor antagonist, angiotensin receptor antagonist valsartan, angiotensin receptor blockers, angiotensin receptor blockers in case, angiotensin receptor blockers therapy, angiotensin receptor neprilysin, angiotensin receptor neprilysin inhibitor, angiotensin receptor neprilysin inhibitor in heart, angiotensin receptor neprilysin inhibitor in heart failure, angiotensin receptors, angiotensin receptors blockers, angiotensin-aldosterone, angiotensin-converting, angiotensin-converting enzyme, angiotensin-converting enzyme inhibitor, angiotensin-converting enzyme inhibitors, angiotensin-receptor, angiotensin-receptor blocker, angiotensin-receptor blockers, angiotensin-receptor neprilysin, angiotensin-receptor neprilysin inhibitors, animal, animal model, animal models, animals, animals with heart, animals with heart failure, animals with metoprolol, ankle-brachial, ankle-brachial index, ankle-brachial index ≤, ann, ann arbor, ann arbor veterans, annual, annual ed, annual ed visits, annual ed visits for chf, annular, annular ms, annular plane, annular plane systolic, annular plane systolic excursion, annular size, annular size reduction, annular size reduction by surgery, annular velocity, annuloplasty, annulus, annulus velocities, annulus velocities during systole, annulus velocity, anoop, anoop shah, anova, anova with differences, ans, ans mice, antagomir, antagonism, antagonism in heart, antagonism in heart failure, antagonist, antagonist therapy, antagonist valsartan, antagonists, antagonists in heart, antagonists in heart failure, antagonists of endothelin, antagonizing excessive β-ar, antagonizing excessive β-ar drive, antecedent, antecedent to heart, antecedent to heart failure, antecedent weight, antecedent weight loss, anterior, anterior descending, anterior descending artery, anterior leaflet, anterior leaflet opening, anthracycline, anthracycline exposure, anthracycline metabolism, anthracycline-containing, anthracycline-containing chemotherapy, anthracycline-induced, anthracycline-induced cardiotoxicity, anthracycline-related, anthracycline-related congestive, anthracycline-related congestive heart, anthracycline-related congestive heart failure, anthracycline-related congestive heart failure in survivors, anthracycline-treated, anthracycline-treated breast, anthracycline-treated breast cancer, anthracycline-treated breast cancer patients, anthracyclines, anti-inflammatory, anti-inflammatory effects, anti-neoplastic, anti-neoplastic agent, anti-oxidant, anti-oxidant defence, antiadrenergic, antiadrenergic therapeutic strategy, antiadrenergic therapeutic strategy in hf, antiarrhythmic, antiarrhythmic drugs, antiarrhythmic medication, antibodies, anticoagulants, anticoagulation, antihyperglycemic, antihyperglycemic agents, antihyperglycemic drugs, antihypertensive, antihypertensive medication, antihypertensive medication use, antioxidant, antiplatelet, antiplatelet agents, antiplatelet agents in combination, antiplatelet drugs, antiplatelet medication, antirheumatic, antirheumatic drug, antitachycardia, antitachycardia pacing, antitumor, antitumor activity, anxiety, aor, aortic, aortic blood, aortic blood flow, aortic constriction, aortic insufficiency, aortic pressure, aortic pressure curve, aortic valve, aortic valve insufficiency, aortic valve procedure, aortic valve procedures, aortic valve repairs, aortic valve replacement, aortic valve surgery, aortocaval, aortocaval fistula, apex, apex during baseline, apical, apical rotation, apoptosis, apoptotic, apoptotic cells, apoptotic signaling pathway, apparent, apparent circulating nt-probnp, apparent circulating nt-probnp concentration, apparent concentration, appendicular, appendicular lean, appendicular lean mass, appendicular lean mass index, applicable, application, applications, applications of readmission, applications of readmission metrics, approach, approach for heartmate, approach for heartmate ii, approach for heartmate ii exchange, approach to chf, approaches, april, arbitrary, arbitrary start, arbitrary start date, arbor, arbor veterans, area, area change, area index, areas, arg16, arginine, arginine vasopressin, arguments, aric, aric hf, aric hf model, arm, arm cuff, armamentarium, arni, arni inhibitors, array, arrest, arrest in humans, arrhythmia, arrhythmia devices, arrhythmia events, arrhythmia substrate, arrhythmia substrate after ami, arrhythmia-related, arrhythmia-related costs, arrhythmias, arterial, arterial compliance, arterial coupling, arterial disease, arterial elastance, arterial hypertension, arterial hypertension medication, arterial pressure, arterial systolic, arterial systolic pressure, arterial systolic pressure relationship, arterial systolic pressure relationship in heart, arterial systolic pressure relationship in heart failure, arterial tonometry, arterial tonometry study, arterial vasculature, arteries, artery, artery bypass, artery bypass grafting, artery bypass surgery, artery calcium, artery calcium scores, artery disease, artery disease in patients, artery ligation, artery occlusion, artery stenosis, artery systolic, artery systolic pressure, artery tonometry, artery tonometry variables, arthritis, article, article by dodson, article by dodson et, article by dodson et al, articles, artificial, artificial pulse, ascending phase, ascertain frailty, aspects, aspects of nursing, aspects of nursing care, aspects of remodeling, aspects to emd, aspects to emd prolongation, assay, assays, assembly, assess national trends, assess np levels, assess risk, assess robot-assisted gait, assess robot-assisted gait therapy, assess social support, assessed hyperkalemia, assessed tm, assessment, assessment of body, assessment of body composition, assessment of ed, assessment of ed patients, assessment of reduction, assessment trial, assessments, assessments of patients, assessors, assignment, assignment to ecct, assist, assist device, assist device implantation, assist device implantations, assist device support, assist device use, assist devices, assist practitioners, assist system, assisted, assisted success, assisted success rate, associate, association, association between frailty, association between preoperative, association between psoriasis, association between race, association between spironolactone, association between spironolactone use, association between treatment, association between treatment variation, association class, association class ii, association class ii to iv hf, association class iii, association class iii heart, association class iii heart failure, association classes, association classification, association functional class, association guidelines, association guidelines on evaluation, association of cognitive, association of cognitive impairment, association of hypoalbuminemia, association with dna, association with exercise, association with exercise training, association with exercise training response, association with mediterranean, association with mediterranean diet, association with mediterranean diet scores, association with outcomes, associations, associations among cardiorespiratory, associations among cardiorespiratory fitness, associations between new york, associations between new york heart, associations between new york heart association, associations between new york heart association class, associations of hhf, associations of mediterranean, assumption, astronaut, asymptomatic, asymptomatic pediatric, asymptomatic pediatric fontan, at nonidentification, at-80, at-risk, at-risk patients, at1, atheromatous, atheromatous coronary, atheromatous coronary disease, atherosclerosis, atherosclerosis risk, atherosclerosis risk in communities, atherosclerosis risk in communities study, atherosclerotic, atherosclerotic cad, atherosclerotic lesions, athletes, atp, atp content, atp demand, atp production, atp production rates, atpase, atpase activity, atrial, atrial area, atrial explant-derived, atrial explants, atrial fibrillation, atrial fibrillation for stroke, atrial fibrillation for stroke prevention, atrial fibrillation for stroke prevention trial, atrial fibrillation in patients, atrial mass, atrial mass removal, atrial myxoma, atrial natriuretic, atrial natriuretic peptide, atrial pacing, atrial pressure, atrial structure, atrial tachyarrhythmias, atrioventricular, atrioventricular delay, atrium, atrium mass, atropine, atropine infusion, attain maximal spironolactone, attain maximal spironolactone dose, attempt, attendance, attention, attention control, attention-controlled, attenuating cardiac remodeling, attenuation, attenuation in lv, attenuation in lv dilatation, attributable, attributable to heart, attributable to heart failure, attributable to titin, attributable to titin hypophosphorylation, attrition, atypical, atypical case, auc, aucs, audible, audience, augment cardiac output, augmented, augmented cardiac vagal, augmented cyclic guanosine, augmented feedback, august, auscultation, australia, australian, australian reference, australian reference data, authors, autologous, automatic, automatic defibrillator, automatic defibrillator implantation, automatic defibrillator implantation trial-cardiac, automatic defibrillator implantation trial-cardiac resynchronization, automatic defibrillator implantation trial-cardiac resynchronization therapy, automatic defibrillator implantation with cardiac, automatic defibrillator implantation with cardiac resynchronization, automatic defibrillator implantation with cardiac resynchronization therapy, autonomic, autonomic balance, autonomic balance in chf, autonomic dysbalance, autonomic imbalance, autonomic modulation, autonomic modulation of repolarization, autonomic modulation of repolarization instability, autonomic nervous, autonomic nervous system, autonomic nervous system activity, autonomic nervous system activity on qtv, autonomic nervous system modulation, autonomic nervous system modulation on qtv, autopsy, autopsy samples, avd, avd variation, average, average age, average age of patients, average follow-up, average hospital, average hospital rates, average hospital rates for hf, average hospital rates for hf patients, average length, average length of stay, average weight, average weight loss, avoidance, avp, avp through vasopressin, avp through vasopressin receptor, avp through vasopressin receptor antagonist, avp through vasopressin receptor antagonist therapy, aware, awareness, awful, awful paradox, axis, axis function, b natriuretic peptides, b-treated, b-type, b-type natriuretic peptide, b-type natriuretic peptide levels, b-type natriuretic peptide levels in patients, b-type np, background, background for aldosterone, background for aldosterone antagonist, background for aldosterone antagonist therapy, background—heart, background—heart failure, balance, balance in chf, band, baroreflex, baroreflex activation, baroreflex activation therapy, baroreflex sensitivity, barrier, barriers, basal, basal contractility, basal heart, basal heart rate, basal rotations, base, base of treatment, based, based definition, based practice, based practice centres, baseline, baseline characteristics, baseline covariates, baseline crf, baseline ea, baseline ecgs, baseline echocardiography, baseline echocardiography before crt, baseline ef, baseline egfr group, baseline egfr group ii, baseline electrocardiogram, baseline examination, baseline glomerular filtration, baseline glomerular filtration rate, baseline hgb, baseline hrqol, baseline in peak, baseline in peak oxygen, baseline in peak oxygen uptake, baseline kccq, baseline kccq scales, baseline nt-probnp, baseline sdqt-to-sdrr ratio, baseline serum, baseline serum creatinine, baseline serum creatinine level, basic, basic helix-loop-helix, basic relevance, basis, basis of heart, basis of heart failure, basis of heart failure treatment, basis of heart failure treatment eras, bat, bat results, battery, battery score, battery scores, bax, bb, bb at enrollment, bb dose, bb doses, bb therapy, bcl-2, bcl2, beagle, beagle dogs, beat, beat method, beat method for cv, beat method for cv events, beat-to-beat, beat-to-beat qt, beat-to-beat qt interval, beat-to-beat qt intervals, beats, beck, beck depression, beck depression inventory, behavior, behaviors, behavioural-change, behavioural-change interventions, belief, beliefs, beneficial, beneficial adaptation, beneficial clinical, beneficial effect, beneficial effect of arni, beneficial effect of exercise, beneficial effect of exercise training, beneficial effect on mortality, beneficial effects, beneficial effects in chf, beneficial effects of hrqol, beneficial impact, beneficial new, beneficial new therapeutic, beneficial new therapeutic approach, beneficial new therapeutic approach to chf, beneficial results, beneficial trends, beneficiaries, benefit, benefit for patients, benefit of af, benefit of af ablation, benefit of bb, benefit of bb therapy, benefit of crt-d, benefit patients, benefits, benefits in exercise, benefits in exercise capacity, benefits in hf, benefits of anemia, benefits of anemia treatment, benefits of exercise, benefits of involvement, benefits of participation, benefits of spironolactone, benign, benign tumors, bet, bet bromodomain-containing protein, bet family, bet family bromodomain, bet family bromodomain proteins, bet inhibition, beta, beta blockade, beta blockers, beta blockers on exercise, beta blockers on exercise capacity, beta receptor, beta receptor blockers, beta-adrenergic, beta-adrenergic receptor, beta-adrenergic responses, beta-adrenergic responses in cardiomyocytes, beta-blocker, beta-blocker dose, beta-blocker hypo-response, beta-blocker therapy, beta-blocker therapy in patients, beta-blockers, beta-dependent, beta-dependent yield, beta1-adrenergic, bets, better-than-usual, better-than-usual support, bhlh, bhlh transcription, bhlh transcription factor, binding, binding protein-c, binding protein-c phosphorylation, binomial, binomial regression, binomial regression models, bioenergetics, bioinformatic, bioinformatic analysis, bioinformatic analysis of microarray, bioinformatic analysis of microarray data, biologic, biological, biological phenotype, biology, biomarker, biomarker approach, biomarker for hfpef, biomarker in heart, biomarker in heart failure, biomarker studies, biomarker-guided, biomarker-guided clinical, biomarker-guided clinical trial, biomarker-guided clinical trial design, biomarker-guided clinical trials, biomarkers, biomarkers in patients, biomedical, biomedical reasons, biomedical treatment, bioprosthetic, bioprosthetic aortic, bioprosthetic aortic valve, bioprosthetic aortic valve replacement, bioprosthetic valve, bioprosthetic valve replacement, biopsies, biopsy, biosynthetic, biosynthetic enzymes, bisoprolol, bisphophonates, bisphosphonate, bisphosphonate users, bisphosphonates, biventricular, biventricular dysfunction, biventricular pacing, biventricular support, bivp, black, black ethnicity, black patients, black race, black race in patients, blacks, bleeding, blinded core, blinded core laboratory, blinded outcome, blinded outcome assessment, blinded outcome assessment trial, block, block electrical activation, block electrical activation sequence, block pattern, block type, blockade, blockade with esmolol, blocked phenylephrine-mediated hypertrophy, blocker, blocker therapy, blocker use, blockers, blockers in case, blockers on exercise, blockers on exercise capacity, blockers therapy, blocks, blood, blood cell, blood cell transfusion, blood cell transfusion strategy, blood flow, blood flow velocity, blood flow velocity over tissue, blood flow velocity over tissue doppler, blood glucose, blood glucose levels, blood loss, blood pressure, blood pressure control, blood testing, blood transfusions, blood urea, blood urea nitrogen, blood work, blood-flow, blood-flow paths, blot, blot analysis, blots, blue, blue histologic, blue histologic analysis, blunted cardiac β-ar, blunted cardiac β-ar responsiveness, blunts, blunts beta-adrenergic responses, blunts beta-adrenergic responses in cardiomyocytes, bmi, bmi-matched, bnp, bnp group, bnp in hf, bnp in hf patients, bnp in women, bnp level, bnp levels, bnp levels in patients, bnp measurements, bnp values, board, board databases, bodies, body, body composition, body composition study, body fat distribution, body mass, body mass index, body mass index categories, body mass index levels, body mass index strata, body mass ratio, body of evidence, body weight, body weight in cc, bolus, bolus of metoprolol, bone, bone morphogenetic protein, borderline, borderline association, bottleneck, bottleneck shape, bottleneck stent, bottleneck stent model, bottleneck stenting, box, box class, bpm, brachial, brachial systolic, brachial systolic pressure, bradyarrhythmias, bradycardia, bradycardic, bradycardic response, brain, brain natriuretic peptide, branch, branch block, branch block electrical activation, branch block electrical activation sequence, branch block pattern, branch block type, branch morphology, branches, brd4, breakdown, breast, breast cancer, breast cancer patients, breath, breath-holding, breathing, breathing control, breathlessness, bridge, bridge to recovery, bridging therapy, brief, brief hypothermic, brief hypothermic circulatory, brief hypothermic circulatory arrest, brief insight, brief review, briefing, briefing reports, briggs, briggs institute, briggs institute evidence, briggs institute evidence based, briggs institute evidence based practice, broad, broad panel, broader, broader discussions, broader discussions about end-of-life, broader discussions about end-of-life treatment, broader discussions about end-of-life treatment preferences, bromodomain, bromodomain inhibition, bromodomain proteins, bromodomain-containing, bromodomain-containing protein, btes, btt, buddy, buddy program, budget, bundle, bundle branch, bundle branch block, bundle branch block electrical activation, bundle branch block electrical activation sequence, bundle branch block pattern, bundle branch block type, bundle branch morphology, bundle-branch, bundle-branch block, burden, burden in adult, burden in adult medicine, burden of heart, burden of heart failure, burden of heart failure hospitalizations, busy, bypass, bypass grafting, bypass surgery, c from enrollment, c level, c statistic, c termini, c'd, c'd hf, c-index, c-statistics, c-terminally, c-terminally truncated, ca2, cabg, cachectic, cachectic heart, cachectic heart failure, cachectic heart failure patients, cachectic heart failure patients with respect, cachexia, cad, calcineurin, calcium, calcium scores, calcium-sensitizing, calcium-sensitizing agents, calculate hazard, calculate hazard ratios, calculated hfpsi, calf, calf muscle, calif, california, california office, california office of statewide, california office of statewide health, california office of statewide health planning, calls, caloric, caloric restriction, calreticulin, camp, camp hydrolysis, camp hydrolytic activity, camp levels, camp production, camp-dependent, camp-dependent protein, camp-dependent protein kinase, campbell, campbell collaboration, canada, canadian, canadian cardiovascular, canadian cardiovascular society, canadian cardiovascular society guidelines, canadian data, canadian data point, canadian special, canadian special access, canadian special access programme, cancer, cancer patients, cancers, candesartan, candesartan in heart, candesartan in heart failure, candesartan in heart failure assessment, candidate, candidate genes, candidates, candidates for cell, candidates for cell therapy, canine, canine electromechanics, canine model, capability, capable, capacity, capacity in adults, capillary, capillary wedge, capillary wedge pressure, capita, carbohydrates, carcinoma, cardiac, cardiac amyloidosis, cardiac angiogenesis, cardiac angiogenesis in heart, cardiac angiogenesis in heart failure, cardiac apoptosis, cardiac arrest, cardiac arrest in humans, cardiac arrhythmia, cardiac arrhythmia devices, cardiac autonomic, cardiac autonomic balance, cardiac autonomic balance in chf, cardiac benign, cardiac benign tumors, cardiac biology, cardiac cachexia, cardiac catheterization, cardiac centre, cardiac chromatin, cardiac chromatin identifies, cardiac comorbidities, cardiac death, cardiac death in athletes, cardiac deaths, cardiac defibrillator, cardiac development, cardiac diameters, cardiac disease, cardiac dysfunction, cardiac dysfunction during insulin, cardiac dysfunction during insulin resistance, cardiac dysfunction with conduction, cardiac dysfunction with conduction abnormalities, cardiac energy, cardiac energy metabolism, cardiac energy metabolism gene, cardiac energy metabolism gene expression, cardiac event, cardiac events, cardiac explant, cardiac explant-derived, cardiac explant-derived cells, cardiac failure, cardiac fibrosis, cardiac filling, cardiac filling pressures, cardiac function, cardiac function among patients, cardiac function in b-treated, cardiac functional, cardiac functional deterioration, cardiac functions, cardiac gene, cardiac gene control, cardiac gene expression, cardiac gene expression programme, cardiac gene therapy, cardiac genes, cardiac genes in hf, cardiac growth, cardiac hypertrophic, cardiac hypertrophic response, cardiac hypertrophy, cardiac hypertrophy in tta, cardiac hypertrophy secondary to pressure-overload, cardiac index, cardiac index ≤, cardiac injury, cardiac insulin-resistance, cardiac l-type, cardiac l-type channel, cardiac l-type channel activity, cardiac looping, cardiac magnetic, cardiac magnetic resonance, cardiac magnetic resonance imaging, cardiac magnetic resonance postcontrast, cardiac mena, cardiac mena deletion, cardiac metabolic, cardiac metabolic gene, cardiac metabolic gene expression, cardiac mrna, cardiac mrna levels, cardiac murmurs, cardiac myocyte-specific, cardiac myocyte-specific mena, cardiac myocyte-specific mena overexpression, cardiac nurse, cardiac nurses, cardiac output, cardiac overexpression, cardiac overexpression of mammalian, cardiac pathogenesis, cardiac pathology, cardiac pathophysiology, cardiac patients, cardiac performance, cardiac performance by β-adrenoceptor, cardiac performance by β-adrenoceptor blockade, cardiac plasma, cardiac plasma membrane, cardiac plasma membrane levels, cardiac procedures, cardiac progenitor, cardiac progenitor function, cardiac rehabilitation, cardiac rehabilitation care, cardiac remodeling, cardiac remodelling, cardiac resynchronization, cardiac resynchronization therapy, cardiac risk, cardiac sodium, cardiac sodium current, cardiac specialty, cardiac specialty hospital, cardiac stress, cardiac support, cardiac surgery, cardiac surgery patients, cardiac sympathetic, cardiac sympathetic activity, cardiac sympathetic tone, cardiac sympathovagal, cardiac sympathovagal balance, cardiac symptoms, cardiac symptoms in children, cardiac tissue, cardiac tissue from mice, cardiac tissues, cardiac transplant, cardiac transplant recipients, cardiac transplant survival, cardiac transplantation, cardiac transplants, cardiac transplants in children, cardiac troponin, cardiac vagal, cardiac vagal tone, cardiac vegf, cardiac vegf expression, cardiac volume, cardiac volume overload, cardiac washout, cardiac β-ar, cardiac β-ar responsiveness, cardiac-resynchronization, cardiac-resynchronization therapy, cardiac-resynchronization therapy in heart, cardiac-resynchronization therapy in heart failure, cardiogenic, cardiogenic shock, cardiography, cardiologist, cardiologists, cardiology, cardiology guidelines, cardiology practices, cardiology services, cardiology-cardiovascular, cardiology-cardiovascular surgery, cardiology-cardiovascular surgery consensus, cardiology-cardiovascular surgery consensus report, cardiomyiopathy, cardiomyocyte, cardiomyocyte bioenergetics, cardiomyocyte-like, cardiomyocyte-like cells, cardiomyocytes, cardiomyocytes from human, cardiomyocytes in response, cardiomyopathic, cardiomyopathic restriction, cardiomyopathies, cardiomyopathy, cardiomyopathy cohort, cardiomyopathy in patients, cardiomyopathy in tuscany, cardiomyopathy origin, cardiomyopathy questionnaire, cardiomyopathy questionnaire in patients, cardiomyopathy questionnaire summary, cardioprotection, cardioprotection via inhibition, cardioprotective, cardioprotective effect, cardioprotective effect of nicorandil, cardioprotective signaling, cardiopulmonary, cardiopulmonary bypass, cardiopulmonary exercise, cardiopulmonary exercise test, cardiopulmonary exercise test investigations, cardiopulmonary exercise test investigations at study, cardiopulmonary exercise test investigations at study enrollment, cardiopulmonary exercise testing, cardiopulmonary exercise testing guide, cardiopulmonary exercise variables, cardiopulmonary resuscitation, cardiorespiratory, cardiorespiratory fitness, cardiotoxicity, cardiovascular, cardiovascular complications, cardiovascular conditions, cardiovascular death, cardiovascular disease, cardiovascular disease at baseline, cardiovascular disease registry, cardiovascular disease registry practice, cardiovascular disease registry practice innovation, cardiovascular diseases, cardiovascular event, cardiovascular event rate, cardiovascular event-free, cardiovascular event-free rate, cardiovascular events, cardiovascular events after adjustment, cardiovascular events as subjects, cardiovascular events for psoriasis, cardiovascular events in patients, cardiovascular function, cardiovascular health, cardiovascular hospitalization, cardiovascular morbidity, cardiovascular mortality, cardiovascular outcomes, cardiovascular outcomes in renal, cardiovascular outcomes in renal atherosclerotic lesions, cardiovascular reason, cardiovascular reserve, cardiovascular risk, cardiovascular risk factors, cardiovascular risk factors on hf, cardiovascular risk factors on hf mortality, cardiovascular society, cardiovascular society guidelines, cardiovascular surgeons, cardiovascular system, cardioversions, cardioverter, cardioverter defibrillator-crt, cardioverter defibrillator-crt in patients, cardioverter defibrillators, cardioverter-defibrillator, cardioverter-defibrillator deactivation, cardioverter-defibrillator deactivation discussions, cardioverter-defibrillator deactivation preferences, cardioverter-defibrillator device, cardioverter-defibrillator shocks, cardioverter-defibrillator shocks at end, cardioverter-defibrillator therapy, cardioverter-defibrillators, care, care clinicians, care delivery, care expenditures, care expenditures of patients, care for patients, care group, care hospital, care hospital for hf, care hospitals, care in heart, care in heart disease, care management, care of patients, care outcomes, care packages, care program, care programme, care providers, care surgery, care surgery in heart, care surgery in heart transplant, care surgery in heart transplant recipients, care system, care systems, care taxonomy, care to outcomes, care transfer, care transfer policy, care unit, careful, careful clinical, careful clinical evaluation, careful consideration, careful evaluation, careful management, carotid, carotid baroreflex, carotid baroreflex activation, carotid baroreflex activation therapy, carotid bodies, carotid intima-media, carotid intima-media thickness, carries prognostic value, carvedilol, carvedilol than metoprolol, carvedilol than metoprolol treatment, cascade, cascades, case, case costing, case costing initiative, case mix, case mix of hf, case of angiotensin, case report, case series, case-control, case-control analysis, case-control study, case-control study design, case-fatality, case-fatality rate, case-fatality rate for patients, cases, caspase, caspase-3, catabolic, catabolic isoenzymes, catabolism, catalytic, catecholamine, catecholamine infusions, catecholamine infusions in rats, catecholamines, categories, categories of actin, categories of actin cytoskeleton, categorization, category, category among patients, catheter, catheter ablation, catheter system, catheter-based, catheter-based percutaneous revascularization, catheter-based revascularization, catheterisation, catheterisation with transoesophageal, catheterization, catheterization findings, cation, cation channel, caucasian, causal, causal in hf, causal in hf pathogenesis, cava, cd133, cd34, cdp, cdp choline, ceballos, cell, cell adhesion, cell adhesion genes, cell death, cell differentiation, cell disease, cell expansion, cell expansion protocols, cell phenotype, cell senescence, cell source, cell therapy, cell transfusion, cell transfusion strategy, cell transplantation, cell yield, cell-derived, cell-derived cardiomyocytes, cells, cellular, cellular dysfunction, cellular metabolism, cellular plasticity, cellular plasticity in cardiomyocytes, cellular responses, cellular responses to heart, cellular responses to heart failure, cent, center, center longitudinal, center longitudinal study, center retrospective observational study, center retrospective observational study in children, centers, centers for medicare, central, central blood, central blood pressure, central end-systolic, central end-systolic pressure, central glycosylated region, central pattern, central pattern generator, central to hf, central to hf pathogenesis, central venous, central venous pressure, centre, centre for reviews, centre in canada, centres, centrifugal, centrifugal flow, centrifugal flow pump, centrifugal-flow, centrifugal-flow chronic, centrifugal-flow chronic lvas, centrimag, centrimag rvad, cerebral, cerebral blood, cerebral blood flow, cerebrovascular, cerebrovascular events, cessation, cf devices, cfa, cfi, cgmp, cgmp synthesis, chagas, chain, challenge, challenges, challenging, challenging therapeutics, chamber, chamber patterning, change, change in c-index, change in cystatin, change in cystatin c, change in cystatin c level, change in distribution, change in lvet, change in mlhf, change in peak, change in percent, change in serum, change in serum cystatin, change in serum cystatin c, change in thigh, change in thigh muscle, change in type, change in type ii, change scores, changes, changes at follow-up, changes at follow-up visits, changes in body, changes in body composition, changes in cardiomyocytes, changes in co, changes in control, changes in control group, changes in energy, changes in energy metabolism, changes in energy metabolism precede, changes in fm, changes in hrqol, changes in nps, changes in pressure, changes in pressure development, changes in prognosis, changes in rs, changes in rs synchrony, changes in sr, changes in treatment, changes on exercise, changing doses, channel, channel activity, channel gene, channel inhibition, channel inhibition by rgk, channel inhibition by rgk proteins, channel isoforms, channel mrna, channel mrna splice, channel mrna splice variants, channel mrnas, channel α-subunit, channel-dependent, channel-dependent processes, channelopathies, channels, characteristic, characteristic curve, characteristics, characteristics of hf, characteristics results, characterization, characterize events, charm, charm programme, chart, chart review, cha₂ds₂vasc, cha₂ds₂vasc score, chelation, chelation choices, chelation regimens, chemical, chemical instability, chemotherapy, chemotherapy-induced, chemotherapy-induced heart, chemotherapy-induced heart failure, chest, chest model, chest radiation, chf, chf after hct, chf atrial explants, chf inhibition, chf inhibition of avp, chf patients, chf predictive model, chf than nontrastuzumab, chf than nontrastuzumab users, chf treatments, chf visit, chf visit rates, chf-derived, chf-developed, chf-developed infarcted animals, chf-dnx, chf-inv, chf-inv animals, chf-inv group, chf-inv rabbits, chf-nyha-ii, chf-nyha-iii, chf-nyha-iiib, childhood, childhood malignant disease, children, china, chinese, chinese herbal, chinese herbal medicine, chloride, chloride channel, chloride channel gene, chm, choice, choice of chelation, choice of chelation regimens, choices, cholesterol, choline, cholinephosphotransferase, chop, chordal, chordal ruptures, chromatin, chromatin hyperacetylation, chromatin identifies, chromatin remodeling, chromatin remodeling events, chromatin structure, chromatin subproteome, chromatin subproteomes, chromatin-associated, chromatin-associated proteins, chromatin-dependent, chromatin-dependent signal, chromatin-dependent signal transduction, chromatin-mediated, chromatin-mediated signal, chromatin-mediated signal transduction, chromatin-mediated signal transduction to pol, chromatin-mediated signal transduction to pol ii, chronic, chronic acf, chronic advanced, chronic advanced heart, chronic advanced heart failure, chronic advanced heart failure patients, chronic decompensated heart, chronic decompensated heart failure, chronic disease, chronic end-stage, chronic end-stage heart, chronic end-stage heart failure, chronic heart, chronic heart failure, chronic heart failure in hungary, chronic hf, chronic hf-ref, chronic hfpef, chronic inflammatory, chronic inflammatory state, chronic insulin, chronic insulin exposure, chronic kidney, chronic kidney disease, chronic kidney disease epidemiology, chronic kidney disease epidemiology collaboration, chronic kidney disease epidemiology collaboration equation, chronic lvas, chronic myocardial, chronic myocardial ischemia, chronic obstructive, chronic obstructive pulmonary, chronic obstructive pulmonary disease, chronic organ, chronic organ failure, chronic pah, chronic pulmonary, chronic pulmonary arterial, chronic pulmonary arterial hypertension, chronic renal, chronic renal failure, chronic stable, chronic stable guideline-directed, chronic stable guideline-directed medical, chronic stable guideline-directed medical therapy, chronic systolic, chronic systolic heart, chronic systolic heart failure, chronic thromboembolic, chronic β-adrenergic, chronic β-adrenergic receptor, chronic β-adrenergic receptor stimulation, chronic β-ar, chronic β-ar stimulation, chronic β-ar stimulation via catecholamine, chronic β-ar stimulation via catecholamine infusions, chronotropic, chronotropic response, ciaraldi, cinahl, circulating, circulating forms, circulating fragments, circulating mediator, circulating nt-probnp, circulating nt-probnp concentration, circulating plasma, circulating plasma ne, circulating progenitor, circulating progenitor cells, circulation, circulation exhibit, circulation of hf, circulation of hf patients, circulatory, circulatory arrest, circulatory assist, circulatory assist device, circulatory derangement, circulatory failure, circulatory support, circumference, circumferential, circumferential shortening, circumferential strain, circumflex, circumflex artery, circumstances, cis, citations, citrate, citrate cycle, city, city cardiomyopathy questionnaire, city cardiomyopathy questionnaire in patients, city cardiomyopathy questionnaire summary, city of hope, ckd, claims, clarity, class, class ii, class ii heart, class ii heart failure, class ii to iv hf, class iii, class iii chronic heart, class iii chronic heart failure, class iii heart, class iii heart failure, class iii hf, class iii to class, class iii to class ii, class iiib, class iiib symptoms, class iii–iv, class iv, classes, classic, classic signaling paradigms, classification, classification of diseases, classified patients, classify interventions, classify patients, clcnka, clcnka gg, clcnka gg genotype, clcnka polymorphism, clcnka snp, clear, clear evidence, clear organic, clear organic lesion, climate, clin, clinic, clinic at university, clinic at university health, clinic at university health network, clinic notes, clinic outpatients, clinical, clinical application, clinical benefit, clinical benefit for patients, clinical burden, clinical burden in adult, clinical burden in adult medicine, clinical care, clinical care delivery, clinical change, clinical characteristics, clinical characteristics results, clinical circumstances, clinical comparisons, clinical composite, clinical composite response, clinical conditions, clinical course, clinical data, clinical deterioration, clinical deterioration of hfpef, clinical diastolic, clinical diastolic dysfunction, clinical doppler, clinical doppler echocardiography, clinical effects, clinical evaluation, clinical excellence, clinical excellence registry, clinical excellence registry from july, clinical findings, clinical follow-up, clinical follow-up of heart, clinical follow-up of heart failure, clinical modification, clinical outcome, clinical outcome in patients, clinical outcomes, clinical outcomes in chf, clinical practice, clinical practice guideline, clinical practice guidelines, clinical prediction, clinical prediction rule, clinical recommendations, clinical response, clinical setting, clinical status, clinical status hospitalizations, clinical studies, clinical symptoms, clinical tool, clinical tool for risk, clinical tool for risk stratification, clinical trial, clinical trial design, clinical trial registries, clinical trials, clinical variables, clinically stable, clinician, clinician belief, clinician expertise, clinician interviews, clinicians, clinics, closure, cluster, cluster analysis, clustering, cm2, cms, cms metric, cms metrics, co-activating, co-activating transcription, co-activating transcription factor, co-activating transcription factor networks, co-morbidities, co-morbidity, co-morbidity burden, co-ordinated, co-ordinated fashion, co-primary, co-primary outcome, co2, coagulability, cochrane, cochrane databases, cochrane effective practice, cochrane library, cocoa, codes, coding, coding system, coding system codes, coefficient, coefficients, cogeneration, cogeneration of nitrite, cognitive, cognitive function, cognitive impairment, cognitive impairment at hospitalization, cohort, cohort analysis, cohort of patients, cohort studies, cohort study, cohort study from denmark, cohort with incident, cohorts, collaboration, collaboration among cardiologists, collaboration equation, collaboration of professionals, collaborative, collaborative research, collaborative research initiatives, collagen, collagen cross-linking, collagen density, collagen deposition, collateral, collateral growth, collateral growth patterns, colleagues, collected clinical data, collected preliminary data, college, college of cardiology, college of physicians, collinearity, collins, collins et, collins et al, colon, colony-forming, colony-forming units, comanagement, combination, combination of exercise, combination with anticoagulants, combinations, combine structure, combined, combined care, combined care management, combined contributions, combined end, combined end point, combined end point of death, combined relative risk, combined training, combined treatment, combined treatment measure, combining parameters, combining salt, combining salt loading, coming decades, comment, comments, commissioning, common, common applications, common applications of readmission, common applications of readmission metrics, common condition, common conditions, common consensus, common contextual, common contextual reasons, common degs, common disorder, common elements, common emergency, common emergency department, common form, common form of heart, common form of heart failure, common forms, common in patients, common inpatient, common inpatient medical, common inpatient medical conditions, common language, common problem, common procedure, common procedure coding, common procedure coding system, common procedure coding system codes, common syndrome, common type, common underlying, common underlying characteristics, commoner, commoner among women, communication, communities, communities study, community, community hf, community hf cohort, community outpatient, community outpatient settings, community perspective, community study, community-based, community-based cohort, community-based cohort with incident, community-based programmes, community-based programmes on completion, comorbid, comorbid conditions, comorbidities, comorbidities in heart, comorbidities in heart failure, comorbidity, comparable, comparable across age, comparable in patients, comparable performance, comparative, comparative effects, compare, compared patients, comparing b-treated, comparison, comparison of outcomes, comparison of predictors, comparisons, compelling, compelling improvement, compelling improvement after device, compelling improvement after device implantation, compensated, compensated hfpef, compensated lv, compensated lv hypertrophy, compensated lv hypertrophy to hf, compensatory, compensatory hypertrophy, competing priorities, competing priorities impact, competing priorities impact prescribing, competing risk, competitive, competitive collateral, competitive collateral growth, competitive collateral growth patterns, complementary, complementary model, complementary model system, complete, complete coronary, complete coronary occlusion, completed surveys, completely normal, completion, completion of training, completion of training protocol, complex, complex set, complex set of variables, complex situations, complex situations in pediatrics, complexities, compliance, compliance with treatment, complication, complications, complications after implantation, complications of therapy, complicity, component, components, composite, composite end, composite end point, composite end point of esrd, composite end-point, composite endpoint, composite hf, composite hf index, composite measure, composite measures, composite measures of quality, composite of death, composite of repeat, composite of repeat procedures, composite primary, composite primary outcome, composite quality, composite quality measure, composite quality measure for heart, composite quality measure for heart failure, composite quality measures, composite response, composition, composition study, comprehensive, comprehensive echocardiography, comprising hospitalization, computational, computational study, compute odds, compute odds ratios, computed, computed tomographic, computed tomographic angiography, computing readmissions, concentration, concentrations, concentric, concentric hypertrophy, concentric remodeling, concept, concepts, concerns, conclusion, conclusions, conclusions—low-volume, conclusions—low-volume eds, concomitant, concomitant downregulation, concomitant treatment, concordance, concrete, concrete data, concurrent, concurrent hf, concurrent with ami, concurrent with ami admission, condition, conditional, conditional gene-targeted, conditioning, conditioning for patients, conditions, conditions in turkey, conductance, conductance catheter, conductance catheter system, conducting long-term, conducting studies, conduction, conduction abnormalities, confer health, confer health benefits, conferred increased increase, conferred increased increase rate, confidence, confidence in estimates, confidence interval, confidence intervals, confidence level, confidence scale, configurations, confirmation, confirmatory, confirmatory diagnostic, confirmatory diagnostic tests, confirmatory factor, confirmatory factor analysis, confirmed hfpef, conflicting results, confounders, congenital, congenital abnormalities, congenital accessory, congenital accessory pathways, congenital heart, congenital heart lesions, congenital lesions, congestion, congestion-like, congestive, congestive heart, congestive heart failure, congestive heart failure exacerbation, congestive heart failure in humans, congestive heart failure in survivors, congestive heart failure patients, congestive heart failure patients in addition, congestive heart failure phenotypes, congestive heart failure trial, congestive heart failure visits, congestive hf, congestive symptoms, congestive symptoms in patients, conjoint, conjoint education, conjunction, connected elevated resistin, connected elevated resistin levels, connecticut, connecticut health, connecticut health center, connecticut heart, connecticut heart failure, connecticut heart failure center, connection, conscious, conscious dogs, conscious hf, conscious hf rats, conscious rabbits, consecutive, consecutive case, consecutive case series, consecutive consenting, consecutive patients, consecutive patients with pad, consecutive patients with ph, consensus, consensus report, consenting, consenting ambulatory hf, consenting ambulatory hf patients, consequence, consequence of heart, consequence of heart rate, consequence of heart rate variation, consequences, conservation, considerable, considerable national, considerable national attention, considerable number, considerable number of patients, consideration, considerations, consistency, consistency among patients, consistent, consistent across hospital, consistent across hospital volume, consistent across hospital volume groups, consistent benefits, consistent with myofibre, consistent with myofibre regeneration, consistent with reports, constant, constants, constriction, construct, construct validity, constructed additional models, consultation, consultation to operation, consultations, consumed erc, consumption, consumption rate, contact, contact before august, contemporaneous, contemporaneous control, contemporaneous control group, contemporary, contemporary chronic, contemporary chronic heart, contemporary chronic heart failure, contemporary heart, contemporary heart failure, contemporary therapeutic, contemporary therapeutic options, contemporary trends, contemporary trends in heart, contemporary trends in heart failure, contemporary use, contemporary use of devices, content, content for sr, content-driven, content-driven telehealth, content-driven telehealth system, content-driven telehealth system with care, content-driven telehealth system with care management, content-driven telehealth technology, contention, contents, contents in addition, context, context of hf, contextual, contextual factors, contextual factors on physician, contextual factors on physician adherence, contextual framework, contextual reasons, continuity, continuity equation, continuity of care, continuity on death, continuous, continuous flow, continuous nris, continuous relationship, continuous relationship between qrs, continuous relationship between qrs duration, continuous wave, continuous wave doppler, continuous wave doppler echocardiography, continuous-flow, continuous-flow lvads, contours, contractile, contractile efficiency, contractile function, contractile reserve, contractile reserve in patients, contractile response, contractility, contracting ventricles, contraindications, contrast, contrast agent, contrast agent administration, contrasting groups, contrasting groups validity, contribution, contribution of nursing, contribution of nursing care, contribution of poc, contribution of poc measurement, contributions, contributions of titin, control, control adenovirus, control animals, control group, control group patients, control model, control of heart, control of heart rate, control studies, control subjects, control therapy, control without exercise, controlled, controlled feasibility, controlled feasibility study, controlled randomized trials, controlled trial, controlling heart, controlling heart rate, controls, controversial, conventional, conventional clinical, conventional surgery, conversations, converting enzyme, converting enzyme inhibitor, converting enzyme inhibitors, converts, cooper, cooper center, cooper center longitudinal, cooper center longitudinal study, coordinate dna, coordinate dna accessibility, copd, coprimary, coprimary end, coprimary end points, coprimary outcome, coral, core, core laboratory, cornerstone, cornerstone of heart, cornerstone of heart failure, coronary, coronary angiography, coronary arteries, coronary artery, coronary artery bypass, coronary artery bypass grafting, coronary artery bypass surgery, coronary artery calcium, coronary artery calcium scores, coronary artery disease, coronary artery disease in patients, coronary artery ligation, coronary artery occlusion, coronary disease, coronary heart, coronary heart disease, coronary intervention, coronary interventions, coronary microembolization-induced, coronary microembolization-induced hf, coronary occlusion, coronary perfusion, coronary perfusion in b-treated, coronary revascularization, coronary syndrome, coronary syndromes, corp, corporeal, corporeal membrane, corporeal membrane oxygenation, correcting nutrition, correction, correction for age, correlates, correlates of increase, correlation, correlation between changes, correlation between performance, correlation coefficient, correlation to changes, correlation with baseline, correlation with baseline hgb, correlations, correlations among metrics, cost, cost analysis, cost analysis of rhythm-control, cost per patient, cost savings, cost-effective, cost-effectiveness, cost-effectiveness analyses, cost-effectiveness analyses of disease, cost-effectiveness analyses of disease management, cost-effectiveness analyses of disease management programs, cost-effectiveness limits, cost-effectiveness limits in models, cost-effectiveness model, cost-effectiveness of disease, cost-effectiveness of disease management, cost-effectiveness of disease management programs, cost-effectiveness of heart, cost-effectiveness of heart failure, cost-effectiveness of heart failure disease, cost-effectiveness of heart failure disease management, cost-effectiveness of heart failure disease management programs, cost-effectiveness ratios, cost-effectiveness ratios from user, cost-effectiveness ratios from user inputs, cost-minimization, cost-minimization approach, costing, costing initiative, costs, costs across volume, costs across volume groups, costs for patients, counseling, counterparts, countries, country, county, coupling, coupling gain, course, covariate, covariate adjustment, covariates, coverage, cox, cox model, cox model analysis, cox modeling, cox models, cox proportional hazard, cox proportional hazard analyses, cox proportional hazard models, cox proportional hazards, cox proportional hazards models, cox proportional hazards regression, cox regression, cox regression analyses, cox regression analysis, cox regression models, cox-proportional, cox-proportional hazard, cox-proportional hazard models, cpcs, cpet, cpg, cpg recommendations, cpg recommendations in hf, cpg-recommended, cpg-recommended pharmacological treatment, cpgs, cpr, creatine, creatine kinase, creatine kinase activity, creating uncertainty, creatinine, creatinine level, credible, credible interval, crf, crf categories, crf distribution, cri, criteria, criteria cardiac transplant, criteria cardiac transplant recipients, criteria cardiac transplant survival, criteria cardiac transplantation, criteriabased institution, criterion, criterion standard, critical, critical for adaptation, cronbach, cross, cross talk, cross talk between cgmp, cross-linking, cross-sectional, cross-talk, crossover, crossover study, crt, crt capability, crt group, crt implantation, crt in dialysis, crt in patients, crt on assignment, crt on versus crt, crt response, crt-d, crt-d recipients, crucial, crucial problem, crucial role, crucial target, crude, crude rates, crude rr, cs during avd, cs during avd variation, cs during vvd, cs during vvd variation, ctnt, cuff, culprit, cultured, cultured cardiomyocytes, cumulative, cumulative administration, cumulative administration of doxorubicin, cumulative anthracycline, cumulative anthracycline exposure, cumulative dose, cumulative hazard, cumulative urine, cumulative urine volume, curative, current, current amplitude, current assays, current cardiology, current dietary, current dietary recommendations, current dietary recommendations for patients, current economic, current economic climate, current guidelines, current knowledge, current measurements, current ongoing, current ongoing cardiovascular, current ongoing cardiovascular outcomes, current ongoing cardiovascular outcomes in renal, current ongoing cardiovascular outcomes in renal atherosclerotic lesions, current practice, current predictors, current predictors of mortality, current status, current status of np, current status of np measurement, current strategies, current study, current treatment, currents, curve, curves, curves for death, customized homogeneous sandwich, customized homogeneous sandwich alphalisa, cutoff, cutoff level, cutoff level of nt-probnp, cutoff point, cutoff value, cutoff value for admission, cutoff value for admission nt-probnp, cutoff value for plasma, cutoff value of nt-probnp, cutoff value of nt-probnp testing, cv death, cv events, cvd, cxl-1020, cxl-1051, cyclase, cycle, cyclic, cyclic adenosine, cyclic guanosine, cystatin, cystatin c, cystatin c from enrollment, cystatin c level, cytoscape, cytoskeletal, cytoskeletal actin, cytoskeletal actin dynamics, cytoskeleton, cytoskeleton pathways, cytotoxic, cytotoxic effect, cytotoxic effect of doxorubicin, czech, czech republic, cα, dacron, dacron patch, dacron patch closure, daily, daily clinical, daily clinical practice, daily equivalent, daily equivalent dose, daily equivalent dose of metoprolol, daily equivalent dose of metoprolol succinate, dakota, damage, danish, danish heart, danish heart failure, danish heart failure database, danish registry, danish registry on dialysis, dapc, dapc protein, dapc protein levels, dash, dash diet, dash diet score, dash diet scores, data, data among groups, data analysis, data extraction, data in duplicate, data in latin, data in latin america, data in patients, data nonpublic, data nonpublic file, data on study, data on study design, data partners, data point, data processing, data sources, data synthesis, database, databases, databases of medline, date, date of death, date of hf, date of hf hospitalization, david, david tools, day, days, days after cabg, days after mi, days for participants, days of acs, days of acs consultation, days of follow-up, days of hospital, days of hospital discharge, days of inclusion, dcm, dd of collagen, dd of collagen deposition, de novo, deacetylases, deactivation, deactivation discussions, deactivation preferences, dearth, death, death during sport, death in athletes, death in crt-d, death in crt-d recipients, death in patients, deaths, deaths attributable to heart, deaths attributable to heart failure, debate, debilitating chronic disease, debilitating stroke, decade, decades, december, decile, deciles, decision-support, decisions, decline, decline in egfr, decline in ejection, decline in ejection fraction, declined participation, declines, declines in early-onset, declines in length, decompensated heart, decompensated heart failure, decompensated hf, decompensated systolic heart, decompensated systolic heart failure, decompensation, decongestion, decongestion end, decongestion end point, decoy, decoy vegf, decoy vegf receptor, decrease, decrease co, decrease in eo-cfus, decrease in length, decrease in re-hospitalization, decrease in score, decrease mitochondrial respiration, decrease mortality, decreased expression, decreased mitochondrial energy, decreased mitochondrial energy production, decreased mortality, decreased mortality rates, decreased parasympathetic activity, decreased risk, decreased rrna transcription, decreased stroke, decreased stroke volume, decreases, decreases in ejection, decreases in ejection fraction, decreases in heart, decreases in lv, decreases in septum, decreasing albumin levels, decrement, decrement of heart, decrement of heart rate, dedicated, dedicated hf, dedicated hf units, defects, defence, defense, defense mechanism, defibrillator, defibrillator implantation, defibrillator implantation trial-cardiac, defibrillator implantation trial-cardiac resynchronization, defibrillator implantation trial-cardiac resynchronization therapy, defibrillator implantation with cardiac, defibrillator implantation with cardiac resynchronization, defibrillator implantation with cardiac resynchronization therapy, defibrillator-crt, defibrillator-crt in patients, defibrillator-only, defibrillator-only therapy, defibrillators, deficiency, deficiency in adult, deficiency in adult patients, deficit, deficit index, deficits, define hf, defined prediction, defined prediction rule, defined set, definition, definition of hfpef, definitions, degenerative, degenerative mitral, degenerative mitral regurgitation, degenerative mitral valve, degenerative mr, degradation, degree, degree of ms, degs, delay, delayed, delayed benefit, delayed enhancement imaging, delayed rhythm, delayed rhythm control, deleterious, deleterious effects, deletion, delineated, deliver specialised care, delivery, delivery of therapies, demand, dementia, demographic, demographic changes, demographics, demonstrated compelling improvement, demonstrated diastolic dysfunction, demonstrated excellent risk, demonstrated excellent risk stratification, demonstrated favorable outcomes, demonstrated reduced kd, demonstrated restricted closure, demonstrated superior reverse, demonstrated superior reverse remodeling, demonstrates initial safety, demonstrating development, demonstration, denervation, denmark, density, department, department of cardiology, department volume, depolarization, deposition, depressed, depressed in acf, depressed left, depressed left ventricular, depressed myofibrillar, depression, depression inventory, depression scale, depression scale score, depression scores, depressive, depressive symptoms, derangement, derivation, derivation cohort, derived absolute improvements, derived composite quality, derived composite quality measure, descending, descending artery, descending coronary artery, descending coronary artery occlusion, describing trends, description, descriptive, descriptive assessment, descriptive research, descriptive research design, descriptive statistics, descriptive study, desensitization, design, designed clinical trials, designs, destination, destination therapy, detailed, detailed transcriptional, detailed transcriptional analysis, detect congenital accessory, detect congenital accessory pathways, detect hf, detectable, detectable change, detecting normal filling, detecting normal filling pressures, detection, detergent, deterioration, deterioration of hfpef, determinant, determinants, determination, determination of risk, determine patient awareness, determine prognostic significance, determined changes, determined chf, determined chf visit, determined chf visit rates, determining individualized assessment, detrimental, detrimental alterations, detrimental alterations in skm, develop atherosclerosis, develop chf, develop treatments, developed, developed acute, developed acute kidney, developed acute kidney injury, developed cardiac apoptosis, developed countries, developed esrd, developed first-in-class, developed first-in-class inhibitor, developed heart, developed heart failure, developed hf, developed incident, developed incident hf, developing congestive heart, developing congestive heart failure, developing heart, developing heart failure, developing hyperkalemia, development, development of chf, development of heart, development of heart failure, development of ie, development of ies, development of rv dysfunction, development patient, development patient discharge, development patient discharge data, development patient discharge data nonpublic, development patient discharge data nonpublic file, developmental, developmental chromatin, developmental chromatin remodeling, developmental chromatin remodeling events, developmental impairment, developments, device, device consideration, device implantation, device implantations, device support, device therapies, device use, device-related, devices, devices in heart, devices in heart failure, dhand, diabetes, diabetes mellitus, diabetes status, diabetic, diagnosed heart, diagnosed heart failure, diagnosed patients, diagnosed systolic heart, diagnosed systolic heart failure, diagnoses, diagnosis, diagnosis of af, diagnosis of chf, diagnosis of heart, diagnosis of heart failure, diagnosis of hfpef, diagnostic, diagnostic approaches, diagnostic devices, diagnostic evaluations, diagnostic features, diagnostic performance, diagnostic procedure, diagnostic procedures, diagnostic role, diagnostic roles, diagnostic roles of bnp, diagnostic test, diagnostic test for hfpef, diagnostic testing, diagnostic tests, dialysis, dialysis patients, dialysis-dependent, dialysis-dependent patients, dialysis-dependent patients with heart, dialysis-dependent patients with heart failure, dialysis-dependent patients with hf, diameter, diameter stenosis, diameters, diastole, diastole to end-systole, diastolic, diastolic blood, diastolic blood pressure, diastolic dysfunction, diastolic dysfunction in patients, diastolic end, diastolic end diameter, diastolic failure, diastolic filling, diastolic filling formalism, diastolic function, diastolic indices, diastolic mitral, diastolic mitral annular velocity, diastolic mitral annulus, diastolic mitral annulus velocity, diastolic mitral flow, diastolic mitral flow velocity, diastolic mitral leaflet, diastolic mitral leaflet motions, diastolic mitral valve, diastolic mitral valve tethering, diastolic murmurs, diastolic properties, diastolic tethering, dichotomized patients, diet, diet adherence, diet group, diet score, diet score components, diet scores, diet scores with mortality, dietary, dietary approaches, dietary interventions, dietary interventions in heart, dietary interventions in heart failure, dietary interventions in heart failure patients, dietary measures, dietary patterns, dietary patterns with outcomes, dietary recommendations, dietary recommendations for patients, dietary sodium, dietary sodium restriction, difference, difference between numbers, difference in heart, difference in heart rate, difference in hf, difference in hf hospitalizations, difference in outcome, difference in outcome ratings, difference-in-differences, differences, differences between patients, differences in bnp, differences in bnp values, differences in plasma, differences in plasma b-type, differences in presentation, differential, differential analysis, differential effect, differential effect of lvef, differential effects, differential g-protein, differential g-protein coupling, differential impact, differential impact on hospital, differential impact on hospital performance, differential relations, differential relations between cpcs, differential response, differentiation, differentiation consistent with myofibre, differentiation consistent with myofibre regeneration, difficult, difficult problems, diffuse myocardial changes, dilatation, dilatation diameter, dilatation improvement, dilatation improvement by et, dilated cardiomyopathy cohort, dilated lv, dilation, dimension, dimension index, dimensions, diminished, diminished akt→forkhead, diminished akt→forkhead box, diminished akt→forkhead box class, diminished cyclic, diminished cyclic adenosine, diminished expression, dipeptidyl, direct, direct comparison, direct effects, direct effects on macrophages, direct interaction, direct observation, direct renin, direct renin inhibitors, disappearance, disappearance of mr, disappointments, discharge, discharge among patients, discharge data, discharge data nonpublic, discharge data nonpublic file, discharge diagnosis, discharge in patients, discharge patients, discharged patients, discharges, disciplines, disclosing prognosis, discontinuation, discontinuation of study, discontinuation of study medication, discordant, discrepancy, discrimination, discrimination improvement, discussion, discussions, discussions about end-of-life, discussions about end-of-life treatment, discussions about end-of-life treatment preferences, disease, disease at baseline, disease by angiotensin, disease by angiotensin ii, disease by angiotensin ii infusion, disease complex, disease epidemiology, disease epidemiology collaboration, disease epidemiology collaboration equation, disease groups, disease in outpatients, disease in patients, disease management, disease management programs, disease management programs in heart, disease management programs in heart failure, disease model, disease phase, disease progression, disease recapitulates, disease registry, disease registry practice, disease registry practice innovation, disease risk, disease risk score, disease severity, disease-specific, disease-specific costs, diseased, diseased cardiomyocytes, diseased human, diseased mouse, diseased mouse heart, diseases, disorder, displaced papillary muscles, displaces bets, display cachexia, displays, disposition, disposition of at-risk, disposition of at-risk patients, dissemination, distance, distinct, distinct circulatory, distinct circulatory derangement, distinct g-protein-coupled, distinct g-protein-coupled receptors, distinct populations, distinct populations of patients, distinct subset, distinct subset of hfpef, distinctive, distinctive components, distressing implantable cardioverter-defibrillator, distressing implantable cardioverter-defibrillator shocks, distribution, distribution in hfref, disturbed intestinal barrier, dithiothreitol, diuretic, diuretic effect, diuretic efficacy, diuretic refractory, diuretic refractory severe-end-stage, diuretic refractory severe-end-stage hf, diuretic resistant, diuretic resistant volume, diuretic resistant volume overload, diuretic resistant volume overload in heart, diuretic resistant volume overload in heart failure, diuretic response, diuretic therapy, diuretic use, diuretic use in heart, diuretic use in heart failure, diuretics, divergent, divergent etiology, diverse, diverse aspects, diverse community-based, diverse community-based cohort, diverse community-based cohort with incident, divided physicians, dna, dna accessibility, dna fragmentation, dnx, dobutamine, dobutamine requirement, doctors, documentation, documented contraindications, documented prognostic factors, dodson, dodson et, dodson et al, dodson et al with interest, dogs, domain, domain heart, domain heart rate, domain heart rate variability, domains, donor, donors, dopamine, doppler, doppler early diastolic, doppler echocardiography, doppler imaging, doppler mitral inflow, doppler mitral inflow velocity, doppler ultrasonography, dosage, dosages, dosages of carvedilol, dose, dose changes, dose increase, dose of doxorubicin, dose of metoprolol, dose of metoprolol succinate, dose uptitration, dose-dependent, dose-dependent reduction, dose-related, dose-related benefits, dose-related gradient, dose-related gradient of hf, dose-related gradient of hf risk, doses, doses of β-blocker, double, double mutant, double-blind, double-blind trial, double-knockout, downregulation, downregulation influences, downregulation influences cardiac hypertrophic response, downregulation processes, downstream, downward, downward regression, downward regression line, downward regression line shift, downward regression line shift in nonsurvivors, doxorubicin, doxorubicin cardiotoxicity, doxorubicin efflux, doxorubicin efflux transporter, doxorubicin in rats, doxorubicin treatment, doxorubicin-induced, doxorubicin-induced cardiotoxicity, doxorubicin-induced heart, doxorubicin-induced heart failure, doxorubicin-induced heart failure in rats, dpp-4, dramatic, dramatic improvement, dramatic induction, dramatic induction of hretn, drive, driveline, driveline infection, driveline injury, drs, drs deciles, drs-stratified, drs-stratified hazard, drs-stratified hazard ratios, drug, drug administration, drug dose, drug treatment, drug-free, drug-free success, drug-free success rates, drug-untreated, drug-untreated failing hearts, drugs, drugs for heart, drugs for heart failure, drugs for hf, dt as implantation, dt as implantation strategies, dt patients, dual, dual energy, dual energy x-ray, dual energy x-ray absorptiometry, dual inhibition, dual ras, dual x-ray, dual x-ray absorptiometry, dual-energy, dual-energy x-ray, dual-energy x-ray absorptiometry, duke, duke activity, duke activity status, duke activity status index, duplicate, duration, duration of antiplatelet, duration of antiplatelet medication, duration on outcomes, dxa, dxa results, dyn, dynamic, dynamic resistance, dynamic resistance training, dynamics, dysbalance, dysfunction, dysfunction during insulin, dysfunction during insulin resistance, dysfunction in patients, dysfunction treatment, dysfunction with conduction, dysfunction with conduction abnormalities, dyspnea, dyssynchronous, dyssynchronous failing heart, dyssynchronous heart, dyssynchronous heart failure, dyssynchronous hf, dyssynchronous nonfailing, dyssynchrony, dystrophin-associated, dystrophin-associated protein, dystrophin-associated protein complex, e'lateral, e'mean, e'septal, e-wave, early, early beneficial, early beneficial clinical, early deaths, early detection, early diastolic, early follow-up, early follow-up visits, early measurement, early medical, early medical management, early medical management of hf, early metabolic, early metabolic changes, early physician, early physician follow-up, early physician follow-up after discharge, early research, early rhythm, early rhythm control, early rhythm control therapy, early risk, early risk of stroke, early transmitral, early transmitral blood, early transmitral blood flow, early transmitral blood flow velocity, early transmitral blood flow velocity over tissue, early transmitral blood flow velocity over tissue doppler, early transmitral flow, early treatment, early-activated, early-activated septum, early-onset, early-onset hf, early-outgrowth, early-outgrowth colony-forming, early-outgrowth colony-forming units, easily treatable, east, ec coupling, ec coupling gain, eccentric, eccentric hypertrophy, ecct, ecct patients, ecg, ecg parameters, ecgs, ecgs at baseline, echo-derived, echo-doppler, echo-doppler cardiography, echo-doppler studies, echocardiograms, echocardiographic, echocardiographic assessment, echocardiographic evaluations, echocardiographic evidence, echocardiographic examination, echocardiographic guidance, echocardiographic measurements, echocardiographic measures, echocardiographic outcomes, echocardiographic predictors, echocardiographic predictors of response, echocardiographic score, echocardiographic score for prediction, echocardiographic substudy, echocardiographic systolic, echocardiographic systolic parameters, echocardiography, echocardiography at baseline, echocardiography before crt, echocardiography evaluations, echocardiography evaluations at baseline, echocardiography with measurement, ecmo, ecmo group, economic, economic analysis, economic analysis of patient, economic analysis of patient management, economic analysis of patient management interventions, economic climate, economic considerations, economic evaluations, economic impact, economic models, economic savings, ecs, ed cases, ed patients, ed physicians, ed use, ed visit, ed visits, ed visits for chf, ed volume, edema, edge, edge detection, edge-to-edge, edge-to-edge anastomosis, eds, education, education at discharge, edwards, edwards lifesciences, ees, ef differences, ef differences in bnp, ef differences in bnp values, effect, effect of arni, effect of caloric, effect of caloric restriction, effect of chf, effect of crt, effect of doxorubicin, effect of exercise, effect of exercise training, effect of follow-up, effect of ie, effect of if-channel, effect of if-channel inhibition, effect of interventions, effect of lvef, effect of nicorandil, effect on crt, effect on hdl, effect on hdl function, effect on heart, effect on heart rate, effect on ie risk, effect on mortality, effect on pb, effect on pb characteristics, effect on quality, effective, effective across transplantation, effective across transplantation eligibility, effective across transplantation eligibility status, effective anti-neoplastic, effective anti-neoplastic agent, effective arterial, effective arterial elastance, effective evidence-based, effective evidence-based therapies, effective for patients, effective in hypertension, effective in myocytes, effective off-pump, effective off-pump sternal, effective practice, effective rate, effective rate control, effective target, effective treatment, effective way, effectiveness, effectiveness of bisoprolol, effectiveness of implementation, effectiveness of implementation strategies, effector, effector molecules, effectors, effects, effects analysis, effects in chf, effects in vivo, effects of air, effects of air pollution, effects of care, effects of care management, effects of carvedilol, effects of exercise, effects of exercise training, effects of fes, effects of hrqol, effects of treatment, effects on heart, effects on heart failure, effects on hrqol, effects on macrophages, effects via stimulation, efficacious, efficacy, efficacy end, efficacy end points, efficacy in vivo, efficacy of carotid, efficacy of carotid baroreflex, efficacy of carotid baroreflex activation, efficacy of carotid baroreflex activation therapy, efficacy of eplerenone, efficacy of spironolactone, efficacy outcome, efficacy outcomes, efficiency, efficiency slope, efficient, efficient rv function, efficient rv function evaluation, efflux, efflux transporter, effort, efforts, ef≥50, egfr, egfr group, egfr group ii, egfr group iii, egfr group iv, eh, ehrlich, ehrlich carcinoma, eight-week-old, eighty-one, eighty-one percent, ejection, ejection fraction, ejection fraction development, ejection fraction outcomes, ejection fraction outcomes trial, ejection fraction ≤, ejection fractions, ejection time, elastance, elastic, elateral, elderly, elderly male, elderly male patients, elderly male patients with chf, elderly patients, elderly people, electric, electric remodeling, electric remodeling in hf, electrical, electrical activation, electrical activation sequence, electrical stimulation, electrocardiogram, electrocardiographers, electrocardiographic, electrocardiographic device, electrocardiographic q, electrocardiographic q waves, electrolytes, electromechanical, electromechanical behavior, electromechanical delay, electromechanics, electron, electron microscopy, electronic, electronic databases, elements, elevated, elevated activation, elevated bnp, elevated cardiac filling, elevated cardiac filling pressures, elevated left, elevated left atrial, elevated left atrial pressure, elevated levels, elevated levels of epinephrine, elevated levels of plasma, elevated levels of plasma catecholamines, elevated levels of plasma norepinephrine, elevated lv, elevated lv filling, elevated lv filling pressures, elevated mena, elevated mena expression, elevated nt-probnp, elevated nt-probnp levels, elevated resistin, elevated resistin levels, elevated sympathetic, elevated sympathetic activity, elevation, elevation in resistin, elevations, elevations in bnp, elevations in tumor, elevations in tumor necrosis, elevations in tumor necrosis factor, eligibility, eligibility status, eligible, eligible patients, eliminated cardiac hypertrophy, eliminates, elucidate, elucidate mechanisms, embase, embolectomy, embolism, embryonic, embryonic gene, embryonic gene programs, embryonic gene programs in heart, embryonic gene programs in heart failure, embryonic kidney, emd, emd prolongation, emean, emergency, emergency cardiac, emergency cardiac catheterization, emergency department, emergency department volume, emergency room, emergency room practice, emission, emission tomography, emission tomography imaging, emotional, emotional status, emotional status in heart, emotional status in heart failure, emotional status in heart failure patients, emotional stress, emphasis-hf, emphasis-hf study, emphasis-hf study subgroups, encounter children, encouraging declines, end, end diameter, end of diastole, end of life, end point, end point of death, end point of esrd, end points, end points reflective of decongestion, end stage, end stage heart, end stage heart failure, end stage kidney, end stage kidney failure, end systolic volume, end systolic volume index, end-diastolic, end-diastolic area, end-diastolic area index, end-diastolic dimension, end-diastolic dimension index, end-diastolic pressure, end-diastolic volume, end-diastolic volume index, end-of-life, end-of-life treatment, end-of-life treatment preferences, end-point, end-stage, end-stage congestive, end-stage congestive heart, end-stage congestive heart failure, end-stage heart, end-stage heart failure, end-stage hf, end-stage renal, end-stage renal disease, end-stage renal disease in outpatients, end-systole, end-systolic, end-systolic elastance, end-systolic pressure, end-systolic volume, end-tidal, endopeptidase, endopeptidase inhibitors, endoplasmic, endoplasmic reticulum, endothelial, endothelial cell, endothelial dysfunction, endothelial function, endothelial function in hfpef, endothelial growth, endothelial growth factor, endothelial growth factor blockade, endothelial growth factor protein, endothelial repair, endothelial-protective, endothelial-protective effects, endothelial-protective effects via stimulation, endothelin, endpoint, endpoints, energy, energy deficit, energy expenditure, energy metabolism, energy metabolism gene, energy metabolism gene expression, energy metabolism precede, energy production, energy substrate, energy substrate metabolism, energy x-ray, energy x-ray absorptiometry, english, english language, english language on anemia, english-language, english-language trials, english-language trials of blood, english-language trials of blood transfusions, enhance decongestion, enhance myocardial function, enhanced, enhanced catabolism, enhanced decongestion, enhanced hemocompatibility, enhancement, enhancement imaging, enhancement of dapc, enhancement of dapc protein, enhancement of dapc protein levels, enhancing medical management, enhancing neoangiogenesis, enormous, enormous clinical, enormous clinical burden, enormous clinical burden in adult, enormous clinical burden in adult medicine, enrichment, enrichment analysis, enrolled, enrolled participants, enrolled patients, enrollment, enrollment period, enrollment periods, ensure effective practice, entire, entire cohort, entry, environment, enzyme, enzyme inhibitor, enzyme inhibitors, enzymes, enzymes in patients, eo-cfus, eov, ephesus, epicatechin, epicatechin-rich, epicatechin-rich cocoa, epidemic, epidemic of heart, epidemic of heart failure, epidemiology, epidemiology collaboration, epidemiology collaboration equation, epifluorescence, epifluorescence microscopy, epigenetic, epigenetic changes, epigenetic readers, epinephrine, epithelial, epitopes, eplerenone, eplerenone in patients, eplerenone post, eplerenone post myocardial infarction, eplerenone post myocardial infarction heart, eplerenone post myocardial infarction heart failure, eplerenone post myocardial infarction heart failure efficacy, equally effective, equation, equipotent, equipotent dosages, equipotent dosages of carvedilol, equitable, equitable access, equivalent, equivalent adverse, equivalent adverse outcomes, equivalent dose, equivalent dose of metoprolol, equivalent dose of metoprolol succinate, er kinase, eras, erasers, erc, error, error of measurement, error of measurement value, erythropoiesis-stimulating, erythropoiesis-stimulating agent, erythropoiesis-stimulating agent therapy, erythropoiesis-stimulating agents, erythropoiesis-stimulating agents in adults, erythropoiesis-stimulating agents in patients, esc, esc advocate, esc advocate pre-participation, esc advocate pre-participation screening, eseptal, esmolol, esrd, esrd in outpatients, essential, essential for prevention, essential role, establish efficacy, established cardiac disease, established preferences, establishment, estimated, estimated glomerular filtration, estimated glomerular filtration rate, estimates, estimates of resource, estimates of resource use, estimating lv, estimating lv filling, estimating lv filling pressure, estimation, et al, et al with interest, et of chf-nyha-iiib, ethically complex, ethics, ethics rounds, ethnic, ethnic groups, ethnicity, etidronate, etiologic, etiologies, etiologies of hf, etiology, etiology of mr, europe, european, european hf, european hf guidelines, european society, european society of cardiology, european society of cardiology guidelines, euthanization, evaluable, evaluable plasma, evaluable plasma samples, evaluate mortality, evaluated associations, evaluated cpcs, evaluated functions, evaluated mice, evaluated protein, evaluated protein levels, evaluated sts, evaluated temporal trends, evaluating implementation, evaluating implementation interventions, evaluation, evaluation study, evaluations, evaluations at baseline, event, event profile, event rate, event rates, event-free, event-free rate, event-free rates, events, events after adjustment, events as subjects, events at follow-up, events at follow-up visits, events evaluation, events for psoriasis, events in heart, events in heart failure, events in patients, eventual, eventual resort, evidence, evidence based, evidence based practice, evidence gaps, evidence in hfpef, evidence of diastolic, evidence of diastolic dysfunction, evidence on associations, evidence points, evidence points to alterations, evidence-based, evidence-based care, evidence-based management, evidence-based medications, evidence-based practices, evidence-based therapies, evidence-based treatment, evidence-based treatments, evident, evolution, exacerbates heart, exacerbates heart failure, exacerbation, examination, examination of dna, examination of dna fragmentation, examination of pka, examination of pka subunits, examine clinical circumstances, examine practice-level variation, examined changes, examined characteristics, examined incidence, examined physician, examined physician volume, examined resistin, examined resistin levels, examined transfusions, examining long-term outcomes, excellence, excellence registry, excellence registry from july, excellent, excellent fit, excellent fit indices, excellent hf, excellent hf prediction, excellent hf prediction model, excellent prognostic, excellent prognostic ability, excellent risk, excellent risk stratification, excessive, excessive secretion, excessive secretion of arginine, excessive secretion of arginine vasopressin, excessive β-ar, excessive β-ar drive, exchange, exchanges, excitation-contraction, exclude cad, excluded patients, exclusion, exclusion criteria, exclusive, excursion, exercise, exercise adherence, exercise attendance, exercise capacity, exercise capacity in adults, exercise duration, exercise group, exercise hemodynamic status, exercise intolerance, exercise intolerance in heart, exercise intolerance in heart failure, exercise modality, exercise parameters, exercise parameters for diagnosis, exercise patients, exercise per week, exercise performance, exercise programme, exercise programme for patients, exercise programmes, exercise protocol, exercise rehabilitation, exercise rehabilitation in china, exercise rehabilitation in patient, exercise score, exercise test, exercise test investigations, exercise test investigations at study, exercise test investigations at study enrollment, exercise testing, exercise testing guide, exercise time, exercise tolerance, exercise training, exercise training for heart, exercise training for heart failure, exercise training in hf, exercise training in patients, exercise training on kccq, exercise training on outcomes, exercise training on peak, exercise training on peak oxygen, exercise training on peak oxygen consumption, exercise training response, exercise training therapy, exercise variables, exercise with placebo, exercise with placebo group, exercise with testosterone, exercise with testosterone group, exercise-induced, exercise-induced increase, exercise-induced pasp, exercise-induced pasp increase, exercise-induced pulmonary, exercise-induced pulmonary artery, exercise-induced pulmonary artery systolic, exercise-induced pulmonary artery systolic pressure, exerted dose-related benefits, exertion, exertional, exertional increase, exertional shortness, exertional shortness of breath, exerts, exerts beneficial effects, exerts endothelial-protective effects, exerts positive inotropic, exhaustion, exhibit, exhibited altered expression, exhibited features, exhibited higher risk, exhibited striking differences, exhibited worse outcomes, exhibits basal, existing measures, existing quality, existing quality indicators, exogenous, exogenous variants, expansion, expansion protocols, expectancy, expected future expansion, expenditure, expenditure on health, expenditures, expenditures of patients, experience, experience in japan, experienced, experienced centers, experienced electrocardiographers, experienced improvements, experienced pronounced decreases, experiencing heart, experiencing heart failure, experimental, experimental evidence, experimental hf, experimental models, experimental procedures, experimental research, experiments, experiments of hf, expertise, explaining variation, explains variance, explant, explant-derived, explant-derived cells, explant-derived progenitor, explant-derived progenitor cells, explants, exploratory, exploratory factor, exploratory factor analysis, explore interactions, explored sex, explored sex differences, exponent, exposed group, exposure, exposure to anthracyclines, expressed genes, expressing human resistin, expression, expression of bax, expression of pluripotency, expression of pluripotency markers, expression of target, expression of target genes, expression of type, expression omnibus, expression profile, expression profiling, expression programme, expressions, expressions of bax, extend, extended, extended criteria, extending emd, extensive, extensive functional, extensive functional characterization, extent, extent of benefit, extent of cad, extent of rv dysfunction, external, external validity, extra, extra corporeal, extra corporeal membrane, extra corporeal membrane oxygenation, extracellular, extracellular flux, extracellular flux analyzer, extracellular matrix, extracellular matrix accumulation, extracellular matrix to fpassive, extracorporeal, extracorporeal life, extracorporeal life support, extracorporeal membrane, extracorporeal membrane oxygenation, extracorporeal membrane oxygenation as bridge, extracorporeal membrane oxygenation membrane, extracorporeal membrane oxygenation membrane support, extracorporeal support, extract data, extraction, extrapolating short-term outcomes, extreme, extreme decile, extreme deciles, face decisions, facilitate documentation, facilitate individualized approaches, facilities, factor, factor analysis, factor beta-dependent yield, factor blockade, factor concentrations, factor dhand, factor in heart, factor in heart failure, factor in patients, factor networks, factor protein, factor-κb, factorial, factorial trial, factors, factors at admission, factors of sh, factors on hf, factors on hf mortality, factors on physician, factors on physician adherence, failing, failing fontan, failing fontan circulation, failing heart, failing hearts, failing interventions, failing myocardium, failing myocardium displays, failure, failure adherence, failure admission, failure admissions, failure after cabg, failure among new users, failure assessment, failure assessment of reduction, failure at rest, failure care, failure center, failure clinic, failure clinic outpatients, failure cost-effectiveness, failure cost-effectiveness model, failure database, failure development, failure discharges, failure disease, failure disease management, failure disease management programs, failure efficacy, failure exacerbation, failure guidelines, failure home, failure hospitalization, failure hospitalizations, failure hospitalizations in patients, failure in children, failure in humans, failure in hungary, failure in latin, failure in latin america, failure in mice, failure in patients, failure in pigs, failure in rats, failure in survivors, failure index, failure index version, failure management, failure management in pah, failure medicines, failure mice, failure mice model, failure model, failure model scores, failure mortality, failure mortality in men, failure myocardial tissue, failure nurse, failure nurse practitioner, failure nurses, failure of xo, failure of xo inhibition, failure patient, failure patient severity, failure patient severity index, failure patients, failure patients from italy, failure patients in addition, failure patients with devices, failure patients with respect, failure phenotypes, failure population, failure questionnaire, failure rats, failure readmission, failure readmission quality, failure readmission quality improvement, failure readmission quality improvement initiative, failure registry, failure research, failure risk, failure risk among patients, failure samples, failure scans, failure survey, failure survey in israel, failure therapy, failure treatment, failure treatment eras, failure trial, failure trials, failure via activation, failure visits, failure with preserved, failure with preserved ejection, failure with preserved ejection fraction, failure with therapy, failure with therapy refractory, failure-related, failure-related hospitalization, failure-related mortality, failure-related qol, familiar, familiar physician, families, family, family bromodomain, family bromodomain proteins, family member, fashion, faster, faster turnaround, faster turnaround times, fastest, fastest growing subclass, fat, fat distribution, fat free, fat free mass, fat loss, fat mass, fat mass index, fat ratio, fat-free, fat-free mass, fat-free mass index, fatal, fatal arrhythmia, fatal arrhythmia events, fatigue, fatty, fatty acids, favorable, favorable adverse, favorable adverse event, favorable adverse event profile, favorable changes, favorable effects, favorable outcome, favorable outcomes, favour, favour of apoptosis, fear, feasibility, feasibility study, feasible, feasible alternative, feasible in heart, feasible in heart failure, feasible in heart failure patients, feasible und, feature, features, features of heart, features of heart failure, february, feedback, feeding, feet, felt implantable cardioverter-defibrillator, felt implantable cardioverter-defibrillator deactivation, female, females, fes, fes group, fes program, fes warrants, fetal, fetal gene, fetal gene program, fever, fewer, fewer admissions, fewer admissions for individuals, fewer cardiac, fewer cardiac procedures, fewer cardioversions, fewer chf, fewer chf patients, fewer days, fewer depressive, fewer depressive symptoms, fewer st-segment-elevation, fewer st-segment-elevation mis, ffm, fiber, fiber shortening, fibrillation, fibrillation for stroke, fibrillation for stroke prevention, fibrillation for stroke prevention trial, fibrillation in patients, fibrosis, fibrosis of heart, fibrosis of heart failure, field, field of investigation, fifty-four, fifty-one, fifty-one percent, fifty-one percent of patients, fig, figure, file, filling, filling flow, filling flow volume, filling formalism, filling in patients, filling pressure, filling pressure in patients, filling pressure response, filling pressures, filling time, filtration, filtration rate, final, final achieved bb, final achieved bb dose, final data, final data analysis, final diagnosis, final evaluation, final multivariate, final multivariate models, financial, financial burden, financial costs, financial incentives, finding, findings, findings from heart, findings through briefing, findings through briefing reports, first, first acute, first acute myocardial, first acute myocardial infarction, first acute myocardial infarction in western australia, first diagnosis, first diagnosis of af, first hf, first hf hospitalization, first hospitalization, first month, first month after discharge, first research, first results, first results of studies, first time, first week, first wk, first-ever, first-ever mi, first-in-class, first-in-class angiotensin, first-in-class angiotensin receptor, first-in-class angiotensin receptor neprilysin, first-in-class angiotensin receptor neprilysin inhibitor, first-in-class angiotensin receptor neprilysin inhibitor in heart, first-in-class angiotensin receptor neprilysin inhibitor in heart failure, first-in-class inhibitor, first-in-man, first-in-man evidence, first-in-man experience, first-time, first-time diagnosis, first-time diagnosis of heart, first-time diagnosis of heart failure, fish, fistula, fit, fit indices, fit men, fitness, fixed ring, fixed ring size, fixed-rate, fixed-rate atrial, fixed-rate atrial pacing, flow, flow pump, flow reserve, flow reserve measurements, flow velocities, flow velocity, flow velocity over tissue, flow velocity over tissue doppler, flow volume, flow-mediated, flow-mediated dilatation, flow-mediated dilatation diameter, flow-mediated dilatation improvement, flow-mediated dilatation improvement by et, fluctuations, fluctuations in beat-to-beat, fluctuations in beat-to-beat qt, fluctuations in beat-to-beat qt intervals, fluid, fluid overload, fluid retention, fluorescence, fluorescence resonance, flutter, flux, flux analyzer, fm, focus, focus of research, focus of research investigations, follow, follow-up, follow-up after discharge, follow-up data, follow-up duration, follow-up echocardiograms, follow-up exercise, follow-up exercise capacity, follow-up levels, follow-up levels of paf, follow-up measurement, follow-up medication, follow-up medication lists, follow-up of heart, follow-up of heart failure, follow-up period, follow-up period in patients, follow-up tests, follow-up times, follow-up visits, follow-up visits as part, followed-up, fontan, fontan adults, fontan adults versus controls, fontan circulation, fontan circulation exhibit, fontan failure, fontan subjects, food, food-frequency, food-frequency questionnaires, force, form, form of heart, form of heart failure, formalism, forms, forms of nt-probnp, forty-one, forty-one patients, forty-six, forty-six patients, foster collaborative research, foster collaborative research initiatives, foundation, foundation of management, foundation working, foundation working group, four-week, four-week aerobic, four-week aerobic training, four-week aerobic training period, fpassive, fractal, fractal scaling, fractal scaling exponent, fraction, fraction development, fraction outcomes, fraction outcomes trial, fraction ≤, fractional, fractional area, fractional area change, fractional flow, fractional flow reserve, fractional flow reserve measurements, fractional shortening, fractions, fragment, fragmentation, fragments, fragments of nt-probnp, frail, frailty, frailty in heart, frailty in heart failure, frailty on hf, frailty on hf risk, frame, framework, framingham, framingham heart, framingham heart study, framingham heart study criteria, free, free mass, free wall, free wall cs, free wall cs during vvd, free wall cs during vvd variation, free wall rs, free-breathing, free-breathing pulse, free-breathing pulse sequence, frequency, frequency of administration, frequency of diabetes, frequency of diabetes mellitus, frequent, frequent comorbidities, frequent comorbidities in heart, frequent comorbidities in heart failure, frequently abnormal, fulfilling world, fulfilling world health, fulfilling world health organization, fulfilling world health organization criteria, full, full advantage, full length, full length nt-probnp, full length nt-probnp molecule, full medicare, full medicare coverage, full potential, full-length, fully magnetically levitated, fully magnetically levitated centrifugal-flow, fully magnetically levitated centrifugal-flow chronic, fully reversible, function, function among patients, function assessment, function clinic, function clinic at university, function clinic at university health, function clinic at university health network, function end, function end point, function evaluation, function in b-treated, function in children, function in hfpef, function in patients, function of baseline, function on body, function on body composition, functional, functional abnormalities, functional assessment, functional capacity, functional characterization, functional class, functional class ii, functional class iii, functional class iii hf, functional class iv, functional classification, functional decline, functional deficits, functional deterioration, functional efficacy, functional electrical, functional electrical stimulation, functional enrichment, functional enrichment analysis, functional etiology, functional etiology of mr, functional mitral, functional mitral stenosis, functional ms, functional properties, functional status, functioning, functions, fundamental, fundamental definitions, fundamental hypothesis, fundamental mechanism, furosemide, furosemide dose, futility, future, future ami, future ami mortality, future ami mortality rates, future expansion, future high, future hospital, future hospital mortality, future mortality, future perspectives, future prospective, future prospective experimental, future prospective experimental research, future studies, future trials, g proteins, g-protein, g-protein coupling, g-protein-coupled, g-protein-coupled receptor, g-protein-coupled receptors, gadolinium-chelate, gadolinium-chelate contrast, gadolinium-chelate contrast agent, gain, gain attention, gait, gait therapy, gaps, gas, gas analysis, gas analysis at baseline, gastrointestinal, gastrointestinal bleeding, gastrointestinal regions, gata4, gating, gating movement, gdmt, gdmt-treated, gdmt-treated nyha, gdmt-treated nyha functional, gdmt-treated nyha functional class, gdmt-treated nyha functional class iii, gdmt-treated nyha functional class iii hf, gem, gender, gender-matched, gender-matched control, gender-matched control subjects, gender-matched subjects, gene, gene control, gene double-knockout, gene expression, gene expression of bax, gene expression omnibus, gene expression profile, gene expression profiling, gene expression programme, gene expressions, gene expressions of bax, gene induction, gene program, gene programs, gene programs in heart, gene programs in heart failure, gene therapy, gene-targeted, general, general anaesthesia, general hospital, general linear, general linear models, general population, general populations, general use, general use of beta-blockers, generally higher, generate estimates, generate predicted outcomes, generating variants, generation, generation nt-probnp, generation nt-probnp assay, generator, genes, genes in hf, genetic, genetic susceptibility, genomic, genomic scale, genotype, genuine, genuine effect, geometry, germline, germline dna, gg, gg genotype, gill, gill index, gln27, global, global attenuation, global changes, global gene, global gene expression, global longitudinal, global longitudinal strain, global proteomics, global proteomics changes, glomerular, glomerular filtration, glomerular filtration rate, gls, glu27, glucocorticoid, glucocorticoid dosage, glucocorticoids, gluconeogenesis, glucose, glucose levels, glucose oxidation, glucose transporter, gly16, glycolysis, glycolysis rates, glycosylated region, goal, goal-directed, goal-directed lipid-lowering, goal-directed lipid-lowering therapy, good, good agreement, good diagnostic, good diagnostic performance, good evidence, good long-term, good long-term value, good model, good results, grade, gradient, gradient of hf, gradient of hf risk, grading, grading of recommendations, grading of recommendations assessment, grading system, grafting, grain, grain intake, great, great number, great number of studies, greater, greater antecedent, greater antecedent weight, greater antecedent weight loss, greater benefit, greater impact, greater impact on patients, greater in patients, greater in subjects, greater incidence, greater reduction, greater risk, greater risk of heart, greater risk of heart failure, greater self-reported, greater self-reported physical, greater self-reported physical activity, greatest, greatest difference, grip, grip strength, gross, gross income, gross morphological, gross morphological development, gross national, gross national income, gross national income per capita, grounded theory, group, group effects, group effects on hrqol, group ii, group iii, group iv, group of patients, group patients, group until day, groups, groups of rats, groups of samples, groups patients, groups validity, groups with heart, groups with heart failure, growing epidemic, growing population, growing subclass, growth, growth factor, growth factor beta-dependent yield, growth factor blockade, growth factor protein, growth patterns, gse9128, gtpase, guanosine, guanylate, guanylate cyclase, guidance, guide, guide health, guide health service, guide health service planning, guide treatment, guideline, guideline recommendations, guideline recommendations in heart, guideline recommendations in heart failure, guideline-directed, guideline-directed medical, guideline-directed medical therapy, guideline-heart, guideline-heart failure, guideline-heart failure registry, guideline-mandated, guideline-mandated usual, guideline-mandated usual care, guideline-recommended, guideline-recommended care, guideline-recommended drugs, guideline-recommended drugs for heart, guideline-recommended drugs for heart failure, guideline-recommended medications, guideline-recommended medications for patients, guideline-recommended medications to adults, guideline-recommended target, guideline-recommended target dose, guideline-recommended target doses, guideline-recommended treatment, guideline-recommended treatment for outpatients, guidelines, guidelines on evaluation, guidelines-heart, guidelines-heart failure, guiding exercise, guiding exercise rehabilitation, gut, h-dko, habc, habc battery, habc battery score, habc battery scores, haematopoietic, haematopoietic cell, haematopoietic cell transplantation, haemodynamic, haemodynamic assessment, haemodynamic outcomes, haemodynamic outcomes in patients, haemodynamic stress, half, half of patients, hall, hall walk, hall walk distance, hallmark, hallmark feature, hallmark of type, halt disease, halt disease progression, halts heart, halts heart failure, hand, hand grip, hand grip strength, hand-searching, hand-searching relevant articles, hand2, hand2-dependent, handling, haplotype, haplotype status, harms, harms of treatments, hart, hazard, hazard analyses, hazard models, hazard models for time, hazard ratio, hazard ratio for death, hazard ratios, hazard ratios for variables, hazards, hazards models, hazards regression, hct, hdl, hdl function, hdl particles, hdl-bound, hdl-bound malondialdehyde, hdl-induced, hdl-mediated, hdl-mediated protective, hdl-mediated protective effects, hdl-mediated vascular, hdl-mediated vascular effects, health, health abc, health abc hf, health abc hf model, health abc hf risk, health abc hf risk model, health abc short physical, health abc short physical performance, health abc short physical performance battery, health behaviors, health benefits, health buddy, health buddy program, health care, health care expenditures, health care expenditures of patients, health care providers, health care system, health care systems, health center, health characteristics, health data, health initiative, health initiative participants, health insurance, health insurance board, health insurance board databases, health interventions, health network, health organization, health organization criteria, health organization website, health outcomes, health per capita, health planning, health problem, health service, health service planning, health service provision, health status, health status in patients, health system, health system data, health system data partners, health systems, health-care, health-care budget, health-related, health-related quality, health-related quality of life, health-related quality-of-life, healthcare, healthcare common procedure, healthcare common procedure coding, healthcare common procedure coding system, healthcare common procedure coding system codes, healthcare programmes, healthcare staff, healthcare utilization, healthcare utilization effects, healthstar, healthy, healthy age-matched, healthy cardiomyocytes, healthy control, healthy control animals, healthy controls, healthy heart, healthy heart muscle, healthy heart muscle cells, healthy individuals, healthy volunteers, healthy volunteers--a, healthy volunteers--a pilot, healthy volunteers--a pilot study, heart, heart association, heart association class, heart association class ii, heart association class ii to iv hf, heart association class iii, heart association class iii heart, heart association class iii heart failure, heart association classes, heart association classification, heart association functional class, heart association guidelines, heart association guidelines on evaluation, heart beat, heart block, heart circulation, heart circulatory failure, heart dilatation, heart disease, heart disease by angiotensin, heart disease by angiotensin ii, heart disease by angiotensin ii infusion, heart disease in patients, heart failure, heart failure adherence, heart failure admission, heart failure admissions, heart failure after cabg, heart failure among new users, heart failure assessment, heart failure assessment of reduction, heart failure at rest, heart failure care, heart failure center, heart failure clinic, heart failure clinic outpatients, heart failure cost-effectiveness, heart failure cost-effectiveness model, heart failure database, heart failure development, heart failure discharges, heart failure disease, heart failure disease management, heart failure disease management programs, heart failure efficacy, heart failure exacerbation, heart failure guidelines, heart failure home, heart failure hospitalization, heart failure hospitalizations, heart failure hospitalizations in patients, heart failure in children, heart failure in humans, heart failure in hungary, heart failure in latin, heart failure in latin america, heart failure in mice, heart failure in patients, heart failure in pigs, heart failure in rats, heart failure in survivors, heart failure index, heart failure index version, heart failure medicines, heart failure mice, heart failure mice model, heart failure model, heart failure model scores, heart failure mortality, heart failure mortality in men, heart failure myocardial tissue, heart failure nurse, heart failure nurse practitioner, heart failure nurses, heart failure patient, heart failure patient severity, heart failure patient severity index, heart failure patients, heart failure patients from italy, heart failure patients in addition, heart failure patients with devices, heart failure patients with respect, heart failure phenotypes, heart failure population, heart failure questionnaire, heart failure rats, heart failure readmission, heart failure readmission quality, heart failure readmission quality improvement, heart failure readmission quality improvement initiative, heart failure research, heart failure risk, heart failure risk among patients, heart failure samples, heart failure scans, heart failure survey, heart failure survey in israel, heart failure therapy, heart failure treatment, heart failure treatment eras, heart failure trial, heart failure trials, heart failure via activation, heart failure visits, heart failure with preserved, heart failure with preserved ejection, heart failure with preserved ejection fraction, heart failure with therapy, heart failure with therapy refractory, heart failure-related hospitalization, heart failure-related mortality, heart failure-related qol, heart foundation, heart foundation working, heart foundation working group, heart function, heart function clinic, heart function clinic at university, heart function clinic at university health, heart function clinic at university health network, heart iron, heart lesions, heart magnetic resonance, heart magnetic resonance imaging, heart magnetic resonance imaging on chelation, heart magnetic resonance imaging on chelation choices, heart mass, heart muscle, heart muscle cells, heart pathology, heart rate, heart rate during exercise, heart rate reduction, heart rate reduction with ivabradine, heart rate response, heart rate variability, heart rate variability in risk, heart rate variability in risk stratification, heart rate variation, heart sound, heart study, heart study criteria, heart team, heart transplant, heart transplant recipients, heart transplantation, heart transplantations, heart twist, heart-specific, heartmate, heartmate ii, heartmate ii exchange, heartmate ii implantation, heartmate ii insertion, heartmate ii lvad, heartmate ii lvads, hearts, hearts of ans, hearts of ans mice, hearts of fish, hearts of tta, heartware, heartware intl, heartware patients, heavy, heavy chain, hek, helix-loop-helix, help patients, helpful, hemocompatibility, hemodynamic, hemodynamic alterations, hemodynamic assessments, hemodynamic disorder, hemodynamic features, hemodynamic perturbations, hemodynamic phenotype, hemodynamic status, hemodynamically distinct, hemodynamically stable, hemodynamically unstable, hemodynamics, hemoglobin, hemoglobin levels, hemoglobin threshold, hemolysis, hemolysis events, hemostasis, hemostasis in patients, henry, henry et, henry et al, hepatic, hepatic function, herbal, herbal medicine, hereditary, heterochromatic, heterochromatic chromatin, heterogeneity, heterogeneous, heterogeneous group, heterogeneous group of patients, heterogeneous region, heterogeneous region with hf, heterogeneous region with hf risk, heterogeneous region with hf risk factors, heterogenous, heterogenous improvement, heterogenous improvement in ejection, heterogenous improvement in ejection fraction, hf, hf admissions, hf after mi, hf care, hf cases, hf clinic, hf clinic outpatients, hf cohort, hf concurrent, hf concurrent with ami, hf concurrent with ami admission, hf cpgs, hf deaths, hf diagnosis, hf during hospitalization, hf epidemiology, hf evolution, hf guidelines, hf hospital, hf hospital admissions, hf hospitalisations, hf hospitalization, hf hospitalization rates, hf hospitalizations, hf in hhd, hf in infancy, hf in la, hf in non-aas, hf in patients, hf in rats, hf index, hf model, hf model of hhd, hf mortality, hf mortality in fit, hf mortality risk, hf mortality risk in men, hf pathogenesis, hf pathophysiology, hf patient, hf patient plasma, hf patient plasma by use, hf patients, hf prediction, hf prediction model, hf progression, hf rats, hf readmissions, hf readmissions in hfref, hf registry, hf remodeling, hf remodeling aspects, hf resources, hf resources within health, hf resources within health systems, hf risk, hf risk factors, hf risk model, hf risk prediction, hf studies, hf symptom, hf symptoms, hf tissue, hf tissue samples, hf tissues, hf trials, hf under drug, hf under drug treatment, hf units, hf volume, hf volume management, hf-induced, hf-induced remodeling aspects, hf-ref, hf-related, hf-related cachexia, hf-related morbidity, hfe, hfpef, hfpef animal, hfpef animal models, hfpef patients, hfpef population, hfpsi, hfpsi model, hfpsi use, hfref, hfref therapy, hfref versus hfpef, hg, hgb, hgb level, hhd, hhf, hhf with saxagliptin, hierarchical, hierarchical regression, hierarchical regression models, high, high barriers, high bnp, high bnp group, high bnp levels, high bnp levels in patients, high clinical, high confidence, high confidence in estimates, high crf, high crf categories, high incidence, high internal, high internal consistency, high internal consistency among patients, high morbidity, high mortality, high muscle, high muscle strip, high pasp, high risk, high risk for hyperkalemia, high risk of hyperkalemia, high sensitivity, high-cost, high-cost medicare, high-cost medicare beneficiaries, high-cost medicare fee-for-service beneficiaries, high-density, high-density lipoprotein, high-density lipoprotein functional, high-density lipoprotein functional properties, high-dose, high-dose bb, high-fat, high-fat diet, high-frequency, high-quality, high-quality work, high-risk, high-risk group, high-risk patient, high-risk patient with heart, high-risk patient with heart failure, high-risk patients, high-risk subgroups, high-sensitivity, high-sensitivity assay, high-strength, high-strength evidence, high-volume, high-volume ed, high-volume ed cases, high-volume eds, high-volume physicians, higher, higher activities, higher activities of paf-ah, higher admission, higher amount, higher amount of malondialdehyde, higher baseline, higher baseline crf, higher baseline sdqt-to-sdrr ratio, higher bb, higher bb doses, higher btes, higher dash, higher dash diet, higher dash diet scores, higher diastolic, higher diastolic blood, higher diastolic blood pressure, higher doses, higher eo-cfus, higher exercise, higher exercise time, higher expenditures, higher fat, higher fat mass, higher frequency, higher frequency of diabetes, higher frequency of diabetes mellitus, higher functional, higher functional capacity, higher furosemide, higher furosemide dose, higher heart, higher heart rate, higher hemoglobin, higher hemoglobin levels, higher hospitalization, higher hospitalization rates, higher in females, higher in la, higher levels, higher metabolic, higher metabolic exercise, higher mortality, higher oxygen, higher oxygen flow, higher pasp, higher phosphorylation, higher psss, higher rate, higher rate of rehospitalization, higher rates, higher rates of hyperkalemia, higher readmission, higher readmission rates, higher risk, higher risk for hf, higher risk for hhf, higher risk of death, higher risks, higher scores, higher serum, higher serum levels, higher serum levels of brain, higher serum levels of creatinine, higher stroke, higher stroke volume, higher than ecct, higher transfusion, higher-than-expected, higher-than-expected rates, highest, highest cardiovascular, highest cardiovascular event, highest cardiovascular event rate, highest cumulative, highest cumulative hazard, highest drs, highest drs deciles, highest quartile, highest quartile of e, highly dynamic, highly effective, highly effective anti-neoplastic, highly heterogeneous, highly predictive, highly relevant, hipsc-cms, histologic, histologic analysis, histological, histological analysis, histone, histone deacetylases, historical, historical data, history, history of angina, history of hf, history of hypertension, hm, hm ii, hno, hno donor, hnorm, hnorm group, hnorm groups, hnorm subjects, hoc, hoc analysis, hogan, hold promise, holosystolic, holosystolic murmur, home, home environment, home telemonitoring, homeostasis, homogeneous, homogeneous sandwich, homogeneous sandwich alphalisa, homozygous, hope, hopeful, hospital, hospital admission, hospital admissions, hospital anxiety, hospital between january, hospital characteristics, hospital claims, hospital clustering, hospital compare, hospital days, hospital days for participants, hospital discharge, hospital discharge in patients, hospital facilities, hospital for heart, hospital for heart failure, hospital for hf, hospital length, hospital length of stay, hospital longitudinal change, hospital mortality, hospital performance, hospital quality, hospital quality improvement, hospital quality improvement initiative, hospital quality of care, hospital quality of care outcomes, hospital rankings, hospital rates, hospital rates for hf, hospital rates for hf patients, hospital readmission, hospital readmission reduction, hospital readmission reduction program, hospital stay, hospital volume, hospital volume groups, hospitalisation, hospitalisation for heart, hospitalisation for heart failure, hospitalisations, hospitalisations for heart, hospitalisations for heart failure, hospitalisations for tm, hospitalisations for tm interventions, hospitalization, hospitalization for heart, hospitalization for heart failure, hospitalization for hf, hospitalization for hyperkalemia, hospitalization for wrf, hospitalization in heart, hospitalization in heart failure, hospitalization in heart failure clinic, hospitalization in heart failure clinic outpatients, hospitalization in hf, hospitalization in hf clinic, hospitalization in hf clinic outpatients, hospitalization rates, hospitalizations, hospitalizations for patients, hospitalizations in patients, hospitalized, hospitalized heart, hospitalized heart failure, hospitalized heart failure among new users, hospitalized hf, hospitalized older adults, hospitalized patients, hospitals, hospitals in new jersey, hours, hours of admission, hretn, hrqol, hrqol from exercise, hrqol from exercise training, hrv, hscrp, human, human embryonic kidney, human failing hearts, human heart, human heart failure, human hf, human hf tissues, human induced, human induced pluripotent, human induced pluripotent stem, human monocytes, human myocardial, human myocardial tissue, human rad, human resistin, human resistin in heart, human resistin in heart failure, human retn, human retn gene, human ventricular, human ventricular systolic, human ventricular systolic hf, human ventricular systolic hf tissue, human ventricular systolic hf tissue samples, human-to-human, human-to-human contact, humanized male mice, humanized mouse, humanized mouse model, humans, humoral, humoral stimuli, hungary, hvad, hvad devices, hybrid, hybrid system, hydrolysis, hydrolytic, hydrolytic activity, hyperacetylation, hyperinsulinemia, hyperkalemia, hyperlipidaemia, hypertension, hypertension diet, hypertension medication, hypertension patients, hypertension with vasodilators, hypertensive, hypertensive heart, hypertensive heart disease, hypertensive heart disease by angiotensin, hypertensive heart disease by angiotensin ii, hypertensive heart disease by angiotensin ii infusion, hypertensive heart failure, hypertensive hfpef, hypertensive lv, hypertensive lv dysfunction, hypertrophic, hypertrophic response, hypertrophic responses, hypertrophied, hypertrophied heart, hypertrophy, hypertrophy after transverse, hypertrophy antecedent, hypertrophy antecedent to heart, hypertrophy antecedent to heart failure, hypertrophy in heart, hypertrophy in heart failure, hypertrophy in tta, hypertrophy of cardiomyocytes, hypertrophy secondary to pressure-overload, hypertrophy to heart, hypertrophy to heart failure, hypertrophy to hf, hypo-response, hypoalbuminemia, hypoalbuminemia before surgery, hypokalemia, hypokalemia with spironolactone, hyponatremia, hypophosphorylation, hypotension, hypothermic, hypothermic circulatory, hypothermic circulatory arrest, hypotheses, hypothesis, hypothesis-generating, hypothesis-generating findings, hypothetical, hypothetical programs, hypoxia, icc, icc values, icd, icd patients, icd shocks, icd-hf, icd-hf patients, icds, icu, icu admission, icu mortality, idealized, idealized lv, identical, identification, identified biomedical reasons, identified patients, identifies, identifies patients, identify benefit, identify chromatin-associated proteins, identify clinical variables, identify factors, identify implementation, identify implementation strategies, identify patients, identify risk, identify risk factors, identifying cad, identifying death, idiopathic, idiopathic-dilated, ie among study, ie among study patients, ie in patients, ie risk, ies, ies among crt-d, ies among crt-d recipients, if-channel, if-channel inhibition, ii exchange, ii fontan, ii fontan adults, ii heart, ii heart failure, ii implantation, ii infusion, ii infusion mouse, ii infusion mouse model, ii insertion, ii lvad, ii lvads, ii to iv hf, ii-iii, iii, iii chronic heart, iii chronic heart failure, iii heart, iii heart failure, iii hf, iii to class, iii to class ii, iiib, iiib symptoms, iii–iv, il6, ill-defined, imaging, imaging on chelation, imaging on chelation choices, imaging techniques, imbalance, immunoassays, immunoblotting, immunodetection, immunodetection of nt-probnp, immunohistochemistry, immunoprecipitation, immunoreactive, immunoreactive nt-probnp, impact, impact of carvedilol, impact of ejection, impact of ejection fraction, impact of et, impact of frailty, impact of heart, impact of implementation, impact of implementation strategies, impact of normalization, impact of physician, impact of physician continuity, impact of qrs, impact of qrs morphology, impact of rm, impact of rv function, impact on hospital, impact on hospital performance, impact on patients, impact pay-for-performance, impact prescribing, impaired, impaired angiogenesis, impaired cardiac, impaired cardiac energy, impaired cardiac energy metabolism, impaired cardiac energy metabolism gene, impaired cardiac energy metabolism gene expression, impaired cardiac metabolic, impaired cardiac metabolic gene, impaired cardiac metabolic gene expression, impaired in fontan, impaired in fontan adults, impaired lv, impaired lv relaxation, impaired right ventricular, impaired right ventricular pump, impaired right ventricular pump function, impaired systolic, impaired systolic function, impairment, impairment at hospitalization, implant, implantable, implantable cardiac, implantable cardiac arrhythmia, implantable cardiac arrhythmia devices, implantable cardiac defibrillator, implantable cardioverter, implantable cardioverter defibrillator-crt, implantable cardioverter defibrillator-crt in patients, implantable cardioverter defibrillators, implantable cardioverter-defibrillator, implantable cardioverter-defibrillator deactivation, implantable cardioverter-defibrillator deactivation discussions, implantable cardioverter-defibrillator deactivation preferences, implantable cardioverter-defibrillator device, implantable cardioverter-defibrillator shocks, implantable cardioverter-defibrillator shocks at end, implantable cardioverter-defibrillator therapy, implantable cardioverter-defibrillators, implantable defibrillators, implantation, implantation strategies, implantation trial-cardiac, implantation trial-cardiac resynchronization, implantation trial-cardiac resynchronization therapy, implantation with cardiac, implantation with cardiac resynchronization, implantation with cardiac resynchronization therapy, implantations, implanted cardioverter-defibrillator device, implanted monitoring, implanted monitoring devices, implants, implement exercise, implement exercise training, implement exercise training therapy, implementation, implementation interventions, implementation issues, implementation of medicare, implementation strategies, implicate, implicate resistin, implicates epigenetic readers, implications, implications of biomarkers, improve cardiac function, improve cardiac functions, improve clinical symptoms, improve health, improve health outcomes, improve hf, improve hf risk, improve hf risk prediction, improve management, improve mortality, improve mortality rates, improve myocardial perfusion, improve outcomes, improve patient safety, improve physician, improve physician adherence, improve prognosis, improve quality, improve short-term mortality, improve short-term mortality rates, improve symptoms, improved, improved cardiac function, improved clinical outcomes, improved clinical status, improved discrimination, improved efficiency, improved functional, improved functional capacity, improved hdl, improved hdl function, improved health-related quality-of-life, improved label-free, improved label-free shotgun, improved label-free shotgun proteomics, improved label-free shotgun proteomics approach, improved mitochondrial, improved mitochondrial structure, improved outcomes, improved outcomes among patients, improved quality, improved renal function, improved short-term, improved survival, improved tac, improved time, improved ventricular-arterial, improved ventricular-arterial coupling, improvement, improvement after device, improvement after device implantation, improvement between baseline, improvement by et, improvement database, improvement in contractile, improvement in contractile function, improvement in egfr, improvement in ejection, improvement in ejection fraction, improvement in outcome, improvement in outcome ratings, improvement in peak, improvement in peak work, improvement in peak work rate, improvement in survival, improvement initiative, improvement of cardiac, improvements, improvements for patients, improvements from baseline, improvements in functioning, improvements in shuttle, improvements in shuttle walk, improvements in shuttle walk test, improves autonomic balance, improves cardiac output, improves cardiomyocyte bioenergetics, improves co, improves diastolic, improves diastolic function, improves endothelial function, improves exercise, improves exercise capacity, improves functional status, improves lv, improves lv contractile, improves lv contractile function, improves outcomes, improves prognostic resolution, improves skm, improves symptoms, improves tac, improving functional capacity, improving hf, improving hf prediction, improving muscle, improving muscle function, improving outcomes, improving patient outcomes, improving physician, improving physician adherence, improving processes, improving quality, improving survival, improving survival rates, improving uptake, in-hospital, in-hospital adverse, in-hospital adverse events, in-trial, in-trial resource, in-trial resource utilization, inability, inactive, inappropriate, inappropriate atp, inappropriate icd shocks, inappropriate implantable, inappropriate implantable cardioverter-defibrillator, inappropriate implantable cardioverter-defibrillator therapy, inappropriate shock, inappropriate shock therapy, inappropriate therapy, inappropriate therapy in heart, inappropriate therapy in heart failure, inappropriate therapy in heart failure patients, incentives, incessant, incessant ventricular, incessant ventricular tachycardia, incessant ventricular tachycardia storm, incidence, incidence in mt, incidence of hf, incidence of hyperkalemia, incidence of pump, incidence of pump dysfunction, incident, incident cardiovascular events, incident cvd, incident hf, incident hf cases, incident systolic heart, incident systolic heart failure, include clinical outcomes, include cognitive function, include information, include proportion, include prospective studies, include recommendations, included ambulatory icd, included ambulatory icd patients, included blood, included blood urea, included blood urea nitrogen, included body, included body mass, included body mass index, included descriptive statistics, included diabetes, included home, included home telemonitoring, included hospitals, included listing, included listing criteria, included markers, included mortality, included patients, included previous revascularization, included reoperation, includes age, including anticoagulation, including calcium-sensitizing agents, including cancer, including cardiac hypertrophy, including death, including fat, including fewer st-segment-elevation, including fewer st-segment-elevation mis, including heart, including heart failure, including hypertension, including implanted monitoring, including implanted monitoring devices, including intravenous inotropes, including lower risk, including medline, including mortality, including nuclear factor, including quality, including relax-ahf, including stress, including stress echocardiography, inclusion, inclusion criteria, income, income per capita, inconsistent, inconsistent results, incorporating nursing-sensitive outcome, incorporating nursing-sensitive outcome measures, increase, increase during exercise, increase in camp, increase in camp hydrolysis, increase in e, increase in ejection, increase in ejection fraction, increase in exercise, increase in exercise capacity, increase in heart, increase in heart rate, increase in incidence, increase in life, increase in life expectancy, increase in lung, increase in lung weight, increase in lv, increase in patients, increase in peak, increase in peak oxygen, increase in peak oxygen uptake, increase long-term survival, increase long-term survival rates, increase mortality, increase rate, increase rehospitalization, increase rehospitalization of medicare, increased, increased atp, increased atp demand, increased attention, increased body, increased body mass, increased body mass index, increased calcineurin, increased cardiac angiogenesis, increased cardiac mrna, increased cardiac mrna levels, increased cardiac vegf, increased cardiac vegf expression, increased contractility, increased energy, increased energy expenditure, increased exercise, increased exercise capacity, increased functional capacity, increased heart, increased heart mass, increased hf, increased hf hospitalization, increased increase, increased increase rate, increased level, increased levels, increased lung, increased lung weight, increased lv, increased lv compliance, increased lv diastolic, increased mortality, increased mrna level, increased parasympathetic activity, increased peak, increased prevalence, increased qtv, increased right grip, increased right grip strength, increased risk, increased sarcomere shortening, increased sdqt, increased sympathetic tone, increased systolic blood, increased systolic blood pressure, increased vagal, increased workload, increases, increases alternative mrna, increases alternative mrna splicing, increases in incidence, increases in lung, increases in lung weight, increasing body, increasing btes, increasing ejection, increasing ejection fraction, increasing evidence, increasing evidence points, increasing number, increasing population, increasing refill, increasing refill compliance, incremental, incremental cost-effectiveness, incremental cost-effectiveness ratios, incremental cost-effectiveness ratios from user, incremental cost-effectiveness ratios from user inputs, incremental shuttle, incremental shuttle walk, incremental shuttle walk test, incubation, incubation of ec, independent, independent association, independent association between spironolactone, independent association between spironolactone use, independent correlates, independent correlates of increase, independent hypotheses, independent of age, independent predictor, independent predictors, independent predictors of mortality, independent prognostic, independent prognostic markers, independent prognostic role, independent prognostic role in hf, independent risk, independent risk factor, indeterminable, indeterminable anaerobic, indeterminable anaerobic threshold, indeterminable anaerobic threshold in heart, indeterminable anaerobic threshold in heart failure, index, index admission, index ami, index beat, index beat method, index beat method for cv, index beat method for cv events, index categories, index ed, index ed visit, index hf, index hf hospitalization, index levels, index of qtv, index score, index score value, index strata, index version, index ≤, indication, indication for ms, indications, indications for lvas, indications for lvas support, indicative, indicative for surgery, indicator, indicator in heart, indicator in heart failure, indicator in patients, indicators, indices, indistinct, individual, individual component, individual measures, individual quality, individual quality measures, individual scales, individualized, individualized approaches, individualized assessment, individuals, induce heart, induce heart failure, induced, induced heart, induced heart disease, induced myocardial infarction, induced pluripotent, induced pluripotent stem, induced recovery, inducible, inducible myocardial, inducible myocardial ischemia, inducing hyperkalemia, induction, induction of hretn, induction of serum, induction of serum resistin, induction of serum resistin levels, industrial, industrial areas, ineligible, ineligible patients, infancy, infarct, infarct size, infarcted animals, infarcted hearts, infarcted left ventricle, infarcted rats, infarction, infarction heart, infarction heart failure, infarction heart failure efficacy, infarction heart failure patients, infarction in western australia, infarction patients, infarction patients with heart, infarction patients with heart failure, infarction-both, infarction-related, infarction-related refractory, infection, inferior, inferior hospitals, inferior vena, inferior vena cava, inflammation, inflammation-stimulated, inflammation-stimulated resistin, inflammation-stimulated resistin levels, inflammatory, inflammatory abdominal, inflammatory abdominal problems, inflammatory biomarkers, inflammatory markers, inflammatory state, inflammatory stimuli, inflow, inflow velocity, influence, influence adherence, influence medical resource, influence medical resource use, influences, influences cardiac hypertrophic response, influences efficacy, influences outcomes, influences patient outcomes, influx, influx via l-type, information, infrastructure, infrequent, infusion, infusion mouse, infusion mouse model, infusions, infusions in rats, ingenuity, ingenuity pathway, ingenuity pathway analysis, inhibit cardiac l-type, inhibit cardiac l-type channel, inhibit cardiac l-type channel activity, inhibit l-type, inhibiting tgf-β receptor, inhibiting tgf-β receptor type, inhibition, inhibition by rgk, inhibition by rgk proteins, inhibition of avp, inhibition of l-type, inhibition of protein, inhibition of protein kinase, inhibition preserves, inhibitor, inhibitor in heart, inhibitor in heart failure, inhibitor ivabradine, inhibitor ivabradine trial, inhibitor prodrug, inhibitor pyridostigmine, inhibitors, inhibitors in heart, inhibitors in heart failure, inhibitory, inhibitory actions, inhibitory actions of rad, inhibits l-type, inhibits l-type currents, inhospital, inhospital mortality, inhospital outcomes, initial, initial approach, initial diagnosis, initial diagnosis of af, initial functional, initial functional class, initial results, initial safety, initiated spironolactone, initiated therapy, initiation, initiation of therapy, initiative, initiative participants, initiatives, injections, injections in patients, injury, injury during spironolactone, injury during spironolactone use, innovation, inoperable, inoperable chronic, inoperable chronic thromboembolic, inotrope-dependent, inotropes, inotropic, inotropic effect, inpatient, inpatient admissions, inpatient admissions from baseline, inpatient data, inpatient medical, inpatient medical conditions, inpatient records, inpatient records of patients, inpatient registry, inpatient use, inputs, inroads, insertion, insight, insight into mechanisms, insights, insights from heart, insights from heart failure, insignificant, insignificant ms, instability, instability in patients, instance, institute, institute evidence, institute evidence based, institute evidence based practice, institution, institutional, institutional experience, institutions, instrumented new zealand, instrumented new zealand white, instrumented new zealand white rabbits, insufficiency, insulin, insulin action, insulin action through activation, insulin exposure, insulin products, insulin receptor, insulin resistance, insulin-resistance, insulin-signaling, insulin-signaling components, insulin-stimulated, insulin-stimulated rates, insulin-stimulated rates of glycolysis, insurance, insurance board, insurance board databases, insurance status, intact, intact hearts, intake, integral, integrate data, integrated discrimination, integrated discrimination improvement, integrated dynamic resistance, integrated dynamic resistance training, intensity, intensive, intensive care, intensive care unit, intensive transitions, intensive transitions of care, intensive transitions of care program, intention-to-treat, intention-to-treat principle, interaction, interaction between race, interaction by ef, interaction effect, interaction term, interaction term analysis, interaction terms, interaction with exercise, interaction with exercise training, interaction with lvef, interactions, interactions with exercise, interactions with exercise training, interactors, interagency, interagency registry, interatrial, interatrial shunt, interatrial shunting, interatrial shunting for treatment, interatrial shunting in patients, interconnected, interconnected molecular, interconnected molecular pathways, interest, interesting, interesting therapeutic, interesting therapeutic concepts, interface, interleukin, interleukin receptor, interleukin receptor family, interleukin receptor family member, intermacs, intermediate, intermediate care, intermediate frail, intermediate frailty, intermediate metabolism, intermediate odds, intermediate odds ratios, intermediate outcomes, intermuscular, intermuscular fat, intermuscular fat ratio, internal, internal consistency, internal consistency among patients, internal diameter, internal reliability, international, international classification, international classification of diseases, international guidelines, international right, international right heart, international right heart foundation, international right heart foundation working, international right heart foundation working group, internists, interplay, interpretation, interquartile, interquartile range, interruption, interval, interval from consultation, interval from transplantation, interval oscillations, intervals, intervention, intervention compliance, intervention on adherence, intervention post, intervention post study, interventions, interventions in heart, interventions in heart failure, interventions in heart failure cost-effectiveness, interventions in heart failure cost-effectiveness model, interventions in heart failure patients, interventricular, interventricular delay, interventricular septum, interventricular septum biopsies, interview, interview data, interviews, intestinal, intestinal barrier, intestinal dysfunction, intestinal morphology, intima-media, intima-media thickness, intl, intolerance, intolerance in heart, intolerance in heart failure, intracellular, intracellular antiadrenergic, intracellular antiadrenergic therapeutic strategy in hf, intraclass, intraclass correlation, intraclass correlation coefficient, intramuscular, intramuscular testosterone, intramuscular testosterone supplementation, intravenous, intravenous atropine, intravenous bolus, intravenous bolus of metoprolol, intravenous inotropes, intravenous iron, intravenous metoprolol, intriguingly, intrinsic, intrinsic left, intrinsic left ventricular, intrinsic left ventricular dysfunction, introduced drug, introduction, intubation, intubation rates, intubations, invasive, invasive alternatives, invasive haemodynamic, invasive haemodynamic assessment, invasive hemodynamic, invasive hemodynamic assessments, inventory, inverse, inverse association, inverse association with mediterranean, inverse association with mediterranean diet, inverse association with mediterranean diet scores, inverse correlation, investigating hf-related cachexia, investigating outcomes, investigation, investigation of apoptosis, investigations, investigations at study, investigations at study enrollment, involve perturbed bone, involved single parameters, involvement, involves cardiac hypertrophy, involves changes, involves failure, involving families, involving ventricular assist, involving ventricular assist devices, involving young adults, ion, ion channelopathies, iron, iron deficiency, iron deficiency in adult, iron deficiency in adult patients, iron homeostasis, iron use, iron-deficient, iron-deficient adult, iron-deficient adult patients, iron-deficient adult patients with heart, iron-deficient adult patients with heart disease, irs1, irs2, irvine, ischaemia, ischemia, ischemia after bottleneck, ischemia after bottleneck stenting, ischemic, ischemic cardiomyopathy, ischemic cerebrovascular, ischemic cerebrovascular events, ischemic conditioning, ischemic conditioning for patients, ischemic etiology, ischemic events, ischemic events in patients, ischemic heart, ischemic heart failure, ischemic heart failure samples, ischemic hf, ischemic hf pathogenesis, ischemic mitral, ischemic mitral regurgitation, ischemic mr, ischemic mr with lv, ischemic mr with lv dilatation, ischemic right, ischemic right heart, ischemic right heart failure, ischemic samples, ischemic-hypertensive, ischemic-hypertensive cardiomyiopathy, isoelectric, isoenzymes, isoforms, isolated, isolated cabg, isolated cardiomyocytes, isolated coronary, isolated coronary artery, isolated coronary artery bypass, isolated coronary artery bypass grafting, isolated heart, isolated heart rate, isolated heart transplant, isolated heartmate, isolated heartmate ii, isolated heartmate ii lvad, isolated lvad, isolated myoctyes, isolated pump, isolated pump replacement, isolated working, isolated working hearts, isoprenaline, isoprenaline infusion, isoproterenol, israel, issues, italy, iv heart, iv heart failure, iv hf, ivabradine, ivabradine group, ivabradine on exercise, ivabradine on exercise capacity, ivabradine trial, ivabradine-treated, ivabradine-treated patients, ivc, ivc occlusion, january, japan, japanese, japanese heart, japanese heart failure, japanese heart failure patients, jehovah, jersey, joanna, joanna briggs, joanna briggs institute, joanna briggs institute evidence, joanna briggs institute evidence based, joanna briggs institute evidence based practice, joint, joint associations, joint associations among cardiorespiratory, joint associations among cardiorespiratory fitness, joint effect, jq1, jugular, jugular venous, jugular venous pressure, july, july to december, june, ka, ka renal chloride, ka renal chloride channel, ka renal chloride channel gene, kaiser, kaiser permanente, kaiser permanente northern, kaiser permanente northern california, kansas, kansas city, kansas city cardiomyopathy questionnaire, kansas city cardiomyopathy questionnaire in patients, kansas city cardiomyopathy questionnaire summary, kaplan-meier, kaplan-meier analyses, kaplan-meier curves, kaplan-meier curves for death, kappa, kappa coefficient, kappa coefficients, kcal, kccq, kccq category, kccq category among patients, kccq domains, kccq overall summary, kccq overall summary scores, kccq scales, kccq summary, kccq summary scores, kcl-ki, kcl-ki treatment, kd, key, key adverse, key adverse events, key biosynthetic, key biosynthetic enzymes, key genes, key health, key health outcomes, key regulator, key regulator of cytoskeletal, key regulator of cytoskeletal actin, key regulator of cytoskeletal actin dynamics, key role, key secondary, key secondary outcomes, kg body, kg body mass, kidney, kidney disease, kidney disease epidemiology, kidney disease epidemiology collaboration, kidney disease epidemiology collaboration equation, kidney failure, kidney index, kidney index score, kidney index score value, kidney infection, kidney injury, kidney injury during spironolactone, kidney injury during spironolactone use, killip, killip class, kilogram, kinase, kinase activity, kinase r-like, kinase r-like er kinase, kinase-2, kinases, kir, knockdown, knockdown of nucleolin, knowledge, l-dko, l-dko mice, l-type, l-type channel, l-type channel activity, l-type channel inhibition, l-type channel inhibition by rgk, l-type channel inhibition by rgk proteins, l-type channel isoforms, l-type channel-dependent processes, l-type currents, la countries, label-free, label-free shotgun, label-free shotgun proteomics, label-free shotgun proteomics approach, lability, laboratory, laboratory characteristics, laboratory report, laboratory report model, laboratory variables, lack, lack of achievement, lack of benefit, lack of correlation, lack of hypertension, lack of improvement, lacking murine, lacking murine resistin, lacking nucleolin, lactate, lad, lad model, lad models, lancet, language, language on anemia, large, large animal, large animal model, large cohort, large cohort study, large idiopathic, large limits, large limits of agreement, large outcomes, large outcomes trial, large outcomes trial of heart, large outcomes trial of heart failure, large phase, large registry, large study, large study sample, large trial, large trials, large-scale, large-scale clinical, large-scale clinical trial, large-scale prospective, large-scale prospective randomized, large-scale prospective randomized multicenter, large-scale prospective randomized multicenter trial, large-scale prospective randomized multicenter trial paradigm-hf, large-scale randomised, large-scale randomised studies, larger, larger fluctuations, larger fluctuations in beat-to-beat, larger fluctuations in beat-to-beat qt, larger fluctuations in beat-to-beat qt intervals, larger randomized control, larger randomized control studies, larger studies, largest, largest increases, largest increases in incidence, largest series, largest series of acs, largest series of acs problems, late-activated, late-activated lateral, late-activated lateral wall, late-onset, late-onset hf, lateral, lateral wall, latin, latin america, lbbb, lc-ms, lcx, lcx model, ldl-cholesterol, leaders, leaflet, leaflet configurations, leaflet motion, leaflet motions, leaflet opening, leaflet repair, leaflet resection, lean, lean body, lean body mass, lean body mass ratio, lean mass, lean mass index, lean mass quantification, left, left anterior descending, left atrial, left atrial area, left atrial pressure, left atrium, left bundle, left bundle branch, left bundle branch block, left bundle branch block pattern, left bundle branch block type, left bundle-branch block, left heart, left heart twist, left main, left pulmonary, left pulmonary artery, left ventricle, left ventricle in heart, left ventricle in heart failure, left ventricle in heart failure patients, left ventricular, left ventricular assist, left ventricular assist device, left ventricular assist device implantation, left ventricular assist devices, left ventricular assist system, left ventricular base, left ventricular biopsies, left ventricular dd, left ventricular diastolic, left ventricular diastolic end, left ventricular diastolic end diameter, left ventricular diastolic function, left ventricular dilatation, left ventricular dysfunction, left ventricular dyssynchrony, left ventricular ejection, left ventricular ejection fraction, left ventricular ejection fractions, left ventricular ejection time, left ventricular filling, left ventricular filling pressure, left ventricular filling pressure response, left ventricular function, left ventricular function assessment, left ventricular hypertrophy, left ventricular mechanics, left ventricular midpapillary, left ventricular midpapillary level, left ventricular systolic, left ventricular tissue, left ventricular tissue from control, left ventricular tissue from control animals, left-hand, left-hand grip, left-hand grip strength, left-to-right, left-to-right interatrial, left-to-right interatrial shunting, left-to-right interatrial shunting for treatment, left-to-right interatrial shunting in patients, leg, leg strength, legal, legal majority, length, length nt-probnp, length nt-probnp molecule, length of follow-up, length of stay, length relations, length-force, length-force relationship, lesion, lesions, lessons, lessons for nurse, lessons for nurse leaders, leu3-gly4, leukocytes, leukocytes of participants, level, level for β-myosin, level of agreement, level of application, level of crf, level of nt-probnp, levels, levels by dnx, levels by renal, levels by renal dnx, levels during lvad, levels during lvad support, levels for sr, levels in patients, levels in women, levels of brain, levels of creatinine, levels of epinephrine, levels of mena, levels of nps, levels of paf, levels of plasma, levels of plasma catecholamines, levels of plasma norepinephrine, levels ≥, levitated, levitated centrifugal-flow, levitated centrifugal-flow chronic, levitated centrifugal-flow chronic lvas, levitated left ventricular, levitated left ventricular assist, levitated left ventricular assist system, levitated lvas, levitated rotor, liberal, liberal transfusion, liberal transfusion protocols, library, life, life assessment, life domains, life expectancy, life for people, life in patients, life score, life support, life-sustaining, life-sustaining treatment, life-threatening, life-threatening anemia, life-threatening situation, lifesaving drugs, lifesciences, ligation, likelihood, likelihood ratio, limbs, limitation, limitations, limited, limited ability, limited amount, limited data, limited evidence, limited maximal cpet, limited mitral, limited mitral valve, limited mitral valve opening, limited mortality, limited mortality at hospital, limited mortality at hospital discharge, limited number, limited number of patients, limited success, limited value, limits, limits in models, limits of agreement, line, line shift, line shift in nonsurvivors, linear, linear mixed, linear mixed models, linear models, linear pathway, link, link between air, link between air pollution, link between inflammation, linked administrative databases, linked administrative health, linked administrative health data, links, lipid-lowering, lipid-lowering therapy, lipolysis, lipoprotein, lipoprotein functional, lipoprotein functional properties, lipoprotein-associated, lipoprotein-associated phospholipase, listing, listing criteria, lists, literature, literature search, littermate, littermate controls, littermates, little, little attention, little impact, little influence, liver, liver disease, liver texture, liver texture changes, liver-specific, load-corrected, load-corrected chronotropic, load-corrected chronotropic response, loading, local, local cardiology, local cardiology services, local myocyte, local myocyte depolarization, log, log rank, log-rank, log-rank testing, log2, logistic, logistic analysis, logistic regression, logistic regression analysis, logistic regression models, lokomat, long, long axis, long axis function, long time, long-acting, long-acting insulin, long-acting insulin products, long-standing, long-standing persistent af, long-term, long-term administration, long-term administration of pyridostigmine, long-term clinical, long-term clinical outcomes, long-term complications, long-term continuity, long-term continuity of care, long-term cost-effectiveness analyses, long-term cost-effectiveness analyses of disease, long-term cost-effectiveness analyses of disease management, long-term cost-effectiveness analyses of disease management programs, long-term costs, long-term effects, long-term follow-up, long-term management, long-term mortality, long-term mortality after hospitalization, long-term mortality as patients, long-term mortality in patients, long-term outcomes, long-term prognosis, long-term support, long-term support to patients, long-term survival, long-term survival in ed, long-term survival in ed patients, long-term survival rates, long-term value, long-term ventricular, longer, longer mutually exclusive, longitudinal, longitudinal analysis, longitudinal change, longitudinal outcome-monitoring, longitudinal outcome-monitoring phase, longitudinal performance, longitudinal rv fiber, longitudinal rv fiber shortening, longitudinal strain, longitudinal study, longitudinal systolic, longitudinal systolic strain, loop, loop diuretics, looping, loss, low, low activity, low apparent, low bnp, low bnp group, low bp, low co-morbidity, low co-morbidity burden, low crf, low crf categories, low left, low left ventricular, low left ventricular ejection, low left ventricular ejection fraction, low left ventricular ejection fractions, low pasp, low performers, low skeletal, low skeletal muscle, low skeletal muscle mass, low systemic, low systemic vascular, low systemic vascular resistance, low testosterone, low testosterone status, low-dose, low-dose bb, low-dose dopamine, low-dose nesiritide, low-frequency, low-quality, low-quality evidence, low-risk, low-risk group, low-sodium, low-sodium dash, low-sodium dash diet, low-strength, low-strength evidence, low-volume, low-volume ed, low-volume ed cases, low-volume eds, low-volume hospitals, low-volume institutions, low-volume physicians, low-volume sites, lower, lower among patients, lower body, lower body mass, lower body mass index, lower btes, lower costs, lower during carvedilol, lower eo-cfus, lower event, lower event rate, lower exercise, lower exercise performance, lower exercise time, lower fat, lower fat mass, lower fat mass index, lower gross, lower gross national, lower gross national income, lower gross national income per capita, lower hf, lower hf mortality, lower hf mortality risk, lower hf mortality risk in men, lower in fit, lower killip, lower killip class, lower limbs, lower median, lower median activities, lower mitral, lower mitral e, lower mortality, lower mortality for hf, lower mortality in women, lower natremia, lower peak, lower rate, lower rate in patients, lower rates, lower rates of death, lower rates of hypokalemia, lower risk, lower risk-adjusted, lower risk-adjusted all-cause, lower risk-adjusted all-cause mortality, lower socioeconomic, lower socioeconomic status, lower socioeconomic status versus whites, lower stimulation, lower stimulation of phosphorylation, lower svr, lower svr index, lower systolic, lower systolic blood, lower systolic blood pressure, lower tapse, lower total, lower total expenditure, lower total expenditure on health, lower volumes, lower volumes of exercise, lower von, lower von willebrand, lower von willebrand factor, lower von willebrand factor concentrations, lowest, lowest cardiovascular, lowest cardiovascular event, lowest cardiovascular event rate, lowest cumulative, lowest cumulative hazard, lp-pla2, lung, lung congestion, lung weight, lusitropic, lv, lv compliance, lv contractile, lv contractile function, lv contractility, lv diastolic, lv diastolic dysfunction, lv dilatation, lv dysfunction, lv ef, lv ejection, lv ejection fraction, lv end, lv end systolic volume, lv end systolic volume index, lv end-diastolic dimension, lv end-diastolic dimension index, lv end-diastolic pressure, lv end-diastolic volume, lv end-systolic volume, lv fibrosis, lv filling, lv filling pressure, lv filling pressures, lv fractional shortening, lv function, lv hypertrophy, lv hypertrophy to hf, lv internal diameter, lv mass, lv posterior wall, lv posterior wall thickness, lv relaxation, lv remodeling, lv reverse, lv reverse remodeling, lv size, lv strain, lv strain rate, lv strain rate at diastole, lv structure, lv systolic, lv systolic dysfunction, lv systolic indices, lvad, lvad implantation, lvad insertion, lvad patients, lvad support, lvad surgery, lvad therapy, lvad use, lvads, lvas, lvas support, lvef, lvef experience, lvet, lvet at entry, lvet at icu, lvet at icu admission, lvet between admission, lvh, lyso-paf, lyso-paf acetyltransferase, lyso-paf-at, m7, macrophages, made policy, made policy recommendations, madit-crt, madit-crt study, madit-crt trial, magnet, magnetic, magnetic resonance, magnetic resonance angiography, magnetic resonance imaging, magnetic resonance imaging on chelation, magnetic resonance imaging on chelation choices, magnetic resonance postcontrast, magnetic resonance spectroscopy, magnetically levitated, magnetically levitated centrifugal-flow, magnetically levitated centrifugal-flow chronic, main, main effect, main effects, main effects analysis, main etiologies, main etiologies of hf, main objective, main outcome, main outcome measure, main outcome measures, main outcomes, maintain sinus, maintain sinus rhythm, maintaining sinus, maintaining sinus rhythm, maintenance, maintenance of sinus, maintenance of sinus rhythm, maintenance scale, maisel, major, major adverse, major adverse neurological, major branches, major cardiovascular, major cardiovascular complications, major changes, major clinical, major clinical trials, major complications, major concerns, major databases, major development, major hf, major hf remodeling, major hf remodeling aspects, major insulin-signaling, major insulin-signaling components, major parameter, major predictor, major public, major public health, major public health problem, major right, major right ventricle, major right ventricle overload, major role, major safety, major safety measures, major underlying, major underlying mechanism, major underlying mechanism of hfpef, majority, majority of patients, majority of studies, maladaptive, maladaptive cardiac, maladaptive cardiac remodelling, maladaptive molecular, maladaptive molecular processes, maladaptive remodelling, male, male gender, male mice, male patients, male patients with chf, male sex, male wistar, male wistar rats, males, malfunctioning heartmate, malfunctioning heartmate ii, malfunctioning heartmate ii lvads, malfunctions, malignancies, malignant, malignant disease, malondialdehyde, mammalian, mammalian myocardium, mammalian myocardium with impact, man, manage af, managed diseases, management, management in pah, management interventions, management interventions in heart, management interventions in heart failure, management interventions in heart failure cost-effectiveness, management interventions in heart failure cost-effectiveness model, management of end, management of end stage, management of end stage heart, management of end stage heart failure, management of heart, management of heart failure, management of hf, management of myocarditis, management of patients, management programs, management programs in heart, management programs in heart failure, management scale, management strategies, mandate, mandatory, manipulation, manner, mapk, mapk during insulin, mapk during insulin resistance, mapping, march, marked, marked cardiac insulin-resistance, marked decreases, marked decreases in heart, marked protection, marked reduction, marked resistance, marker, marker nanog, markers, markers for coagulability, markers of hemostasis, markers of skm, markers of skm growth, masked outcome, masked outcome assessments, mass, mass index, mass index categories, mass index levels, mass index strata, mass quantification, mass ratio, mass removal, mass spectrometric analysis, mass spectrometry, mass t-score, massive, massive embolism, matched cohort, matched cohort study, matched control, matched control group, matched controls, matched-pairs, matched-pairs signed-rank tests, matching donors, material, materials, matrix, matrix accumulation, matrix to fpassive, max, maximal, maximal cardiopulmonary, maximal cardiopulmonary exercise, maximal cardiopulmonary exercise test, maximal cpet, maximal exercise, maximal medical, maximal medical treatment, maximal spironolactone, maximal spironolactone dose, maximal systolic, maximal systolic elastance, maximal treadmill, maximal treadmill exercise, maximal treadmill exercise testing, maximal ventricular, maximal ventricular power, maximal ventricular power index, maximum, maximum oxygen, maximum oxygen consumption, mdc, mdc95, meaning, measurable, measurable benefits, measure, measure aspects, measure for heart, measure for heart failure, measure of health, measure of health status, measure of hf, measure of patients, measured baseline, measurement, measurement of nps, measurement systems, measurement value, measurements, measurements of cpcs, measures, measures of quality, measuring frailty, measuring heart, measuring heart failure, measuring heart failure care, measuring hospital, measuring np levels, mechanical, mechanical cardiac, mechanical cardiac support, mechanical circulatory, mechanical circulatory support, mechanical dyssynchrony, mechanical support, mechanical support devices, mechanics, mechanism, mechanism of action, mechanism of cardioprotection, mechanism of hfpef, mechanisms, mechanisms of disease, mechanistic, mechanistic insight, median, median activities, median age, median baseline, median bnp, median bnp in women, median bnp level, median bnp levels, median body, median body mass, median body mass index, median egfr, median exercise-induced, median exercise-induced pasp, median exercise-induced pasp increase, median follow, median follow-up, median follow-up duration, median rate, median rate ratio, median stay, mediated reduction, mediator, mediator of insulin, mediator of insulin resistance, medicaid, medicaid services, medicaid services demonstration, medical, medical center, medical conditions, medical history, medical hospitalization, medical hospitalization in hf, medical hospitalization in hf clinic, medical hospitalization in hf clinic outpatients, medical literature, medical management, medical management of heart, medical management of heart failure, medical management of hf, medical outcomes, medical outcomes study, medical outcomes study short-form, medical outcomes study short-form quality, medical outcomes study short-form quality of life, medical outcomes study short-form quality of life domains, medical records, medical resource, medical resource use, medical resources, medical staff, medical support, medical therapies, medical therapy, medical treatment, medical treatment for heart, medical treatment for heart failure, medical treatment for hf, medical treatment guidelines, medicare, medicare beneficiaries, medicare coverage, medicare data, medicare fee-for-service beneficiaries, medicare hospital, medicare hospital claims, medicare inpatient data, medicare patient, medicare patient safety, medicare patient safety monitoring, medicare patient safety monitoring system, medication, medication changes, medication changes at follow-up, medication changes at follow-up visits, medication dose, medication lists, medication regimen, medication use, medications, medications among outpatients, medications for patients, medications to adults, medicine, medicines, mediterranean, mediterranean diet, mediterranean diet score, mediterranean diet scores, medium, medline, meeting magnet, meeting specific inclusion, mellitus, member, membrane, membrane levels, membrane oxygenation, membrane oxygenation as bridge, membrane oxygenation membrane, membrane oxygenation membrane support, membrane support, membrane translocation, membrane translocation of glucose, membrane translocation of glucose transporter, men, mena, mena deletion, mena expression, mena levels, mena overexpression, mena overexpression in tta, mesenchymal, mesenchymal transition, mesenchymal transition markers, messenger, messenger rna, meta-analyses, meta-analysis, meta-analyzed, meta-analyzed mortality, metabolic, metabolic abnormalities, metabolic changes, metabolic enzymes, metabolic enzymes in patients, metabolic exercise, metabolic gene, metabolic gene expression, metabolic pathways, metabolic risk, metabolic risk factors, metabolic risk model, metabolism, metabolism gene, metabolism gene expression, metabolism precede, method, method for cv, method for cv events, methodology, methods, methotrexate, methylatropine, metoprolol, metoprolol in heart, metoprolol in heart failure, metoprolol succinate, metoprolol treatment, metric, metric choice, metrics, mets, mg daily equivalent dose, mg daily equivalent dose of metoprolol, mg daily equivalent dose of metoprolol succinate, mi, mi animals, mi animals with metoprolol, mi characteristics, mi-induced, mi-induced decreases, mice, mice model, mice via phenylephrine, michigan, michigan hf, michigan hf clinic, microarray, microarray data, microembolization-induced, microembolization-induced hf, micronutrients, micrornas, micrornas in heart, micrornas in heart failure, microscopy, microstructure, microstructure at baseline, mid, mid lad, middle-aged, middle-aged recreational, middle-aged recreational athletes, midpapillary, midpapillary level, midregional, midregional proanp, midwestern, midwestern state, midwestern state like south, midwestern state like south dakota, migration, mild, mild clinical, mild clinical diastolic, mild clinical diastolic dysfunction, mild disease, mild heart, mild heart failure, mild hf, mild mitral, mild mitral regurgitation, mild mr, mild patients, mild patients hospitalization, mild restriction, milliseconds, min, min after rehabilitation, min decrease, min in peak, min without bolus, mind, mineralocorticoid, mineralocorticoid receptor, mineralocorticoid receptor antagonists, mineralocorticoid receptor antagonists in heart, mineralocorticoid receptor antagonists in heart failure, mini-sentinel, mini-sentinel program, minimal, minimal detectable, minimal detectable change, minimal physical, minimal physical exertion, minnesota, minnesota quality, minnesota quality of life, minnesota residents, minnesota residents with hf, minor, minor improvement, minutes, minutes of exercise, mirnas, mis, misdiagnosis, misdiagnosis of heart, misdiagnosis of heart failure, mitochondrial, mitochondrial complex, mitochondrial damage, mitochondrial dysfunction, mitochondrial energy, mitochondrial energy production, mitochondrial function, mitochondrial oxidation, mitochondrial oxidation of glucose, mitochondrial oxidative, mitochondrial oxidative metabolism, mitochondrial oxidative phosphorylation, mitochondrial oxidative phosphorylation capacity, mitochondrial oxidative stress, mitochondrial proteome, mitochondrial proteome changes, mitochondrial respiration, mitochondrial structure, mitochondrial ultrastructural, mitochondrial ultrastructural changes, mitochondrial-targeted, mitochondrial-targeted antioxidant, mitochondrial-targeted peptide, mitochondrial-targeted peptide drugs, mitochondrial-targeted peptides, mitogen-activated, mitogen-activated protein, mitogen-activated protein kinase, mitral, mitral annular, mitral annular velocity, mitral annulus, mitral annulus velocities, mitral annulus velocities during systole, mitral annulus velocity, mitral e, mitral filling, mitral filling flow, mitral flow, mitral flow velocity, mitral inflow, mitral inflow velocity, mitral leaflet, mitral leaflet motions, mitral regurgitation, mitral stenosis, mitral valve, mitral valve area, mitral valve opening, mitral valve tethering, mix, mix of hf, mixed, mixed linear, mixed linear models, mixed models, mixed-methods, mixed-methods study, mlhf, mlhf questionnaire, mlhf total score, mlhf total score with exercise, mm, mm for psoriasis, mm for reference, mm for reference subjects, mmhg, mmol, modality, model, model analysis, model fit, model of hhd, model scores, model system, model-predicted, model-predicted survival, modeling, models, models for time, moderate, moderate anemia, moderate heart, moderate heart failure, moderate level, moderate level of crf, moderate lv, moderate lv dilatation, moderate reduction, moderate reduction in lvef, moderate reductions, moderate reductions in lvef, moderate-intensity, moderate-quality, moderate-quality evidence, moderate-severe, moderate-severe right, moderate-severe right ventricular, moderate-severe right ventricular dysfunction, moderate-strength, moderate-strength evidence, moderately effective, modern, modern acute, modern acute heart, modern acute heart failure, modern rhythm, modern rhythm control, modern rhythm control therapy, modern society, modes, modes of l-type, modes of l-type channel, modes of l-type channel inhibition, modest, modest clinical, modest clinical benefit, modest clinical benefit for patients, modest conservation, modest effects, modest effects on heart, modest effects on heart failure, modest reduction, modest reduction in mva, modestly lower, modifiable, modifiable risk, modifiable risk factors, modification, modification of diet, modification of pka, modification of pka subunits, modified rankin, modified rankin score, modified seattle, modified seattle heart, modified seattle heart failure, modified seattle heart failure model, modifying antirheumatic drug, modulate hf-related, modulate hf-related morbidity, modulates, modulates ea, modulation, modulation of repolarization, modulation of repolarization instability, modulation on qtv, molecular, molecular analysis, molecular biomarkers, molecular dysfunction, molecular level, molecular mechanism, molecular pathways, molecular pathways in patients, molecular processes, molecular scaffolds, molecular scaffolds in heart, molecular scaffolds in heart pathology, molecule, molecules, monitoring, monitoring board, monitoring devices, monitoring of lvad, monitoring of lvad use, monitoring system, monoclonal, monoclonal antibodies, monocytes, monomeric, monomeric g proteins, monophosphate, month, month after discharge, month follow-up, months, months after ablation, months of follow-up, months of follow-up data, months of treatment, months post-procedure, morbidity, morphogenetic, morphogenetic protein, morpholino-based, morpholino-based knockdown, morpholino-based knockdown of nucleolin, morphological, morphological development, morphologically comparable, morphology, mortality, mortality after hospitalization, mortality as patients, mortality at hospital, mortality at hospital discharge, mortality for hf, mortality for sts, mortality for sts hh, mortality in adults, mortality in childhood, mortality in fit, mortality in heart, mortality in heart failure, mortality in hfpef, mortality in icd-hf, mortality in icd-hf patients, mortality in men, mortality in patients, mortality in women, mortality outcomes, mortality outcomes of heart, mortality outcomes of heart failure, mortality predictors, mortality predictors in icd-hf, mortality predictors in icd-hf patients, mortality rate, mortality rates, mortality risk, mortality risk in men, motion, motions, motivate hospitals, mouse, mouse heart, mouse heart failure, mouse hearts, mouse hf, mouse hf model, mouse hf model of hhd, mouse model, mouse myocardium, mouse rad, mouse tac, mouse tac model, mouse ventricular, mouse ventricular myocytes, movement, mpsms, mr with lv, mr with lv dilatation, mr-proadm, mr-proanp, mri, mri scanner, mri-based, mri-based models, mrna, mrna expression, mrna level, mrna level for β-myosin, mrna levels, mrna levels for sr, mrna splice, mrna splice variants, mrna splicing, mrnas, msec, mt group, multiacquisition, multicenter, multicenter automatic defibrillator, multicenter automatic defibrillator implantation, multicenter automatic defibrillator implantation trial-cardiac, multicenter automatic defibrillator implantation trial-cardiac resynchronization, multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy, multicenter automatic defibrillator implantation with cardiac, multicenter automatic defibrillator implantation with cardiac resynchronization, multicenter automatic defibrillator implantation with cardiac resynchronization therapy, multicenter studies, multicenter study, multicenter trial, multicenter trial paradigm-hf, multihospital, multihospital study, multimarker-based, multimarker-based strategy, multiorgan, multiorgan failure, multiparametric, multiparametric echocardiographic, multiparametric echocardiographic score, multiple, multiple cardiac, multiple cardiac genes, multiple cardiac genes in hf, multiple disciplines, multiple domains, multiple myeloma, multiple non-diastolic, multiple non-diastolic abnormalities, multiple procedures, multiple-procedure, multiple-procedure drug-free, multiple-procedure drug-free success, multiple-procedure drug-free success rates, multisite, multisite studies, multisite studies in practice, multisite studies in practice settings, multisite study, multisite study extend, multisystem, multisystem disease, multivariable, multivariable adjustment, multivariable analysis, multivariable cox, multivariable cox modeling, multivariable hierarchical, multivariable hierarchical regression, multivariable hierarchical regression models, multivariable logistic, multivariable logistic analysis, multivariable models, multivariable regression, multivariable-adjusted, multivariable-adjusted hazard, multivariable-adjusted hazard ratios, multivariate, multivariate analyses, multivariate analysis, multivariate assessment, multivariate cox, multivariate cox model, multivariate cox model analysis, multivariate cox proportional hazards, multivariate cox proportional hazards regression, multivariate cox regression, multivariate cox regression analyses, multivariate logistic regression, multivariate logistic regression analysis, multivariate model, multivariate models, multivariate regression, multivariate-adjusted, multivariate-adjusted odds, multivariate-adjusted odds ratio, murine, murine equivalent, murine myocardium, murine myocardium to heart, murine myocardium to heart failure, murine resistin, murmur, murmurs, murphy, muscle, muscle abnormalities, muscle aerobic capacity, muscle cells, muscle function, muscle mass, muscle mass t-score, muscle pump, muscle sarcomere structure, muscle sarcomere structure in patients, muscle strength, muscle strip, muscle strips, muscle wasting, muscle-wasting, muscle-wasting syndrome, muscles, muscular, muscular strength, mutant, mutant mice, mutant riα, mutant riα proteins, mutually exclusive, mva, myeloma, myocardial, myocardial angiogenesis, myocardial changes, myocardial collagen, myocardial dd, myocardial dd of collagen, myocardial dd of collagen deposition, myocardial diastolic, myocardial diastolic dysfunction, myocardial extracellular, myocardial extracellular matrix, myocardial extracellular matrix accumulation, myocardial fibrosis, myocardial function, myocardial glycolysis, myocardial glycolysis rates, myocardial infarction, myocardial infarction heart, myocardial infarction heart failure, myocardial infarction heart failure efficacy, myocardial infarction in western australia, myocardial infarction-both, myocardial insulin, myocardial insulin resistance, myocardial ischaemia, myocardial ischemia, myocardial ischemic, myocardial ischemic events, myocardial ischemic events in patients, myocardial loss, myocardial oxygen, myocardial oxygen consumption, myocardial perfusion, myocardial remodelling, myocardial tissue, myocardial tissues, myocardial titin, myocardial titin hypophosphorylation, myocardial washout, myocarditis, myocardium, myocardium displays, myocardium in response, myocardium to heart, myocardium to heart failure, myocardium with impact, myoctyes, myocyte, myocyte depolarization, myocyte diameter, myocyte differentiation, myocyte hypertrophy, myocyte hypertrophy antecedent, myocyte hypertrophy antecedent to heart, myocyte hypertrophy antecedent to heart failure, myocyte-specific, myocyte-specific mena, myocyte-specific mena overexpression, myocytes, myofiber, myofiber dynamics, myofiber shortening, myofiber shortening onset, myofiber shortening velocity, myofibre, myofibre regeneration, myofibrillar, myofilament, myosin, myxoma, myxomas, n-terminal, n-terminal fragment, n-terminal pro-b-type, n-terminal pro-b-type natriuretic peptides in plasma, n-terminal pro-brain, n-terminal pro-brain natriuretic, n-terminal pro-brain natriuretic peptide, n-terminal pro-brain-type, n-terminal pro-brain-type natriuretic peptide, n-terminal pro-brain-type natriuretic peptide assessment, n-terminal probnp, n2bus, nanog, nanomolar, nanomolar doses, narrow, narrow qrs, narrow qrs complex, national, national attention, national cardiovascular, national cardiovascular disease, national cardiovascular disease registry, national cardiovascular disease registry practice, national cardiovascular disease registry practice innovation, national efforts, national income, national income per capita, national inpatient, national inpatient registry, national medicare, national medicare data, national patient, national patient safety, national patient safety initiatives, national trends, nationwide, nationwide retrospective, nationwide retrospective cohort, nationwide retrospective cohort study, nationwide retrospective cohort study from denmark, natremia, natriuretic, natriuretic peptide, natriuretic peptide assessment, natriuretic peptide levels, natriuretic peptide levels in patients, natriuretic peptide system, natriuretic peptides, natriuretic peptides in plasma, natural, natural vasodilatory, naviaux, nbdmard, ncdr, ncdr pinnacle, ncdr pinnacle program, nct00180271, nct00232180, necrosis, necrosis factor, negative, negative binomial, negative binomial regression, negative binomial regression models, negative coronary, negative coronary angiography, negative cross, negative cross talk, negative cross talk between cgmp, negative inotropic, negative inotropic effect, negative likelihood, negative likelihood ratio, negative predictive, negative predictive value, negative rates, negative rates of changes, neoangiogenesis, neonatal, neonatal rat, neonatal rat ventricular, neonatal rat ventricular cardiomyocytes, nephrectomy, nephropathy, neprilysin, neprilysin blocks, neprilysin inhibition, neprilysin inhibitor, neprilysin inhibitor in heart, neprilysin inhibitor in heart failure, neprilysin inhibitor prodrug, neprilysin inhibitors, nervous, nervous system, nervous system activity, nervous system activity on qtv, nervous system modulation, nervous system modulation on qtv, nervous systems, nesiritide, nesiritide strategy, nested, nested case-control, nested case-control study, nested case-control study design, net, net economic, net economic savings, net reclassification, net reclassification improvement, net-reclassification-improvement, network, networks, neuro-hormonal, neuro-hormonal system, neurohormonal, neurohormonal abnormalities, neurohormonal activation, neurohormonal stimulation, neurohormonal systems, neurohormone, neurohormones, neurohumoral, neurohumoral blockers, neurological, neuronal, neuronal stressors, neurotransmission, neutral, neutral endopeptidase, neutral endopeptidase inhibitors, neutral results, new, new antiarrhythmic, new antiarrhythmic drugs, new approach, new chromatin, new chromatin subproteome, new conditions, new jersey, new onset, new onset heart, new onset heart failure, new options, new pharmacologic, new pharmacologic targets, new prevention, new prevention strategies, new strategies, new systematic, new systematic review, new targets, new targets in disease, new targets in disease management, new therapeutic, new therapeutic approach, new therapeutic approach to chf, new therapeutic approaches, new therapeutic targets, new therapeutic targets for hhd, new understanding, new users, new users of saxagliptin, new york, new york heart, new york heart association, new york heart association class, new york heart association class ii, new york heart association class ii to iv hf, new york heart association class iii, new york heart association class iii heart, new york heart association class iii heart failure, new york heart association classes, new york heart association classification, new york heart association functional class, new zealand, new zealand white, new zealand white rabbits, new-onset, new-onset aortic insufficiency, new-onset esrd, new-onset post-lvad, new-onset post-lvad ai, new-onset severe, new-user, new-user cohort, new-user cohort study, newer, newer drugs, newer imaging, newer imaging techniques, nf-κb, nfat, nhs, nicorandil, nights, ninety-three, ninety-three hf, ninety-three hf patients, ninth, ninth revision, nitric, nitric oxide, nitric oxide donors, nitrite, nitrogen, nitroxyl, nmol, noc, noc outcomes, nodularity, nomenclature, nominal, non-aa, non-aa participants, non-aas, non-biological, non-biological disease, non-cachectic, non-cachectic chf, non-diabetic, non-diabetic patients, non-diastolic, non-diastolic abnormalities, non-dilated, non-dilated left, non-dilated left ventricle, non-dnx, non-fatal, non-fatal stroke, non-frail, non-frail participants, non-hf, non-hf populations, non-invasively, non-ischemic, non-ischemic heart, non-ischemic heart failure, non-ischemic heart failure samples, non-lbbb, non-linear, non-linear measures, non-randomized, non-sudden, non-sudden cardiac, non-sudden cardiac death, non-survivors, non-urbanized, non-urbanized midwestern, non-urbanized midwestern state, non-urbanized midwestern state like south, non-urbanized midwestern state like south dakota, nonadherence, noncardiac, noncardiologist, noncardiologist physicians, noncardiovascular, noncardiovascular diagnoses, noncardiovascular drugs, noncoding rnas, nondeveloped, nondeveloped countries, nondiabetes risk, nondiabetes risk factors, nondiabetic, nondiabetic patients, nonfailing, nonfatal, nonfatal outcomes, nonfunctional, nonfunctional channels, nonidentification, noninvasive, noninvasive assessments, noninvasive surrogates, noninvasive surrogates for changes, noninvasive tools, nonischemic, nonischemic cardiomyopathies, nonmitochondrial, nonmitochondrial protein, nonmitochondrial protein changes, nonpace, nonpace dnx, nonpublic, nonpublic file, nonselective, nonselective β-blocker, nonsignificant, nonsignificant trend, nonspecific, nonstandardized n-terminal pro-b-type, nonsurvivors, nonterminal, nonterminal epitopes, nontrastuzumab, nontrastuzumab users, nontraumatic, nontraumatic death, nontraumatic death during sport, nontreatment, nordic, nordic walking, nordic walking in patients, norepinephrine, norepinephrine requirement, norepinephrine-induced, norepinephrine-induced hypertrophic, norepinephrine-induced hypertrophic responses, normal, normal albumin, normal albumin concentration, normal albumin levels, normal cardiac, normal cardiac function, normal coronary, normal coronary arteries, normal filling, normal filling pressures, normal geometry, normal hearts, normal lv, normal lv ejection, normal lv ejection fraction, normal reference, normal samples, normal sized, normal sized lv, normal systolic, normal systolic ventricular, normal systolic ventricular function, normalization, normalizing mena, normalizing mena levels, north, north america, northern, northern california, northwest, northwest united, northwest united states, nosignificant, nosignificant changes, nosignificant changes in control, nosignificant changes in control group, notable, notes, novel, novel approach, novel bottleneck, novel bottleneck stent, novel finding, novel heart, novel heart failure, novel heart failure mice, novel heart failure mice model, novel intracellular, novel intracellular antiadrenergic, novel intracellular antiadrenergic therapeutic strategy in hf, novel mouse, novel mouse hf, novel mouse hf model, novel mouse hf model of hhd, novel noninvasive, novel noninvasive tools, novel percutaneous, novel porcine, novel porcine model, novel pure, novel pure hno, novel pure hno donor, novel therapeutic, novel therapeutic approaches, novel therapeutic targets, novel therapeutic targets for heart, novel therapeutic targets for heart failure, novel treatment, novel treatment strategies, november, novo, np, np assessment, np assessment of ed, np assessment of ed patients, np levels, np measurement, nps, nri, nris, nt-pro, nt-pro bnp, nt-probnp, nt-probnp assay, nt-probnp concentration, nt-probnp cutoff, nt-probnp cutoff point, nt-probnp in patients, nt-probnp levels, nt-probnp molecule, nt-probnp testing, nt-probnp to age, nuclear, nuclear factor, nucleolin, nucleotides, nucleotides contents, nucleotides contents in addition, number, number of cases, number of hf, number of hf risk, number of hf risk factors, number of hospital, number of hospital days, number of patients, number of studies, numbers, nurse, nurse assessment, nurse leaders, nurse practitioner, nurses, nursing, nursing actions, nursing care, nursing care to outcomes, nursing facilities, nursing interventions, nursing management, nursing outcomes, nursing outcomes classification, nursing terminologies, nursing to outcomes, nursing-sensitive, nursing-sensitive outcome, nursing-sensitive outcome change, nursing-sensitive outcome change scores, nursing-sensitive outcome measures, nutrition, nutrition in heart, nutrition in heart failure, nutritional, nutritional abnormalities, nutritional strategies, nuts, nyha, nyha class, nyha class iii, nyha class iiib, nyha class iiib symptoms, nyha classification, nyha functional, nyha functional assessment, nyha functional class, nyha functional class ii, nyha functional class iii, nyha functional class iii hf, nyha functional class iv, o-1, o2, obese, obese body, obese body mass, obese body mass index, obese body mass index categories, obese men, obese older, obese older patients, obese older patients with heart, obese older patients with heart failure, obese older patients with hfpef, obese participants, obesity, objective, objective criteriabased institution, objectives, observation, observation period, observational, observational cohort, observational cohort studies, observational cohort study, observational studies, observational studies of transfusion, observational study, observational study in children, obstruction, obstructive, obstructive pulmonary, obstructive pulmonary disease, obvious, occluded, occluded stent, occlusion, occlusion time, occurrence, occurrence of heart, occurrence of heart failure, occurrence of hf, occurring rad, occurring rad variant, oct, odds, odds of chf, odds of future, odds ratio, odds ratios, oedema, off, off-pump, off-pump sternal, office, office hours, office of statewide, office of statewide health, office of statewide health planning, office-based, oht, oht in recipients, old, old with heart, old with heart failure, older, older adults, older adults with heart, older adults with heart failure, older adults with hf, older age, older age group, older athletes, older breast, older breast cancer, older breast cancer patients, older counterparts, older obese, older obese participants, older patients, older patients with breast, older patients with breast cancer, older patients with heart, older patients with heart failure, older patients with hfpef, older persons, older with type, older women, oldest, olmsted, olmsted county, omnibus, on, on assignment, on versus crt, one-year, one-year event-free, one-year event-free rates, ongoing, ongoing cardiovascular, ongoing cardiovascular outcomes, ongoing cardiovascular outcomes in renal, ongoing cardiovascular outcomes in renal atherosclerotic lesions, ongoing gdmt, ongoing rhythm, online, online material, onset, onset af, onset af at risk, onset heart, onset heart failure, onset hfref, onset of heart, onset of heart failure, onset of hf, onset of symptoms, ontario, ontario case, ontario case costing, ontario case costing initiative, open, open chest, open chest model, open stent, open surgery, open-label, open-label crossover, open-label crossover study, opening, operating characteristic curve, operation, operationalized hospital, operationalized hospital quality, operations, operative, operative outcomes, opposing action, opposing actions, opposing responses, optimal, optimal combined treatment, optimal combined treatment measure, optimal cutoff, optimal cutoff level, optimal cutoff level of nt-probnp, optimal diuretic, optimal diuretic therapy, optimal medical, optimal medical management, optimal nt-probnp, optimal nt-probnp cutoff, optimal nt-probnp cutoff point, optimal therapy, optimal treatment, optimization, optimization of diastolic, optimization strategies, optimization strategies evaluation, optimize quality, optimizing cardiac progenitor, optimizing cardiac progenitor function, option, options, oral, oral glucocorticoid, oral glucocorticoid dosage, oral glucocorticoids, orchestrate genomic, order, organ, organ failure, organic, organic lesion, organisation, organisation of care, organisation of care taxonomy, organization, organization criteria, organization website, organizations, orientation, origin, original, original construct, orthotopic, orthotopic heart, orthotopic heart transplantation, oscillations, oscillatory, oscillatory ventilation, osprey, osteomedullary, osteomedullary biopsy, osteoporosis, out-patient, out-patient follow-up, outcome, outcome assessment, outcome assessment trial, outcome assessments, outcome change, outcome change scores, outcome data, outcome in heart, outcome in heart failure, outcome in heart failure patients, outcome in patients, outcome measure, outcome measures, outcome of death, outcome performance, outcome ratings, outcome ratings from admission, outcome-monitoring, outcome-monitoring phase, outcomes, outcomes after adjustment, outcomes after discharge, outcomes among patients, outcomes classification, outcomes for adults, outcomes for patients, outcomes in african, outcomes in african americans, outcomes in chf, outcomes in exercise, outcomes in exercise training, outcomes in heart, outcomes in heart failure, outcomes in heart failure patients, outcomes in hf, outcomes in hf patients, outcomes in patients, outcomes in renal, outcomes in renal atherosclerotic lesions, outcomes of care, outcomes of catheter, outcomes of catheter ablation, outcomes of exercise, outcomes of exercise training, outcomes of heart, outcomes of heart failure, outcomes of nursing, outcomes of nursing care, outcomes study, outcomes study short-form, outcomes study short-form quality, outcomes study short-form quality of life, outcomes study short-form quality of life domains, outcomes trial, outcomes trial of heart, outcomes trial of heart failure, outflow, outline, outline strategies, outpatient, outpatient assessments, outpatient assessments of patients, outpatient models, outpatient setting, outpatient settings, outpatients, outpatients with heart, outpatients with heart failure, outpatients with hf, output, over-represented, overall summary, overall summary scores, overexpress, overexpression, overexpression in tta, overexpression of mammalian, overlapping, overlapping part, overload, overload in heart, overload in heart failure, overstimulation, overstimulation in heart, overstimulation in heart failure, overview, overweight, overweight body, overweight body mass, overweight body mass index, overweight body mass index strata, overwhelming, overwhelming contribution, oxidase, oxidase inhibition, oxidase inhibition preserves, oxidation, oxidation of glucose, oxidative, oxidative metabolism, oxidative phosphorylation, oxidative phosphorylation capacity, oxidative stress, oxidative stress markers, oxide, oxide donors, oxygen, oxygen consumption, oxygen flow, oxygen pulse, oxygen uptake, oxygenation, oxygenation as bridge, oxygenation membrane, oxygenation membrane support, p-value, p-value for difference, p38, p38alpha, p38α, p70s6, pace, pace dnx, paced groups, paced myocardium, pacemaker, pacemakers, pacing, pacing period, pacing-induced, pacing-induced chf, packages, paco2, pad, paediatric, paediatric cardiac, paediatric cardiac transplants, paediatric cardiac transplants in children, paediatric heart, paediatric heart failure, paf, paf biosynthetic enzymes, paf levels, paf-acetylhydrolase, paf-ah, paf-cpt, pah, pairs, pairwise, pairwise comparisons, palliation, palliative, palliative care, palliative care of patients, panel, papillary, papillary muscles, paradigm, paradigm shift, paradigm-hf, paradigms, paradox, parallel, parallel with paf, parallel with paf levels, parallel-group, parameter, parameters, parameters for diagnosis, parameters in patients, parametrized diastolic, parametrized diastolic filling, parametrized diastolic filling formalism, parasympathetic, parasympathetic activity, parasympathetic control, parasympathetic function, parasympathetic neurotransmission, parasympathetic tone, parasympathetic tone by pyridostigmine, parasympathetic tone by pyridostigmine prevents, part, partial, partial attenuation, partial improvement, partial pressure, partial reduction, partial reversal, partial reversal of changes, partially reversible, participant, participant contact, participant contact before august, participant satisfaction, participant satisfaction responses, participants, participating clinics, participating nurses, participation, participation of apoptosis, participatory, particles, partners, pasp, pasp increase, pasp increase during exercise, pasp relationship, passive, past, past decades, patch, patch closure, patent, pathobiology, pathogenesis, pathogenesis of heart, pathogenesis of heart failure, pathological, pathological cardiac, pathological cardiac gene, pathological cardiac gene expression, pathological cardiac gene expression programme, pathological changes, pathological changes in cardiomyocytes, pathological gene, pathological gene expression, pathological gene induction, pathological heart, pathological heart disease, pathological hypertrophy, pathological remodelling, pathological stress, pathology, pathophysiologic, pathophysiologic mechanism, pathophysiologic mechanisms, pathophysiologic state, pathophysiological, pathophysiological origin, pathophysiology, pathophysiology of heart, pathophysiology of heart failure, pathophysiology of hf, pathophysiology of hfpef, paths, pathway, pathway alterations, pathway alterations in tac, pathway analysis, pathway changes, pathways, pathways in patients, patient, patient awareness, patient care, patient categorization, patient circulation, patient compliance, patient consultation, patient discharge, patient discharge data, patient discharge data nonpublic, patient discharge data nonpublic file, patient enrollment, patient factors, patient identification, patient management, patient management interventions, patient management interventions in heart, patient management interventions in heart failure, patient management interventions in heart failure cost-effectiveness, patient management interventions in heart failure cost-effectiveness model, patient outcomes, patient perceptions, patient plasma, patient plasma by use, patient population, patient preferences, patient presentation, patient safety, patient safety initiatives, patient safety monitoring, patient safety monitoring system, patient satisfaction, patient severity, patient severity index, patient with diagnosis, patient with heart, patient with heart failure, patient-level, patient-level regression, patient-operated, patient-operated electrocardiographic, patient-operated electrocardiographic device, patient-years, patients, patients as control, patients at risk, patients for ras, patients from italy, patients from québec, patients hospitalization, patients in addition, patients in heart, patients in heart failure, patients in new york, patients in new york heart, patients in new york heart association, patients in sinus, patients in sinus rhythm, patients into hf, patients with ahf, patients with baseline, patients with baseline ef, patients with breast, patients with breast cancer, patients with cad, patients with chf, patients with chf-nyha-ii, patients with chf-nyha-iii, patients with dcm, patients with devices, patients with diabetes, patients with dyspnea, patients with end, patients with end stage, patients with end stage heart, patients with end stage heart failure, patients with heart, patients with heart disease, patients with heart failure, patients with heart failure home, patients with hf, patients with hfpef, patients with hfref, patients with ic, patients with new york, patients with new york heart, patients with new york heart association, patients with new york heart association class, patients with new york heart association class iii, patients with non-lbbb, patients with pad, patients with ph, patients with qrs, patients with qrs prolongation, patients with ras, patients with respect, patients with systolic, patients with thalassaemia, patients with thalassaemia major, patients with type, patients without diabetes, patients without uptitration, pattern, pattern generator, patterning, patterns, patterns with outcomes, paucity, paucity of data, pause, pause release, pay-for-performance, pb, pb characteristics, pb cycle, pb in patients, pcwp, pcwp estimation, pd initiation, pde, pde2, pdrelated, pdrelated complications, peak, peak aerobic, peak aerobic capacity, peak early diastolic, peak oxygen, peak oxygen consumption, peak oxygen uptake, peak quadriceps, peak quadriceps force, peak respiratory quotient, peak work, peak work rate, pediatric, pediatric cohort, pediatric fontan, pediatric heart, pediatric heart failure, pediatric mechanical, pediatric mechanical cardiac, pediatric mechanical cardiac support, pediatrics, pef, penalties, people, people with heart, people with heart failure, peptide, peptide assessment, peptide drugs, peptide levels, peptide levels in patients, peptide system, peptides, peptides in plasma, perceived barriers, perceived benefit, perceived lack, perceived social support, perceived social support score, percent, percent lean body, percent lean body mass, percent of hospitals, percent of patients, percent relative reduction, percentage, percentage of chf, percentage of chf patients, percentage of fibrosis, percentage points, percentiles, perceptions, percutaneous, percutaneous coronary, percutaneous coronary intervention, percutaneous coronary revascularization, percutaneous revascularization, performance, performance battery, performance by β-adrenoceptor, performance by β-adrenoceptor blockade, performance goal, performance measurement, performance measurement systems, performed confirmatory factor, performed confirmatory factor analysis, performed regression, performed regression analyses, performed symptom, performers, perfusion, perfusion in b-treated, period, period in patients, period of pulseless, periodic, periodic breathing, periods, perioperative, peripheral, peripheral abnormalities, peripheral arterial, peripheral arterial disease, peripheral artery, peripheral artery disease, peripheral edema, peripheral muscle, peripheral muscle pump, peripheral muscles, peripheral oedema, peripheral vascular, peripheral vascular disease, periprocedural, periprocedural deaths, peritoneal, peritoneal dialysis, perk, perk activation, perk inhibition, perkins, permanent, permanent periodic, permanent periodic breathing, permanente, permanente northern california, permeability, persistent, persistent af, persistent af patients, persons, perspective, perspectives, perturbations, perturbations in components, perturbed bone, perturbed mitochondrial function, pevk, pevk segment, pf cohort, pg, ph with heart, ph with heart failure, pharmaceuticals, pharmaceuticals in patients, pharmacologic, pharmacologic management, pharmacologic studies, pharmacologic studies of therapeutics, pharmacologic targets, pharmacologic therapies, pharmacologic treatment, pharmacological, pharmacological armamentarium, pharmacological treatment, phase, phenotype, phenotypes, phenylephrine, phenylephrine-induced, phenylephrine-induced genes, phenylephrine-mediated, phenylephrine-mediated hypertrophy, phenylephrine-mediated hypertrophy of cardiomyocytes, phosphocreatine, phosphocreatine resynthesis, phosphocreatine to atp, phosphodiesterase-2, phospholamban, phospholipase, phosphorylation, phosphorylation capacity, phosphorylation in hf, phosphorylation sites, physical, physical activity, physical activity controls, physical examination, physical exertion, physical exhaustion, physical performance, physical performance battery, physical therapy, physician, physician adherence, physician adherence to class, physician adherence to hf, physician adherence to hf cpgs, physician continuity, physician continuity on death, physician follow-up, physician follow-up after discharge, physician specialty, physician volume, physician volume within strata, physicians, physicians into quintiles, physio, physio ring, physiologic, physiologic processes, physiologic processes in chf, physiologic processes in chf inhibition, physiological, physiological proteolysis, physiological significance, physiology, pigs, pilot, pilot program, pilot project, pilot study, pilot trial, pilot trial of heart, pilot trial of heart failure, pinnacle, pinnacle program, pioglitazone, pka, pka subunits, place, placebo, placebo group, placebo groups, placebo in addition, placebo-controlled, placebo-controlled clinical, placebo-controlled clinical trial, placebo-treated, placebo-treated group, placebo-treated patients, plane, plane systolic, plane systolic excursion, planning, plans, plans for patients, plasma, plasma b-type, plasma b-type natriuretic peptide, plasma by use, plasma catecholamines, plasma membrane, plasma membrane levels, plasma membrane translocation, plasma membrane translocation of glucose, plasma membrane translocation of glucose transporter, plasma n-terminal pro-b-type, plasma ne, plasma norepinephrine, plasma nps, plasma of heart, plasma of heart failure, plasma of heart failure patients, plasma samples, plasticity, plasticity in cardiomyocytes, plasty, plateau, plateau phase, platelet-activating, platelet-activating factor, pleasanton, pluripotency, pluripotency marker, pluripotency marker nanog, pluripotency markers, pluripotent, pluripotent stem, pluripotent stem cell-derived cardiomyocytes, pna, pneumonia, poc, poc measurement, poc measurement of nps, poc systems, poc technology, poc testing, poc testing of np, point, point of care, point of death, point of esrd, point-of-care, point-of-care systems, points, points reflective of decongestion, points to alterations, pol, pol ii, policy, policy recommendations, pollution, pollution on heart, pollution on heart failure, polymerase, polymerase ii, polymorphism, polymorphisms, polytetrafluoroethylene, polytetrafluoroethylene tube, pool, pool results, pooled placebo, pooled placebo group, poor, poor myocardial, poor myocardial function, poor outcome, poor outcomes, poor patient, poor patient compliance, poor prognosis, poor prognosis after lvad, poor prognosis after lvad surgery, poor social, poor social support, poorer, population, population characteristics, population of anthracycline, population-based, population-based rotterdam, population-based rotterdam study, population-based study, population-specific, population-specific health, population-specific health interventions, populations, populations of patients, porcine, porcine model, portal, portal hypertension, portion, positive, positive effects, positive inotropic, positron, positron emission, positron emission tomography, positron emission tomography imaging, possibility, possibility of ms, post, post hoc analysis, post myocardial infarction, post myocardial infarction heart, post myocardial infarction heart failure, post myocardial infarction heart failure efficacy, post study, post-aac, post-acute, post-acute care, post-acute care transfer, post-acute care transfer policy, post-dash, post-hct, post-lvad, post-lvad ai, post-myocardial, post-myocardial infarction, post-myocardial infarction heart, post-myocardial infarction heart failure, post-myocardial infarction heart failure patients, post-myocardial infarction patients, post-myocardial infarction patients with heart, post-myocardial infarction patients with heart failure, post-pd, post-pd initiation, post-procedure, post-tac, post-tac cardiac, post-tac cardiac functional, post-tac cardiac functional deterioration, post-translational, post-translational modification, post-translational modification of pka, post-translational modification of pka subunits, post-translational state, post-translational states, post-transplant, post-transplant morbidity, post-transplant mortality, postcontrast, posterior, posterior wall, posterior wall infarction, posterior wall thickness, postexercise, postexercise phosphocreatine, postexercise phosphocreatine resynthesis, postischemic, postischemic heart, postischemic heart failure, postmarketing, postmarketing trials, postmenopausal, postmenopausal women, postmenopausal women with hf, postnatal, postnatal mammalian, postnatal mammalian myocardium, postnatal mammalian myocardium with impact, postoperative, postoperative echocardiography, postoperative months, postoperative mortality, postoperative mortality in patients, postoperative normalization, postoperative survival, postoperative survival of patients, postoperatively secondary, postsystolic, postsystolic function, potassium, potassium level, potent, potent inhibition, potent inhibition of l-type, potential, potential benefit, potential benefits, potential candidates, potential candidates for cell, potential candidates for cell therapy, potential cation, potential cation channel, potential clinical, potential clinical application, potential contribution, potential contribution of poc, potential contribution of poc measurement, potential duration, potential dysfunction, potential effectiveness, potential efficacy, potential for success, potential of diuretics, potential of mirnas, potential predictors, potential preventable, potential preventable readmission, potential therapeutic, potential therapeutic implications, potentials, power, power index, power spectral analysis, powerful, powerful independent, powerful independent predictor, powerful prognostic, powerful prognostic composite, powerful prognostic composite hf, powerful prognostic composite hf index, ppr, practical, practical recommendations, practice, practice centres, practice guideline, practice guidelines, practice innovation, practice rates, practice rates of treatment, practice settings, practice site, practice-level, practice-level differences, practice-level prescription, practice-level prescription rates, practice-level variation, practice-level variation in rates, practice-level variation in use, practices, practitioner, practitioners, pre-crt, pre-crt lv, pre-defined, pre-defined inclusion, pre-defined inclusion criteria, pre-hct, pre-hct chest, pre-hct chest radiation, pre-hct exposure, pre-hct exposure to anthracyclines, pre-hct germline, pre-hct germline dna, pre-participation, pre-participation screening, pre-pd, pre-post, pre-post comparisons, pre-specified, pre-specified analysis, pre-specified analysis of subgroups, pre-specified subgroup, pre-specified subgroup analyses, precapillary, precapillary ph, precapillary ph with heart, precapillary ph with heart failure, precapillary pulmonary, precapillary pulmonary hypertension, precede, precedes hf, preceding mechanisms, precipitating, precipitating factor, precise, precise role, precise role of mena, pred, predict heart, predict heart failure, predict inhospital mortality, predict mortality, predict prognosis, predicted death, predicted outcomes, predicted values, predicting crt, predicting crt response, predicting death, predicting survival, prediction, prediction model, prediction of lv, prediction of lv reverse, prediction of lv reverse remodeling, prediction rule, predictive, predictive cutoff, predictive cutoff value, predictive cutoff value for admission, predictive cutoff value for admission nt-probnp, predictive cutoff value for plasma, predictive cutoff value of nt-probnp, predictive cutoff value of nt-probnp testing, predictive model, predictive validity, predictive value, predictive value for heart, predictive value for heart failure, predictor, predictors, predictors in icd-hf, predictors in icd-hf patients, predictors of esrd, predictors of heart, predictors of mortality, predictors of response, predicts clinical outcome, predicts clinical outcomes, predominately male, preferences, preliminary, preliminary data, preliminary descriptive, preliminary descriptive study, preliminary report, preliminary study, preoperative, preoperative albumin, preoperative clinical, preoperative clinical characteristics, preoperative demographics, preoperative hypoalbuminemia, preoperative renal, preoperative renal dysfunction, preoperative serum, prescribe exercise, prescribe exercise rehabilitation, prescribed, prescribed medications, prescribed therapy, prescribing, prescribing angiotensin, prescribing guideline-recommended medications, prescription, prescription rates, prescriptive, presence, presence of diastolic, presence of diastolic dysfunction, presence of mr, presence of signs, presentation, presentations, presents guidelines, preserve atrial structure, preserve renal function, preserved, preserved cardiac index, preserved ef, preserved ejection, preserved ejection fraction, preserved ejection fraction development, preserved ejection fraction outcomes, preserved ejection fraction outcomes trial, preserved left ventricular, preserved lv, preserved lv ejection, preserved lv ejection fraction, preserved lvef, preserved lvef experience, preserved mitral valve, preserved mitral valve opening, preserved phosphocreatine, preserved systolic function, preserves, prespecified, prespecified criteria, pressure, pressure control, pressure curve, pressure development, pressure gradient, pressure in patients, pressure overload, pressure relationship, pressure relationship in heart, pressure relationship in heart failure, pressure response, pressure ulcers, pressure volume, pressure volume relation, pressure ≥, pressure-overload, pressure-overload hypertrophy, pressure-overload-induced, pressure-overload-induced heart, pressure-overload-induced heart failure, pressure-overload-induced hypertrophy, pressure-volume, pressure-volume conductance, pressure-volume conductance catheter, pressure-volume conductance catheter system, pressures, prevalence, prevalence of heart, prevalence of heart failure, prevalence of hf, prevalent, prevalent coronary, prevalent coronary heart, prevalent coronary heart disease, prevalent hf, prevent adverse outcomes, prevent cardiovascular complications, prevent readmissions, prevent sudden death, preventable, preventable readmission, prevented insulin, prevented insulin action, prevention, prevention of hf, prevention strategies, prevention trial, preventive, preventive measures, prevents, prevents cell, prevents cell senescence, prevents ventricular dysfunction, previous, previous pacemaker, previous revascularization, previous spironolactone, previous spironolactone use, previous studies, primary, primary care, primary care clinicians, primary composite, primary composite endpoint, primary culprit, primary diagnosis, primary efficacy, primary efficacy end, primary efficacy end points, primary efficacy outcome, primary end, primary end point, primary endpoint, primary isolated cabg, primary mechanism, primary oscillations, primary outcome, primary outcome of death, primary outcomes, primary safety, primary safety end, primary safety end point, primary study, primary study end, primary study end point, primary symptom, primary symptoms, principal, principal discharge, principal discharge diagnosis, principal findings, principal mechanisms, principle, principles, prior, prior cardiovascular, prior cardiovascular disease, prior hf, prior hf hospitalisations, prior myocardial, prior myocardial infarction-both, prior stroke, prior stroke score, priorities, priorities impact, priorities impact prescribing, pro-adrenomedullin, pro-b-type, pro-b-type natriuretic peptide, pro-b-type natriuretic peptides, pro-b-type natriuretic peptides in plasma, pro-brain, pro-brain natriuretic, pro-brain natriuretic peptide, pro-brain-type, pro-brain-type natriuretic peptide, pro-brain-type natriuretic peptide assessment, pro2-leu3, pro6-gly7, pro75-arg76, proangiogenic, proangiogenic effects, proanp, probability, probability after catheter, probability after catheter ablation, problem, problematic, problems, problems in patients, probnp, procedural, procedural adverse, procedural adverse events, procedure, procedure coding, procedure coding system, procedure coding system codes, procedure-related, procedure-related major, procedure-related major adverse, procedure-related major adverse neurological, procedures, process, process redesign, process redesign contextual framework, processed forms, processes, processes in chf, processes in chf inhibition, processes of care, processes of care delivery, processing, prodrug, produce test, produce test results, produced cardiac dysfunction, produced conflicting results, produced reverse remodeling, produces beneficial effects, production, production by ec, production of ec, production rates, products, professionals, profile, profile of paf, profiling, profound, profound change, progenitor, progenitor cells, progenitor function, progenitors, prognosis, prognosis after lvad, prognosis after lvad surgery, prognosis in heart, prognosis in heart failure, prognosis in hfpef, prognosis in patients, prognosis of c'd hf, prognosis of patients, prognostic, prognostic ability, prognostic assessment, prognostic benefit, prognostic biomarkers, prognostic biomarkers in patients, prognostic composite, prognostic composite hf, prognostic composite hf index, prognostic factor, prognostic factor in heart, prognostic factor in heart failure, prognostic factor in patients, prognostic factors, prognostic factors at admission, prognostic indicator, prognostic indicator in heart, prognostic indicator in heart failure, prognostic indicator in patients, prognostic information, prognostic markers, prognostic meaning, prognostic power, prognostic purposes, prognostic relevance, prognostic resolution, prognostic role, prognostic role in hf, prognostic significance, prognostic significance of bnp, prognostic value, prognostic value in patients, program, program infrastructure, program of exercise, program of exercise rehabilitation, programme, programme for patients, programmed cell, programmed cell death, programmes, programmes on completion, programs, programs in heart, programs in heart failure, progress, progress in anticoagulation, progression, progression from hypertrophy, progression of heart, progression of heart failure, progression of hf, progression to heart, progression to heart failure, progressive, progressive development, progressive disease, progressive loss, project, projecting long-term costs, projections, projections of resource, projections of resource use, prolapse, prolongation, prolonged, prolonged electromechanical delay, prolonged emd, promise, promising, promising alternative, promising biomarker, promising biomarker in heart, promising biomarker in heart failure, promising biomarkers, promising field, promising field of investigation, promising targets, promote adoption, promotes cardiac angiogenesis, promotes restoration, promoting transcriptional pause, promoting transcriptional pause release, prone, pronounced decreases, pronounced increases, pronounced symptoms, pronto, proof-of-principle, proof-of-principle cohort, proof-of-principle cohort study, propensity, propensity score, propensity score decile, propensity score-matched analyses, propensity-score, propensity-score matched control, propensity-score matched control group, properties, property, proportion, proportion of deficits, proportion of patients, proportional, proportional hazard, proportional hazard analyses, proportional hazard models, proportional hazards, proportional hazards models, proportional hazards regression, proportional to lv, proportional to lv dilatation, propose fundamental definitions, propranolol, prospective, prospective assessment, prospective assessment of body, prospective assessment of body composition, prospective data, prospective experimental, prospective experimental research, prospective hf, prospective hf registry, prospective randomized, prospective randomized multicenter, prospective randomized multicenter trial, prospective randomized multicenter trial paradigm-hf, prospective studies, prospective study, prospective validation, prospective validation cohort, prostate, protection, protection of mitochondrial, protective, protective effects, protective effects of exercise, protective effects of exercise training, protective mechanisms, protective peptides, protective role, protein, protein changes, protein complex, protein content, protein content for sr, protein expression, protein kinase, protein kinase r-like, protein kinase r-like er kinase, protein levels, protein response, protein-c, protein-c phosphorylation, proteins, proteolysis, proteome, proteome changes, proteome of hdl, proteome of hdl particles, proteomic, proteomic alterations, proteomic remodeling, proteomics, proteomics approach, proteomics changes, protocol, protocol-driven, protocol-driven poc, protocol-driven poc testing, protocol-driven poc testing of np, protocols, provide brief insight, provide clinical recommendations, provide consensus, provide information, provide insight, provide long-term support, provide patients, provide potential benefit, provide support, provided better-than-usual support, provided self-care education, provided venoarterial dilation, provider, providers, providing guideline-recommended care, providing prognostic information, province, province of alberta, province of québec, provision, provoke acute rv, provoke acute rv decompensation, proximal, proximal circumflex, proximal circumflex artery, proximal lad, proximal lad model, proximal lcx, psoriasis, psoriasis patients, psss, psychometric, psychometric profile, psychometric testing, psychosocial, psychosocial factors, psycinfo, public, public health, public health problem, public reporting, public reporting on quality, public reporting on quality aims, publications, published literature, published taxonomy, published techniques, published trials, pubmed, pulmonary, pulmonary arterial, pulmonary arterial hypertension, pulmonary arterial hypertension medication, pulmonary arterial pressure, pulmonary arterial systolic, pulmonary arterial systolic pressure, pulmonary arterial systolic pressure relationship, pulmonary arterial systolic pressure relationship in heart, pulmonary arterial systolic pressure relationship in heart failure, pulmonary arterial vasculature, pulmonary arteries, pulmonary artery, pulmonary artery systolic, pulmonary artery systolic pressure, pulmonary capillary, pulmonary capillary wedge, pulmonary capillary wedge pressure, pulmonary congestion, pulmonary disease, pulmonary embolectomy, pulmonary embolism, pulmonary hypertension, pulmonary hypertension patients, pulmonary resistance, pulmonary vascular, pulmonary vascular resistance, pulsatile, pulsatile afterload, pulsatile devices, pulse, pulse sequence, pulse-wave, pulse-wave velocity, pulseless, pulseless ventricular fibrillation, pump, pump dysfunction, pump exchanges, pump failure, pump function, pump malfunctions, pump replacement, pump thrombosis, pump-exchange, pump-exchange technique, pure, pure epicatechin, pure hno, pure hno donor, purely hemodynamic, purpose, purpose of review, purposes, pvf, pyridostigmine, pyridostigmine administration, pyridostigmine prevents, pyridostigmine prevents ventricular dysfunction, q waves, q65p, q66p, qol, qrs, qrs complex, qrs duration, qrs morphology, qrs prolongation, qrs width, qt, qt interval, qt intervals, qt variability, qtv, quadriceps, quadriceps force, qualitative, qualitative study, quality, quality aims, quality for hf, quality improvement, quality improvement database, quality improvement initiative, quality indicators, quality measure, quality measure for heart, quality measure for heart failure, quality measures, quality of care, quality of care outcomes, quality of care programme, quality of life, quality of life assessment, quality of life domains, quality of life score, quality of lv, quality of lv dysfunction, quality of outcome, quality of outcome measures, quality-adjusted, quality-adjusted survival, quality-of-life, quality-of-life score, quality-of-life scores, quantification, quantify changes, quantitative, quantitative analysis, quantitative proteomics, quarterly, quarterly inpatient, quarterly inpatient admissions, quarterly inpatient admissions from baseline, quartile, quartile of e, quartiles, quasi-experiment, questionnaire, questionnaire in patients, questionnaire summary, questionnaires, questions, quick, quintile, quintile of performance, quintiles, quotient, québec, québec health, québec health insurance, québec health insurance board, québec health insurance board databases, r-like, r-like er kinase, r-r, r-r interval, r-r interval oscillations, ra population, raas, rabbits, rac1, rac2, race, race by treatment, race by treatment interaction, race in patients, race influences, race influences efficacy, rad, rad variant, radial, radial arterial, radial arterial tonometry, radial artery, radial artery tonometry, radial artery tonometry variables, radial strain, radiation, radiological, radiological signs, radiological signs of hf, raft, raise awareness, raised blood, raised blood glucose, raised blood glucose levels, rales, raloxifene, raloxifene-treated, raloxifene-treated patients, ramirez-sanchez, random-effects, random-effects models, randomised, randomised studies, randomised-controlled, randomised-controlled trials, randomization, randomization group, randomized, randomized aldactone, randomized aldactone evaluation, randomized aldactone evaluation study, randomized clinical, randomized clinical trial, randomized clinical trials, randomized control, randomized control studies, randomized controlled feasibility, randomized controlled feasibility study, randomized controlled trial, randomized multicenter, randomized multicenter trial, randomized multicenter trial paradigm-hf, randomized study, randomized study of exercise, randomized study of exercise training, randomized trial, randomized trials, range, range muscle, range muscle wasting, rank, ranked hospitals, rankin, rankin score, rankings, rapid, rapid onset, rapid r-r interval, rapid r-r interval oscillations, rapid right, rapid right ventricular, rapid right ventricular pacing, rare, rare in outpatients, ras, ras blockers, ras-blocker, ras-blocker uptitration, rat, rat left ventricular, rat metabolic, rat metabolic risk, rat metabolic risk model, rat model, rat ventricular, rat ventricular cardiomyocytes, rate, rate at diastole, rate at systole, rate control, rate during exercise, rate for patients, rate in patients, rate of chf, rate of death, rate of rehospitalization, rate ratio, rate reduction, rate reduction with ivabradine, rate response, rate variability, rate variability in risk, rate variability in risk stratification, rate variation, rate-control, rate-control group, rate-control patients, rate-control strategies, rate-control treatment, rate-control treatment strategies, rates, rates for hf, rates for hf patients, rates of changes, rates of death, rates of ed, rates of ed visits, rates of energy, rates of energy substrate, rates of energy substrate metabolism, rates of glycolysis, rates of hyperkalemia, rates of hypertension, rates of hypokalemia, rates of patients, rates of treatment, ratings, ratings from admission, ratio, ratio ees, ratio for death, ratio form, ratio of lv, ratio of lv strain, ratio of lv strain rate, ratio of peak, ratio of phosphocreatine, rationale, ratios, ratios for pcwp estimation, ratios for variables, ratios from user, ratios from user inputs, rats, rats after heart, rats after heart failure, rcts, re-activating, re-activating transcription, re-express, re-hospitalization, reach statistical significance, reached primary outcome, reaching statitistical significance, reactivation, reader, reader proteins, readers, readmission, readmission after discharge, readmission among patients, readmission metric choice, readmission metrics, readmission quality, readmission quality improvement, readmission quality improvement initiative, readmission rate, readmission rate for patients, readmission rates, readmission reduction, readmission reduction program, readmissions, readmissions as part, readmissions in heart, readmissions in heart failure, readmissions in hfref, real, real progress, real world, real-time, real-world, real-world setting, reality, reality of heart, reality of heart failure, reason, reasons, reasons for nontreatment, reasons per patient, recapitulates, receive bisoprolol, receive cardiac resynchronization, receive cardiac resynchronization therapy, receive ongoing gdmt, received spironolactone, received surgical palliation, received transplants, received trastuzumab, received uptitration, receiver, receives little attention, receiving angiotensin-converting enzyme, receiving angiotensin-converting enzyme inhibitors, receiving carvedilol, receiving chemotherapy, receiving ecmo, receiving extracorporeal membrane, receiving extracorporeal membrane oxygenation, receiving extracorporeal membrane oxygenation membrane, receiving extracorporeal membrane oxygenation membrane support, receiving guideline-recommended drugs, receiving implantable cardioverter, receiving implantable cardioverter defibrillator-crt, receiving methotrexate, receiving metoprolol, receiving optimal therapy, receiving pd, receiving ventricular assist, receiving ventricular assist device, receiving ventricular assist device support, receptor, receptor activation, receptor agonist, receptor antagonist, receptor antagonist therapy, receptor antagonist valsartan, receptor antagonists, receptor antagonists in heart, receptor antagonists in heart failure, receptor blockade, receptor blocker, receptor blocker therapy, receptor blocker use, receptor blockers, receptor blockers in case, receptor blockers therapy, receptor family, receptor family member, receptor haplotype, receptor neprilysin, receptor neprilysin inhibitor, receptor neprilysin inhibitor in heart, receptor neprilysin inhibitor in heart failure, receptor potential cation, receptor potential cation channel, receptor stimulation, receptor type, receptors, receptors blockers, recipients, reciprocal, reciprocal downregulation, reciprocal downregulation influences, reciprocal regulation, reciprocal regulation in mouse, reciprocal regulation in mouse hearts, reclassification, reclassification improvement, reclassification of risk, recognition, recommend blood, recommend blood transfusions, recommend cardiac resynchronization, recommend cardiac resynchronization therapy, recommendation, recommendations, recommendations assessment, recommendations for patients, recommendations in heart, recommendations in heart failure, recommendations in hf, recommended medications, recommended target, recommended target dose, recommended therapies, recommended therapies registry, reconstructed, reconstructed aortic, reconstructed aortic pressure, reconstructed aortic pressure curve, recorded improvements, recorded mortality, records, records of patients, records of surface, records of surface ecgs, recovery, recovery period, recreational, recreational athletes, recruitment, recurrent, recurrent hf, red, red blood, red blood cell, red blood cell transfusion, red blood cell transfusion strategy, redesign, redesign contextual framework, redo, redo sternotomy, reduce all-cause mortality, reduce cardiovascular complications, reduce costs, reduce morbidity, reduce mortality, reduced, reduced atp, reduced atp content, reduced average length, reduced cardiac diameters, reduced cardiac fibrosis, reduced clinic, reduced ef, reduced ejection, reduced ejection fraction, reduced gross income, reduced hospitalizations, reduced kd, reduced long axis, reduced long axis function, reduced lv, reduced lv contractility, reduced lv ejection, reduced lv ejection fraction, reduced lvef, reduced mitochondrial, reduced mitochondrial complex, reduced mortality, reduced mortality risk, reduced parasympathetic control, reduced peak, reduced peak oxygen, reduced peak oxygen uptake, reduced quality, reduced risk, reduced skeletal muscle, reduced skeletal muscle mass, reduced sympathetic control, reduced sympathetic tone, reduced ventricular mass, reduced wall, reduces afterload, reduces morbidity, reduces total mortality, reducing all-cause mortality, reducing ea, reducing length, reducing mortality, reduction, reduction by ivabradine, reduction by surgery, reduction in blood, reduction in blood pressure, reduction in ea, reduction in hospital, reduction in hospital length, reduction in lv, reduction in lvef, reduction in mortality, reduction in mva, reduction in patients, reduction in risk, reduction program, reduction with ivabradine, reductions, reductions in lv, reductions in lv end, reductions in lvef, reference, reference data, reference lists, reference subjects, reference values, referent, referent age, referent age group, referral, referral centre, referrals, refill, refill compliance, reflect postsystolic, reflect postsystolic function, reflecting marked decreases, reflecting rapid r-r, reflecting rapid r-r interval, reflecting rapid r-r interval oscillations, reflective, reflective of decongestion, refractory, refractory cardiogenic, refractory cardiogenic shock, refractory congestive, refractory congestive heart, refractory congestive heart failure, refractory right heart, refractory right heart failure, refractory severe-end-stage, refractory severe-end-stage hf, regeneration, regimen, regimens, region, region of messenger, region of messenger rna, region with hf, region with hf risk, region with hf risk factors, regional, regional circumferential, regional circumferential strain, regional strain, regional strain contributions, regions, registries, registry, registry from july, registry on dialysis, registry practice, registry practice innovation, regression, regression analyses, regression analysis, regression line, regression line shift, regression line shift in nonsurvivors, regression models, regular, regular physical, regular physical activity, regular physical activity controls, regulate expression, regulates cardiac sodium, regulates cardiac sodium current, regulates ventricular action, regulating cellular metabolism, regulation, regulation in mouse, regulation in mouse hearts, regulation of feeding, regulation of rad, regulator, regulator of cytoskeletal, regulator of cytoskeletal actin, regulator of cytoskeletal actin dynamics, regulator of growth, regulatory, regulatory involvement, regulatory subunit, regurgitation, rehabilitation, rehabilitation care, rehabilitation in china, rehabilitation in patient, rehabilitation in patients, rehospitalization, rehospitalization for stroke, rehospitalization of medicare, relation, relation of hemoglobin, relation to sustainability, relations, relations between cpcs, relationship, relationship between length, relationship between pathobiology, relationship between physician, relationship between physician volume, relationship between qrs, relationship between qrs duration, relationship between sex, relationship between tapse, relationship in heart, relationship in heart failure, relationships, relationships with mortality, relative, relative appendicular, relative appendicular lean, relative appendicular lean mass, relative appendicular lean mass index, relative decrease, relative minimal, relative minimal detectable, relative minimal detectable change, relative reduction, relative risk, relative risk among trials, relative value, relative value of mdc, relative wall, relax-ahf, relaxation, release, relevance, relevant, relevant articles, relevant health, relevant health service, relevant health service provision, relevant to individuals, reliability, reliable, reliable diagnostic, reliable in patients, reliable measure, reliable measure of health, reliable measure of health status, reliable mortality, reliable mortality predictors, reliable mortality predictors in icd-hf, reliable mortality predictors in icd-hf patients, relieve congestive symptoms, religious, religious beliefs, rem, rem2, remaining indices, remaining patients, remarkable, remarkable increase, remarkable increase in camp, remarkable increase in camp hydrolysis, remarkable role, remodeling, remodeling after crt, remodeling aspects, remodeling aspects to emd, remodeling aspects to emd prolongation, remodeling events, remodeling in hf, remodeling in systolic, remodeling parameters, remodelling, remote, remote ischemic, remote ischemic conditioning, remote ischemic conditioning for patients, remote monitoring, removal, remove heart, remove heart iron, renal, renal artery, renal artery stenosis, renal atherosclerotic, renal atherosclerotic lesions, renal chloride, renal chloride channel, renal chloride channel gene, renal denervation, renal disease, renal disease in outpatients, renal dnx, renal dysfunction, renal failure, renal function, renal function end, renal function end point, renal function in children, renal function in patients, renal impairment, renal optimization, renal optimization strategies, renal optimization strategies evaluation, renal underperfusion, renastur, renastur cohort, renin, renin inhibitors, renin-angiotensin, renin-angiotensin system, renin-angiotensin system blocker, renin-angiotensin-aldosteron, renin-angiotensin-aldosterone, renin-angiotensin-aldosterone system, renin-angiotensin-aldosterone system inhibitors, renin-angiotensin-aldosterone system inhibitors in heart, renin-angiotensin-aldosterone system inhibitors in heart failure, reoperation, reoperation for bleeding, repair, repairs, repeat, repeat ed, repeat ed visits, repeat metabolic, repeat procedures, repeated echocardiography, repeated interventions, repeated measures, reperfusion, reperfusion therapy, replacement, replicating resource, replicating resource use, repolarization, repolarization instability, repolarization instability in patients, repolarization lability, report, report model, report severe perturbations, reported greater risk, reporting, reporting on quality, reporting on quality aims, reports, represents true change, repression, reproducible, reprogramming events, republic, require consultation, required biventricular support, required heartmate, required heartmate ii, required heartmate ii insertion, required isolated heartmate, required isolated heartmate ii, required isolated heartmate ii lvad, requirement, requirements, requires careful evaluation, requires confirmation, requires diagnostic procedures, requires new prevention, requires new prevention strategies, requiring biventricular support, requiring isolated heartmate, requiring isolated heartmate ii, requiring isolated lvad, requiring pump, requiring pump replacement, requiring revision, requiring surgery, requiring surgical intervention, requiring temporary rv, requiring temporary rv support, research, research design, research initiatives, research investigations, research questions, research requirements, research studies, researchers, resection, reserve, reserve in patients, reserve measurements, residents, residents of olmsted, residents of olmsted county, residents with hf, residual, resistance, resistance training, resistance training intervention, resistant, resistant hypertension, resistant volume, resistant volume overload, resistant volume overload in heart, resistant volume overload in heart failure, resistin, resistin in heart, resistin in heart failure, resistin levels, resistin levels in women, resistive, resolution, resonance, resonance angiography, resonance imaging, resonance imaging on chelation, resonance imaging on chelation choices, resonance postcontrast, resonance spectroscopy, resort, resource, resource use, resource utilization, resources, resources within health, resources within health systems, respect, respect to alterations, respective, respective age, respective age categories, respective molecular, respective molecular pathways, respective molecular pathways in patients, respiration, respiration for quantification, respiratory, respiratory gas, respiratory gas analysis, respiratory gas analysis at baseline, respiratory quotient, response, responses, responses in cardiomyocytes, responses to heart, responses to heart failure, responsible, responsible diagnosis, responsible diagnosis of heart, responsible diagnosis of heart failure, responsive, responsiveness, rest, resting hemodynamics, resting tension, restoration, restorative, restorative effects, restored β-ar responsiveness, restoring functional capacity, restricted closure, restriction, restrictive, restrictive red, restrictive red blood, restrictive red blood cell, restrictive red blood cell transfusion, restrictive red blood cell transfusion strategy, result, result of shortcomings, results, results of patients, results of studies, results—retrospective, results—retrospective cohort, resuscitation, resynchronization, resynchronization therapy, resynchronization-defibrillation, resynchronization-defibrillation for ambulatory heart, resynchronization-defibrillation for ambulatory heart failure, resynchronization-defibrillation for ambulatory heart failure trial, resynthesis, retention, retention trial, reticular, reticulum, retn, retn gene, retrospective, retrospective chart, retrospective chart review, retrospective cohort, retrospective cohort study, retrospective cohort study from denmark, retrospective descriptive, retrospective descriptive research, retrospective descriptive research design, retrospective observational, retrospective observational study, retrospective observational study in children, retrospective studies, revascularization, reversal, reversal of changes, reverse, reverse cardiac remodeling, reverse remodeling, reverse remodeling after crt, reverse remodeling parameters, reverses remodeling, reversibility, reversibility of heart, reversibility of heart failure, reversible, reversible by metoprolol, reversible myocardial, reversible myocardial ischemia, reversible with metoprolol, review, review protocol, reviewers, reviews, revision, rgk, rgk protein, rgk proteins, rheumatic, rheumatic fever, rheumatoid, rheumatoid arthritis, rhythm, rhythm at follow-up, rhythm control, rhythm control therapy, rhythm-control, right, right atrial, right atrial area, right atrial mass, right atrial mass removal, right atrial myxoma, right atrial pressure, right atrium, right atrium mass, right coronary, right coronary artery, right grip, right grip strength, right heart, right heart circulation, right heart failure, right heart failure with therapy, right heart failure with therapy refractory, right heart foundation, right heart foundation working, right heart foundation working group, right pulmonary, right pulmonary artery, right ventricle, right ventricle in heart, right ventricle in heart failure, right ventricle overload, right ventricular, right ventricular contractile, right ventricular contractile function, right ventricular contractile reserve, right ventricular contractile reserve in patients, right ventricular dysfunction, right ventricular ejection, right ventricular ejection fraction, right ventricular end-diastolic, right ventricular end-diastolic area, right ventricular end-diastolic area index, right ventricular fractional, right ventricular fractional area, right ventricular fractional area change, right ventricular function, right ventricular pacing, right ventricular pressure, right ventricular pressure overload, right ventricular pump, right ventricular pump function, right ventricular support, right ventricular-pulmonary, right ventricular-pulmonary arterial, right ventricular-pulmonary arterial coupling, right-sided, right-sided cardiac, right-sided cardiac catheterization, rigorous, rigorous investigation, riiα, ring, ring annuloplasty, ring implantation, ring size, rise, rise in camp, rise in camp levels, risk, risk among patients, risk among trials, risk avoidance, risk factor, risk factors, risk factors on hf, risk factors on hf mortality, risk for esrd, risk for heart, risk for heart failure, risk for hf, risk for hhf, risk for hospitalized, risk for hospitalized heart, risk for hospitalized heart failure, risk for hyperkalemia, risk for stroke, risk in communities, risk in communities study, risk in men, risk model, risk of chf, risk of death, risk of event, risk of gls, risk of heart, risk of heart disease, risk of heart failure, risk of hf, risk of hf hospital, risk of hf hospital admissions, risk of hf mortality, risk of hospital, risk of hospital admission, risk of hospitalization, risk of hyperkalemia, risk of ie, risk of incident, risk of incident cvd, risk of mortality, risk of potassium, risk of stroke, risk prediction, risk predictor, risk reduction, risk score, risk stratification, risk stratification for death, risk stratification models, risk stratification of patient, risk-adjusted, risk-adjusted all-cause, risk-adjusted all-cause mortality, risk-adjusted mortality, risk-standardized, risk-standardized mortality, risks, risks of hospitalization, riα, riα proteins, rm interventions, rm strategies, rmsea, rna, rna polymerase, rna polymerase ii, rnas, robot-assisted, robot-assisted gait, robot-assisted gait therapy, robot-assisted training, robot-assisted training for heart, robot-assisted training for heart failure, robust, robust predictor, role, role for inflammation, role for micrornas, role in cc, role in downregulation, role in hf, role in hf care, role of bets, role of mena, role of nucleolin, role of vasopressin, roles, roles of bnp, room, room practice, ros, ros effects, rose, rose acute, rose acute heart, rose acute heart failure, rotation, rotations, rotor, rotterdam, rotterdam study, rounds, routine, routine bnp, routine bnp measurements, routine clinical, routine clinical tool, routine clinical tool for risk, routine clinical tool for risk stratification, routine measurement, routine np, routine np assessment, routine np assessment of ed, routine np assessment of ed patients, rrna, rrna transcription, rs synchrony, rs10927887, rs13058338, rs1799945, rs8187710, rtq-pcr, rule, ruptures, rural, rural south, rural south dakota, rv decompensation, rv dysfunction, rv failure, rv failure management, rv failure management in pah, rv fiber, rv fiber shortening, rv function, rv function evaluation, rv function on body, rv function on body composition, rv length-force relationship, rv support, rvad, rvads, rvpo, rvpo with bivp, rwt, s'lateral, s'septal, s12884, s1pr1, s1pr1s, s3991, saf, saf cohort, saf versus pf, safe, safe pump-exchange, safe pump-exchange technique, safety, safety end, safety end point, safety initiatives, safety measures, safety monitoring, safety monitoring board, safety monitoring system, safety of catheter, safety of catheter ablation, safety of chm, safety of rhythm, safety of rhythm control, safety of rhythm control therapy, safety of spironolactone, salt, salt intake, salt loading, sample, samples, sampling frame, sandwich, sandwich alphalisa, sarcomere, sarcomere shortening, sarcomere structure, sarcomere structure in patients, sarcomeric, sarcomeric microstructure, sarcomeric microstructure at baseline, sarcopenic, sarcopenic range, sarcopenic range muscle, sarcopenic range muscle wasting, sarcoplasmic, satisfaction, satisfaction responses, savings, saxagliptin, saxagliptin users, saxagliptin versus insulin, saxagliptin versus pioglitazone, saxagliptin versus sitagliptin, saxagliptin versus sulfonylureas, scaffold, scaffold protein, scaffold proteins, scaffolds, scaffolds in heart, scaffolds in heart pathology, scale, scale dimensions, scale score, scales, scaling, scaling exponent, scanner, scans, scar, scar size, scarce, scenario, scenarios, schfi, sci, science, scientific, scientific literature, scn5a, score, score components, score decile, score for prediction, score of minnesota, score of minnesota quality, score range, score value, score with death, score with exercise, score-matched, score-matched analyses, scores, scores with mortality, screened participants, screening, screening patients, sdqt, sdqt in hnorm, sdqt in hnorm subjects, sdqt-to-sdrr, sdqt-to-sdrr ratio, sdrr, search, seattle, seattle heart, seattle heart failure, seattle heart failure model, seattle heart failure model scores, second, second evaluation, second hf, second trial, second-generation, second-generation sulfonylureas, secondary, secondary end, secondary end point, secondary end points, secondary end points reflective of decongestion, secondary endpoints, secondary outcome, secondary outcome measures, secondary outcome of death, secondary outcomes, secondary study, secondary study end, secondary study end point, secondary to multiorgan, secondary to multiorgan failure, secondary to pressure-overload, seconds, secretion, secretion of arginine, secretion of arginine vasopressin, seer-medicare, segment, select, select patients, selected antihyperglycemic agents, selected cardiac surgery, selected cardiac surgery patients, selected citations, selected practices, selecting controls, selecting patients, selection, selective, selective beta-blockers, selective heart, selective heart rate, selective heart rate reduction, selective heart rate reduction with ivabradine, selective β-blocker, selective β-blocker metoprolol, self-care, self-care confidence, self-care confidence scale, self-care education, self-care education at discharge, self-care maintenance, self-care maintenance scale, self-care management, self-care management scale, self-care of heart, self-care of heart failure, self-care of heart failure index, self-care of heart failure index version, self-identified, self-identified black, self-identified black patients, self-management, self-management counseling, self-management training, self-management training of patients, self-rated, self-rated depression, self-rated depression scores, self-reported, self-reported physical, self-reported physical activity, senescence, sensitive, sensitive measure, sensitivity, separate, separate cohort, separate cox, separate cox regression, separate scale, separate scale dimensions, separate sub-sample, sepsis, septal, septal defects, septal wall, septal wall cs, septal wall cs during avd, septal wall cs during avd variation, september, septum, septum biopsies, sequence, sequence-specific, sequence-specific binding, sequential, sequential phosphorylation, ser77, ser83, ser96, serial, serial evaluation, serial measurements, serial measurements of cpcs, series, series of acs, series of acs problems, serum, serum albumin levels, serum creatinine, serum creatinine level, serum cystatin, serum cystatin c, serum cystatin c from enrollment, serum factors, serum levels, serum levels of brain, serum levels of creatinine, serum potassium, serum potassium level, serum resistin, serum resistin levels, serum resistin levels in women, serum sodium, serum sodium levels, service, service planning, service provision, services, services demonstration, set, set of transcription, set of transcription factors, set of variables, setting, setting of disease, setting of disease recapitulates, settings, seventy-seven, seventy-seven cases, severe, severe ai, severe anemia, severe cad, severe developmental, severe developmental impairment, severe end-stage, severe end-stage hf, severe frailty, severe heart, severe heart failure, severe hf, severe hyperkalemia, severe hypertension, severe hyponatremia, severe ischemia, severe ischemia after bottleneck, severe ischemia after bottleneck stenting, severe left, severe left ventricular, severe left ventricular dilatation, severe lv, severe lv fibrosis, severe lv systolic, severe lv systolic dysfunction, severe mr, severe perturbations, severe perturbations in components, severe pulmonary, severe pulmonary hypertension, severe reductions, severe reductions in lvef, severe systolic, severe systolic dysfunction, severe systolic heart, severe systolic heart failure, severe systolic hf, severe-end-stage, severe-end-stage hf, severity, severity index, severity of heart, severity of heart failure, sex, sex differences, sex-adjusted, sex-adjusted risk, sex-matched, sex-matched controls, sex-matched reference, sex-matched reference values, sex-specific, sex-specific model, sex-specific models, sh, shah, sham, sham explants, sham group, sham levels, sham levels by dnx, sham levels by renal, sham levels by renal dnx, sham-dnx, sham-innervated, sham-inv, sham-operated, sham-operated animals, shams, shape, sheet, sheet orientation, shift, shift in nonsurvivors, shock, shock therapy, shocks, shocks at end, short, short follow-up, short physical, short physical performance, short physical performance battery, short-form, short-form quality, short-form quality of life, short-form quality of life domains, short-term, short-term fractal, short-term fractal scaling, short-term fractal scaling exponent, short-term improvements, short-term improvements in functioning, short-term mortality, short-term mortality rates, short-term outcomes, short-term treatment, short-term treatment with ivabradine, shortcomings, shortcomings in research, shortcomings in research studies, shortened lvet, shortening, shortening onset, shortening velocity, shortens, shorter, shorter in patients, shortness, shortness of breath, shotgun, shotgun proteomics, shotgun proteomics approach, showing minor improvement, shunt, shunt implantation, shunt implants, shunting, shunting for treatment, shunting in patients, shunts, shuttle, shuttle walk, shuttle walk test, sickle, sickle cell, sickle cell disease, side, side effects, signal, signal transduction, signal transduction cascade, signal transduction to pol, signal transduction to pol ii, signaling, signaling paradigms, signaling pathway, signaling pathway changes, signaling pathways, signalling, signalling cascades, signalling pathway, signalling pathways, signalling proteins, signed-rank, signed-rank tests, significance, significance of bnp, signifies repolarization, signifies repolarization lability, signs, signs in hfpef, signs of heart, signs of heart failure, signs of hf, simple, simple clinical, simple clinical prediction, simple clinical prediction rule, simple ecg, simple ecg parameters, simple experimental, simple experimental procedures, simple sex-specific, simple sex-specific model, simpler, simpler laboratory, simpler laboratory report, simpler laboratory report model, simulation, simulation models, simulation results, simulation tool, simulations, simultaneous, simultaneous activation, simultaneous reduction, single, single center, single center retrospective observational study in children, single diagnostic, single diagnostic test, single diagnostic test for hfpef, single parameters, single tertiary, single tertiary referral, single tertiary referral centre, single-arm, single-arm analysis, single-center, single-centre, single-cohort, single-cohort study, single-cohort study designs, single-institution, single-institution cohort, single-payer, single-payer perspective, sinus, sinus rhythm, sinus rhythm at follow-up, sitagliptin, sitagliptin users, sitagliptin versus insulin, sitagliptin versus pioglitazone, sitagliptin versus sulfonylureas, site, site specific riiα, site-specific, site-specific monoclonal, site-specific monoclonal antibodies, sites, sites in north, sites in north america, situation, situations, situations in pediatrics, sixteen, sixteen new york, sixteen new york heart, sixteen new york heart association, sixteen new york heart association class, sixty-one, sixty-one patients, sixty-one patients with hfpef, size, size reduction, size reduction by surgery, sized, sized lv, skeletal, skeletal muscle, skeletal muscle abnormalities, skeletal muscle mass, skeletal muscle mass t-score, skeletal muscle sarcomere structure in patients, skilled, skilled nursing, skilled nursing facilities, skinfold, skinfold thickness, skm, skm biopsies, skm growth, skm mitochondrial structure, slope, slow hf, slow hf evolution, slow progression, slowed conduction, slower, slower increase, slower increase in heart, slower increase in heart rate, slowness, slows myofiber shortening, slows myofiber shortening velocity, smad, small, small gtpase, small muscle, small muscle strips, small noncoding rnas, small pilot, small pilot study, small retrospective, small retrospective studies, small studies, small subgroup, small subgroup of children, small trial, small trial of patients, small-molecule, small-molecule inhibitors, smaller, smallest, smallest difference, smoking, smoking cessation, snp, so-called, so-called end, so-called end stage, social, social mandate, social support, social support score, society, society guidelines, society of cardiology, society of cardiology guidelines, socioeconomic, socioeconomic status, socioeconomic status versus whites, sodium, sodium current, sodium levels, sodium restriction, sodium-restricted, sodium-restricted dash, sodium-restricted dash diet, sodium-restricted dietary, sodium-restricted dietary approaches, solid, solid ehrlich, solid ehrlich carcinoma, soluble, soluble concentrations, soluble guanylate, soluble guanylate cyclase, sonographic, sound, sound mind, source, sources, south, south dakota, southeastern, southeastern minnesota, southeastern minnesota residents, southeastern minnesota residents with hf, span, sparing approach, spearman, spearman correlations, special, special access, special access programme, special therapeutic, special therapeutic interventions, special treatment, specialised, specialised care, specialized, specialized hf, specialized hf resources, specialized hf resources within health, specialized hf resources within health systems, specialty, specialty hospital, specific, specific aetiologies, specific antagomir, specific diagnostic, specific effector, specific effector molecules, specific inclusion, specific research, specific research questions, specific riiα, specific signalling pathways, specificity, specificity for cad, speckle, speckle tracking, speckle tracking echocardiography, spectral, spectral analysis, spectrometric, spectrometric analysis, spectrometry, spectroscopy, sphingosine-1-phosphate, spironolactone, spironolactone dose, spironolactone in adults, spironolactone in non-aas, spironolactone use, spite, spite of developments, splice, splice variants, splicing, spontaneous, spontaneous cardiac, spontaneous cardiac dysfunction, spontaneous ventricular, spontaneous ventricular tachycardia, spontaneous vt, sport, sprague-dawley, sprague-dawley rats, srd, ss20, ss31, sst2, st-segment-elevation, st-segment-elevation mis, st2, stabilized chronic heart, stabilized chronic heart failure, stable, stable body, stable body weight, stable body weight in cc, stable cad, stable chronic, stable chronic heart, stable chronic heart failure, stable clinical, stable clinical conditions, stable coronary, stable coronary artery, stable coronary artery disease, stable guideline-directed, stable guideline-directed medical, stable guideline-directed medical therapy, stable heart, stable heart failure, stable heart failure patients, stable hf, stable hfpef, stable phenotypes, stable severe, stable severe systolic, stable severe systolic heart, stable severe systolic heart failure, stable severe systolic hf, stable situation, staff, stage, stage heart, stage heart failure, stage kidney, stage kidney failure, stage of chf, stages, stages of heart, stages of heart failure, stand-alone, stand-alone diagnostic, stand-alone diagnostic devices, standard, standard cardiac, standard cardiac rehabilitation, standard cardiac rehabilitation care, standard care, standard clinical, standard clinical practice, standard criteria, standard echocardiographic, standard echocardiographic measurements, standard error, standard error of measurement, standard error of measurement value, standard heart, standard heart failure, standard heart failure medicines, standard practice, standard therapy, standardized, standardized exercise, standardized exercise protocol, standardized nursing, standardized nursing terminologies, standards, standards in biomarker, standards in biomarker studies, standing blood, standing blood pressure, start, start date, state, state like south, state like south dakota, state of pka, state of pka subunits, states, statewide, statewide health, statewide health planning, statistic, statistical, statistical improvement, statistical model, statistical parameters, statistical significance, statistical standards, statistical standards in biomarker, statistical standards in biomarker studies, statistics, statitistical, statitistical significance, status, status hospitalizations, status in heart, status in heart failure, status in heart failure patients, status in patients, status index, status of np, status of np measurement, status versus whites, stay, stay increase, stay increase rehospitalization, ste, ste analysis, ste analysis of twist, steady, steady decline, steady decline in egfr, steady improvement, steady improvement in egfr, stem, stem cell, stem cell source, stem cell-derived cardiomyocytes, stenosis, stenotic, stenotic physiology, stent, stent model, stent occlusion, stenting, step, sternal, sternal sparing approach, sternotomy, stiffness, stimulation, stimulation of cgmp, stimulation of cgmp synthesis, stimulation of phosphorylation, stimulation via catecholamine, stimulation via catecholamine infusions, stimuli, stop hypertension, stop hypertension diet, storm, strain, strain contributions, strain rate, strain rate at diastole, strain rate at systole, strata, strata of hospital, strata of hospital volume, strategies, strategies evaluation, strategies in patients, strategy, strategy in hf, stratification, stratification for death, stratification models, stratification of patient, strength, strength of race, strengths, stress, stress conditions, stress doppler, stress doppler echocardiography, stress echocardiography, stress markers, stressors, stretch, stretch rate, strict, strict statistical, strict statistical standards, strict statistical standards in biomarker, strict statistical standards in biomarker studies, striking differences, strip, strips, stroke, stroke prevention, stroke prevention trial, stroke score, stroke volume, stroke volume index, strokes, strong, strong acid, strong predictors, strong predictors of mortality, strong recommendation, strong reliable, strong reliable mortality, strong reliable mortality predictors, strong reliable mortality predictors in icd-hf, strong reliable mortality predictors in icd-hf patients, stronger, strongest, strongest for internists, structural, structural heart, structural heart disease, structurally normal, structure, structure in patients, structured, structured exercise, structured exercise programme, structured exercise programme for patients, structured telephone, structured telephone support, sts, sts hh, sts interventions, student, studies, studies in hf, studies in practice, studies in practice settings, studies of therapeutics, studies of transfusion, studies per outcome, studies with arni, studies with arni inhibitors, study, study breathing, study breathing control, study closure, study cohort, study criteria, study design, study designs, study drug, study drug dose, study drugs, study end, study end point, study enrollment, study extend, study from denmark, study group, study in children, study in heart, study in heart failure, study medication, study objectives, study of exercise, study of exercise training, study participants, study patients, study period, study population, study sample, study selection, study short-form, study short-form quality, study short-form quality of life, study short-form quality of life domains, study sites, study subgroups, study-a, study-a multicenter, study-drug, study-drug discontinuation, study-related, sub-groups, sub-sample, subcellular, subcellular alterations, subcellular alterations by metoprolol, subclass, subclinical, subclinical atherosclerosis, subdomains, subgroup, subgroup analyses, subgroup analysis, subgroup analysis of patients, subgroup of children, subgroups, subgroups of patients, subject, subjects, subjects with heart, subjects with heart failure, subjects with ra, subjects with rv dysfunction, subjects without psoriasis, suboptimal, suboptimal care, suboptimal care of patients, subproteome, subproteomes, subpulmonary, subpulmonary ventricle, subscales, subsequent, subsequent cardiotoxicity, subsequent events, subsequent heart, subsequent heart failure, subsequent hf, subsequent meta-analyses, subset, subset of hfpef, subspecialty, subspecialty groups, substantial, substantial improvement, substantial improvement in survival, substantial proportion, substantial proportion of patients, substantial subset, substitution, substrate, substrate after ami, substrate metabolism, substudy, subtle, subtle changes, subtle changes on exercise, subunit, subunit expression, subunits, suburban, suburban hospitals, suburban hospitals in new jersey, subvalvular, success, success rate, success rates, successful, successful approaches, successful mitral, successful mitral valve, successful reperfusion, successful reperfusion therapy, successful valve, succinate, sudden, sudden cardiac, sudden cardiac death, sudden cardiac death in athletes, sudden cardiac deaths, sudden death, sufficient, suggesting myocardial angiogenesis, suggesting postcontrast, sulfonylureas, summary, summary scores, superior, superior reverse, superior reverse remodeling, supplementation, support, support devices, support lvad, support lvad use, support score, support to patients, supporting iron, supporting iron use, supporting patients, supports natural vasodilatory, suppression, surface, surface ecgs, surface ecgs at baseline, surgeons, surgery, surgery by echocardiography, surgery consensus, surgery consensus report, surgery in heart, surgery in heart transplant, surgery in heart transplant recipients, surgery patients, surgical, surgical conditions, surgical correction, surgical indication, surgical indication for ms, surgical indications, surgical intervention, surgical method, surgical palliation, surgical patients, surgical revascularization, surgical ring, surgical ring implantation, surgical tactics, surgical treatment, surgical treatment of post-lvad, surgical treatment of post-lvad ai, surrogate, surrogates, surrogates for changes, survey, survey in israel, surveys, survival, survival estimates, survival in ed, survival in ed patients, survival in patients, survival of patients, survival projections, survival rates, survival rates of patients, survival study, survival study in heart, survival study in heart failure, survival to hospital, survival to hospital discharge, surviving left ventricle, survivors, survivors of childhood, susceptibility, susceptible, suspected hfpef, sustainability, sustained, sustained improvement, sv, svr, svr index, sweden, swedish, swedish national, swedish national inpatient, swedish national inpatient registry, swedish web-system, swedish web-system for enhancement, swine, swine model, swine with heart, swine with heart failure, sympathetic, sympathetic activity, sympathetic control, sympathetic control of heart, sympathetic control of heart rate, sympathetic nervous, sympathetic nervous systems, sympathetic outflow, sympathetic tone, sympathovagal, sympathovagal balance, symptom, symptom domains, symptomatic, symptomatic adult, symptomatic adult fontan, symptomatic chronic, symptomatic chronic advanced, symptomatic chronic advanced heart, symptomatic chronic advanced heart failure, symptomatic chronic advanced heart failure patients, symptomatic improvement, symptomatic on exertion, symptomatic systolic, symptomatic systolic heart, symptomatic systolic heart failure, symptoms, symptoms in children, symptoms in patients, symptoms of anxiety, symptoms of heart, symptoms of heart failure, symptoms of hfpef, synchrony, syndrome, syndromes, synthase, synthase activation, synthesis, system, system activity, system activity on qtv, system blocker, system codes, system data, system data partners, system in heart, system in heart failure, system in heart failure patients, system inhibitors, system inhibitors in heart, system inhibitors in heart failure, system modulation, system modulation on qtv, system with care, system with care management, systematic, systematic monitoring, systematic monitoring of lvad, systematic monitoring of lvad use, systematic review, systematic review protocol, systematic search, systemic, systemic adverse, systemic adverse events, systemic adverse events evaluation, systemic blood, systemic blood pressure, systemic hypertension, systemic vascular, systemic vascular resistance, systems, systems level, systems proteomics, systole, systolic, systolic blood, systolic blood pressure, systolic dysfunction, systolic dysfunction treatment, systolic elastance, systolic excursion, systolic function, systolic heart, systolic heart failure, systolic heart failure treatment, systolic hf, systolic hf tissue, systolic hf tissue samples, systolic human, systolic human heart, systolic human heart failure, systolic indices, systolic mitral, systolic mitral annulus, systolic mitral annulus velocity, systolic parameters, systolic pressure, systolic pressure relationship, systolic pressure relationship in heart, systolic pressure relationship in heart failure, systolic strain, systolic ventricular, systolic ventricular function, systolic volume, systolic volume index, szeto-schiller, t-score, t2d, tac, tac model, tac surgery, tac-induced, tac-induced proteomic, tac-induced proteomic alterations, tachyarrhythmias, tachycardia, tachycardia in response, tachycardia storm, tachycardia-induced, tachycardia-induced heart, tachycardia-induced heart failure, tachycardic, tachycardic response, tachypacing-induced, tachypacing-induced hf, tactics, tailored follow-up, takes place, talk, talk between cgmp, tapse, tapse-to-pasp, tapse-to-pasp ratio, target, target audience, target dose, target doses, target genes, target patient population, target sodium, targeting, targeting abnormal exercise, targeting individuals, targeting nonterminal epitopes, targeting specific effector, targeting specific effector molecules, targets, targets for heart, targets for heart failure, targets for hhd, targets in disease, targets in disease management, targets of bets, taub, taxonomy, team, technical, technical advisors, technique, technique to exchange, techniques, technology, telehealth, telehealth system, telehealth system with care, telehealth system with care management, telehealth technology, telemonitoring, telephone, telephone calls, telephone support, temporal, temporal incidence, temporal trends, temporal trends in hf, temporary, temporary centrimag, temporary centrimag rvad, temporary right, temporary right ventricular, temporary right ventricular support, temporary rv, temporary rv support, ten-year, ten-year experience, tendency, tension, term, term analysis, terminal, terminal heart, terminal heart failure, terminal phase, terminal regions, terminal stage, terminal stage of chf, termini, terminologies, terms, terms of medication, terms of recruitment, tertiary, tertiary referral, tertiary referral centre, test, test distance, test for hfpef, test for interaction, test in patients, test investigations, test investigations at study, test investigations at study enrollment, test results, test-retest, test-retest reliability, testimonies, testing, testing guide, testing of np, testosterone, testosterone group, testosterone levels, testosterone status, testosterone supplementation, testosterone therapy, testosterone therapy during exercise, testosterone therapy during exercise rehabilitation, tests, tethering, texas, texas cancer, texture, texture changes, tgf-β, tgf-β inhibition, tgf-β receptor, tgf-β receptor type, thalassaemia, thalassaemia major, theory, therapeutic, therapeutic alternative, therapeutic approach, therapeutic approach to chf, therapeutic approaches, therapeutic concepts, therapeutic functions, therapeutic implications, therapeutic implications of biomarkers, therapeutic interruption, therapeutic interventions, therapeutic left-to-right, therapeutic left-to-right interatrial, therapeutic left-to-right interatrial shunting, therapeutic left-to-right interatrial shunting in patients, therapeutic options, therapeutic potential, therapeutic strategies, therapeutic strategy, therapeutic strategy in hf, therapeutic targets, therapeutic targets for heart, therapeutic targets for heart failure, therapeutic targets for hhd, therapeutic treatments, therapeutics, therapies, therapies registry, therapy, therapy during exercise, therapy during exercise rehabilitation, therapy in heart, therapy in heart failure, therapy in heart failure patients, therapy in patients, therapy refractory, therapy refractory cardiogenic shock, therapy with ivabradine, therapy with saxagliptin, thickness, thigh, thigh muscle, third, third heart, third heart sound, third trial, thirds, thirds of patients, thirteen, thirteen patients, thirty-day, thirty-day all-cause readmissions, thirty-day mortality, thirty-day rehospitalization, thirty-seven, thirty-seven hospitals, thoratec, thoratec corp, thr197, three-year, three-year hf, three-year hf hospitalization, three-year hf hospitalization rates, threefold, threefold increase, threshold, threshold in heart, threshold in heart failure, thromboembolic, thromboembolic events, thromboembolic events in heart, thromboembolic events in heart failure, thromboembolic events in patients, thromboembolic pulmonary hypertension, thromboembolism, thrombosis, thrombotic, thrombotic obstruction, throughput, tidal, tidal respiration, tidal respiration for quantification, time, time domain, time domain heart, time domain heart rate, time domain heart rate variability, time frame, time interval, time of admission, time of discharge, time of heartmate, time of heartmate ii, time of heartmate ii implantation, time of inclusion, time of surgery, time period, time span, time to death, time to esrd, time-dependent, time-dependent analysis, time-dependent covariates, time-dependent cox, time-dependent cox regression, time-dependent cox regression analysis, time-dependent variable, time-domain, time-limited, time-varying, time-varying covariates, time-varying seattle, time-varying seattle heart, time-varying seattle heart failure, time-varying seattle heart failure model, time-varying seattle heart failure model scores, timed, times, timing, tissue, tissue doppler, tissue doppler early diastolic, tissue doppler imaging, tissue from control, tissue from control animals, tissue from mice, tissue samples, tissuefaxs, tissuefaxs technology, tissues, titin, titin hypophosphorylation, titin isoforms, titin modification, tm during office, tm during office hours, tm interventions, tnf, tnf antagonist, tnf antagonists, tobacco, tobacco use, tolerance, tolerance in heart, tolerance in heart failure, tolvaptan, tomographic, tomographic angiography, tomography, tomography imaging, tone, tone by pyridostigmine, tone by pyridostigmine prevents, tonometric, tonometric indices, tonometry, tonometry study, tonometry variables, tool, tool for risk, tool for risk stratification, tools, tools for economic analysis, tools for risk, tools for risk stratification, topic, topics, topics of debate, toronto, total, total adiponectin, total adiponectin at baseline, total arterial, total arterial compliance, total cholesterol, total cost, total cost per patient, total ed, total ed visits, total expenditure, total expenditure on health, total expenditures, total mortality, total myosin, total sample, total score, total score with exercise, total symptom, total symptom domains, toxicity, tracking, tracking echocardiography, tracking va, tracking va patients, tract, tract infection, traditional, traditional cost-effectiveness, traditional cost-effectiveness limits, traditional cost-effectiveness limits in models, traditional heart, traditional heart failure, traditional myocardial, training, training for heart, training for heart failure, training in hf, training in patients, training intervention, training of patients, training on kccq, training on outcomes, training on peak, training on peak oxygen, training on peak oxygen consumption, training period, training protocol, training response, training therapy, training-induced, training-induced changes, training-induced changes in hrqol, trainings, trainings per week, trans, transcatheter, transcatheter aortic, transcatheter aortic valve, transcatheter aortic valve procedure, transcatheter approaches, transcript, transcription, transcription factor, transcription factor dhand, transcription factor networks, transcription factors, transcriptional, transcriptional analysis, transcriptional pause, transcriptional pause release, transduction, transduction cascade, transduction pathways, transduction to pol, transduction to pol ii, transfer, transfer policy, transfer-based, transfer-based assays, transforming growth, transforming growth factor, transfusion, transfusion protocols, transfusion requirements, transfusion strategy, transfusions, transfusions in patients, transgenic, transgenic mice, transient receptor, transition, transition markers, transitions, transitions of care, transitions of care program, translational, translational repression, translocation, translocation of glucose, translocation of glucose transporter, transmitral, transmitral blood, transmitral blood flow, transmitral blood flow velocity, transmitral blood flow velocity over tissue, transmitral blood flow velocity over tissue doppler, transmitral e-wave, transmitral flow, transmitral flow velocities, transoesophageal, transoesophageal echocardiographic guidance, transoesophageal echocardiography, transplant, transplant ineligible patients, transplant pool, transplant process, transplant recipients, transplant survival, transplant with mt, transplant-ineligible, transplant-ineligible patients, transplantation, transplantation eligibility, transplantation eligibility status, transplantation to consultation, transplantations, transplants, transplants in children, transporter, transseptal, transseptal catheterisation, transseptal catheterisation with transoesophageal, transthoracic echocardiography, transverse, transverse aortic, transverse aortic constriction, trastuzumab, trastuzumab administration, trastuzumab use, trastuzumab users, trastuzumab-related, trastuzumab-related cardiotoxicity, trastuzumab-related chf, trastuzumab-treated, trastuzumab-treated patients, trastuzumb-related, trastuzumb-related chf, treadmill, treadmill exercise, treadmill exercise testing, treadmill testing, treat rheumatoid arthritis, treatable, treatable pdrelated, treatable pdrelated complications, treated hypertension, treated survivors, treating advanced hf, treating heart, treating heart failure, treating patients, treatment, treatment aims, treatment algorithms, treatment algorithms for de, treatment algorithms for de novo, treatment eras, treatment for heart, treatment for heart failure, treatment for hf, treatment for outpatients, treatment for patients, treatment group, treatment group effects, treatment group effects on hrqol, treatment groups, treatment guidelines, treatment heart, treatment heart failure, treatment implications, treatment in patients, treatment interaction, treatment measure, treatment of anemia, treatment of chf, treatment of end, treatment of end stage, treatment of end stage heart, treatment of end stage heart failure, treatment of heart, treatment of heart failure, treatment of hf, treatment of hfpef, treatment of hfref, treatment of mi, treatment of mi animals, treatment of patients, treatment of post-lvad, treatment of post-lvad ai, treatment options, treatment period, treatment plans, treatment plans for patients, treatment preferences, treatment strategies, treatment strategies in patients, treatment variation, treatment with carvedilol, treatment with crt-d, treatment with ivabradine, treatments, treatments for anemia, trend, trend for improvement, trend toward enrollment, trends, trends in heart, trends in heart failure, trends in hf, trial, trial design, trial of exercise, trial of exercise training, trial of heart, trial of heart failure, trial of patients, trial paradigm-hf, trial registries, trial results, trial-cardiac, trial-cardiac resynchronization, trial-cardiac resynchronization therapy, trials, trials of blood, trials of blood transfusions, trials of tnf, trials of tnf antagonists, trials-enriching, trials-enriching patient identification, triangular, triangular resection, trichrome, trichrome blue, trichrome blue histologic, trichrome blue histologic analysis, tricuspid, tricuspid annular plane, tricuspid annular plane systolic, tricuspid annular plane systolic excursion, tricuspid valve, trigger, trigger for excitation-contraction, trigger hemoglobin, trigger hemoglobin threshold, triggers desensitization, troponin, troponin t, trpm7, true, true change, truncated, truncated fragments, tta, tube, tug, tug test, tumor, tumor necrosis, tumor necrosis factor, tumors, tunel, tunel assay, tunel method, tunel-positive, tunel-positive cells, turbulence, turkey, turnaround, turnaround times, tuscany, twenty-one, twenty-one rcts, twenty-seven, twenty-seven studies, twenty-seven symptomatic adult, twenty-seven symptomatic adult fontan, twice daily, twist, two-center, two-center pilot, two-center pilot project, two-vessel, two-vessel disease, two-vessel disease model, two-vessel model, twofold, twofold increase, twofold increase in lung, twofold increase in lung weight, twofold increase in lv, type, type ii, types, types of beta-blockers, types of heart, types of heart failure, typical, typical adverse, typical adverse event, typical amyloidotic, typical amyloidotic pattern, typically exertional, ulcers, ultrasonography, ultrastructural, ultrastructural changes, um cohort, unadjusted, unadjusted practice-level, unadjusted practice-level prescription, unadjusted practice-level prescription rates, unaffected, unaltered, uncertain, uncertainty, unchanged, unclear, unclear etiology, uncommon, uncontrolled, uncontrolled hypertension, und, undecided, undergo coronary angiography, undergo reverse remodeling, undergoing anthracycline-containing chemotherapy, undergoing isolated heart, undergoing isolated heart transplant, undergoing lvad, undergoing lvad implantation, undergoing mt, undergoing procedures, undergoing renal dnx, undergoing vad, undergone, undergone coronary angiography, undergone randomization, underlying, underlying characteristics, underlying clinical trials, underlying heart, underlying heart disease, underlying hypertension, underlying mechanism, underlying mechanism of hfpef, underlying myocardial dd, underlying pathophysiology, underlying pathophysiology of heart, underlying pathophysiology of heart failure, underperfusion, understanding, underuse, underuse of eplerenone, underwent aortic valve, underwent aortic valve surgery, underwent baseline, underwent baseline echocardiography, underwent cardiopulmonary exercise, underwent cardiopulmonary exercise testing, underwent catheterization, underwent crt, underwent crt implantation, underwent device, underwent device implantation, underwent echo-doppler studies, underwent follow-up, underwent follow-up echocardiograms, underwent hct, underwent heart, underwent heart transplant, underwent heartmate, underwent heartmate ii, underwent heartmate ii lvad, underwent lvad implantation, underwent mitral valve, underwent prospective assessment, underwent redo, underwent redo sternotomy, underwent standard criteria, underwent testing, underwent triangular, underwent triangular resection, undiagnosed, undiagnosed heart, undiagnosed heart disease, uneventful, uneventful recovery, unfamiliar, unfamiliar physician, unfamiliar physicians, unfavorable, unfavorable outcome, unfavourable, unfavourable clinical, unfavourable clinical outcome, unfit, unfit men, unfolded, unfolded protein, unfolded protein response, unidirectional, unidirectional left-to-right, unidirectional left-to-right interatrial, unidirectional left-to-right interatrial shunting, unidirectional left-to-right interatrial shunting for treatment, uniform, uniform nomenclature, unilateral, unilateral renal, unilateral renal denervation, unilateral renal dnx, uninephrectomy, uninephrectomy with ang, uninephrectomy with ang ii, uninephrectomy with ang ii infusion, unintentional, unintentional weight, unintentional weight loss, unique, unique indication, unique post-translational, unique post-translational states, unique property, unique to patients, unique to rv failure, unique to rv failure management, unit, unit costs, unit increase, united, united states, units, univariable, univariable analysis, univariate, univariate analysis, universal, universal definition, university, university health, university health network, university hospital, university of connecticut, university of connecticut health, university of connecticut health center, university of connecticut heart, university of connecticut heart failure, university of connecticut heart failure center, university of michigan, university of michigan hf, university of michigan hf clinic, unknown, unloading, unplanned, unplanned admission, unplanned readmission, unreliable, unstable, unsuccessful, unsuitable, untranslated, untranslated region, untranslated region of messenger, untranslated region of messenger rna, untreated, untreated acf, untreated acf groups, up-regulated, upcoming, upcoming years, update, upper, upr, upr effectors, upregulated, upregulated transforming growth, upstream, upstream signal, uptake, uptake of class, uptake of clinical practice, uptake of clinical practice guideline, uptitration, uptitrations, uptitrations in patients, urban, urban academic, urban academic medical, urban academic medical center, urea, urea nitrogen, urgent, urgent all-cause, urgent all-cause readmission, urgent cardiac, urgent cardiac transplant, urgent readmission, urgent readmission after discharge, urinary, urinary tract, urinary tract infection, urine, urine volume, us healthcare, us healthcare programmes, use, use in heart, use in heart failure, use of angiotensin, use of antagonists, use of antibodies, use of beta-blockers, use of biomarkers, use of bisoprolol, use of devices, use of erc, use of exercise, use of immunoprecipitation, use of loop, use of loop diuretics, use of spironolactone, use of trastuzumab, user, user inputs, users, users of alendronate, users of bisphophonates, users of bisphosphonates, users of saxagliptin, usual, usual care, usual care group, uti, utility, utilization, utilization effects, utilizing voluntary testimonies, uv, uv treatment, va cohort, va health, va health care, va health care systems, va patients, va-rt, va-rt cohort, va-rt cohorts, vad, vad group, vad groups, vad support, vads, vagal, vagal tone, valid, valid approach, valid measure, valid measure of patients, validated clinical tool, validated measure, validation, validation cohort, validation studies, validity, valsartan, valuable, value, value for admission, value for admission nt-probnp, value for age-by-lvef, value for age-by-lvef interaction, value for heart, value for heart failure, value for plasma, value in hf, value in hf risk, value in hf risk prediction, value in patients, value of mdc, value of nt-probnp, value of nt-probnp testing, values, valve, valve area, valve insufficiency, valve opening, valve procedure, valve procedures, valve repairs, valve replacement, valve surgery, valve tethering, valvular, valvular disease, valvular regurgitation, variability, variability in qt, variability in qt intervals, variability in risk, variability in risk stratification, variability measures, variable, variables, variance, variant, variants, variants of genes, variants with angii, variation, variation in rates, variation in use, variations, varying atrioventricular delay, varying combinations, varying regional strain, varying regional strain contributions, vascular, vascular disease, vascular diseases, vascular effects, vascular endothelial, vascular endothelial growth, vascular endothelial growth factor, vascular endothelial growth factor blockade, vascular endothelial growth factor protein, vascular resistance, vascular stiffness, vasculature, vasodilator, vasodilator effects, vasodilator effects in vivo, vasodilators, vasodilatory, vasopeptidase, vasopeptidase inhibitors, vasopressin, vasopressin receptor, vasopressin receptor antagonist, vasopressin receptor antagonist therapy, vasopressin type, vco2, vector, vegetables, vegf, vegf expression, vegf inhibition, vegf pathway, vegf receptor, vegfr2, vehicle, vehicle-treated, vehicle-treated rats, velocities, velocities during systole, velocity, velocity over tissue, velocity over tissue doppler, velocity time, ven, vena, vena cava, venoarterial, venoarterial dilation, venous, venous pressure, venous thromboembolic, venous thromboembolic events, venous thromboembolism, ventilation, ventilatory, ventilatory efficiency, ventilatory efficiency slope, ventricle, ventricle end-diastolic pressure, ventricle in heart, ventricle in heart failure, ventricle in heart failure patients, ventricle overload, ventricles, ventricular, ventricular action, ventricular action potentials, ventricular assist, ventricular assist device, ventricular assist device implantation, ventricular assist device support, ventricular assist device use, ventricular assist devices, ventricular assist system, ventricular base, ventricular biopsies, ventricular cardiomyocytes, ventricular cardiomyocytes in response, ventricular contractile, ventricular contractile function, ventricular contractile reserve, ventricular contractile reserve in patients, ventricular dd, ventricular diastolic, ventricular diastolic end, ventricular diastolic end diameter, ventricular diastolic function, ventricular dilatation, ventricular dysfunction, ventricular dyssynchrony, ventricular ejection, ventricular ejection fraction, ventricular ejection fractions, ventricular ejection time, ventricular end-diastolic, ventricular end-diastolic area, ventricular end-diastolic area index, ventricular end-diastolic pressure, ventricular fibrillation, ventricular filling, ventricular filling in patients, ventricular filling pressure, ventricular filling pressure in patients, ventricular filling pressure response, ventricular fractional, ventricular fractional area, ventricular fractional area change, ventricular function, ventricular function assessment, ventricular hypertrophy, ventricular hypertrophy in heart, ventricular hypertrophy in heart failure, ventricular longitudinal, ventricular longitudinal systolic, ventricular longitudinal systolic strain, ventricular mass, ventricular mechanics, ventricular midpapillary, ventricular midpapillary level, ventricular myocytes, ventricular pacing, ventricular power, ventricular power index, ventricular pressure, ventricular pressure overload, ventricular pump, ventricular pump function, ventricular structure, ventricular support, ventricular systolic, ventricular systolic dysfunction, ventricular systolic hf, ventricular systolic hf tissue, ventricular systolic hf tissue samples, ventricular tachycardia, ventricular tachycardia storm, ventricular tissue, ventricular tissue from control, ventricular tissue from control animals, ventricular wall, ventricular wall stress, ventricular-arterial, ventricular-arterial coupling, ventricular-pulmonary, ventricular-pulmonary arterial, ventricular-pulmonary arterial coupling, version, veterans, viable, viable option, video, video edge, video edge detection, view, virtual, virtual cohorts, viscoelastic, visit, visit rates, visits, visits as part, visits for chf, vital, vivo, vivo assessment, vivo coronary, vivo coronary perfusion, vivo experiments, vivo experiments of hf, vivo inhibition, vivo phosphorylation, vivo phosphorylation sites, vo2, vo2max, voltage-gated, voltage-gated cardiac, volume, volume groups, volume index, volume management, volume of patients, volume overload, volume overload in heart, volume overload in heart failure, volume relation, volume status, volume within strata, volumes, volumes of exercise, voluntary, voluntary testimonies, volunteers, volunteers--a, volunteers--a pilot, volunteers--a pilot study, von, von willebrand, von willebrand factor, von willebrand factor concentrations, vvd, vvd variation, vvd variations, w rehabilitation, waist, waist circumference, walk, walk distance, walk test, walk test distance, walked distance, walking, walking distance, walking in patients, wall, wall cs, wall cs during avd, wall cs during avd variation, wall cs during vvd, wall cs during vvd variation, wall infarction, wall rs, wall stress, wall thickness, warrants, washout, wasting, water, wave, wave doppler, wave doppler echocardiography, wave ratio, waves, way, ways, weak, weak grip, weak grip strength, weak recommendation, weakest, weakest for cardiologists, web, web of complicity, web-based, web-based program, web-based simulation, web-based simulation tool, web-system, web-system for enhancement, website, wedge, wedge pressure, week, weekly, weekly trastuzumab, weekly trastuzumab administration, weeks, weeks after aac, weeks mi animals, weeks of diet, weeks of pacing, weeks rapid right ventricular pacing, weeks with repeat, weeks with repeat metabolic, weight, weight in cc, weight loss, well-being, well-recognised, well-recognised risk, well-recognised risk factor, well-treated, well-treated cohort, western, western australia, western australian, western blot, western blot analysis, western blots, western society, white, white rabbits, whites, wide, wide blood-flow, wide blood-flow paths, wide qrs complex, widespread, widespread use, width, wilcoxon, wilcoxon matched-pairs, wilcoxon matched-pairs signed-rank tests, wild, wild type, wild-type, wild-type littermates, wild-type rad, willebrand, willebrand factor, willebrand factor concentrations, window, wistar, wistar rats, wistar-kyoto, withdrawal, within-day, within-day test-retest, within-day test-retest reliability, witness, wk, wk of pyridostigmine, wk of pyridostigmine administration, wk of treatment, woman, women, women vs men, women with heart, women with heart failure, women with hf, work, work rate, working, working group, working hearts, workload, workload during stress, world, world health, world health organization, world health organization criteria, world health organization website, worldwide, worldwide epidemic, worldwide increase, worldwide increase in life, worldwide increase in life expectancy, worse, worse heart, worse outcomes, worsened echocardiographic outcomes, worsened prognosis, worsening, worsening gls, worsening heart, worsening heart failure, worsening of heart, worsening of heart failure, worsening renal function, worst, wrf, writer, wt, wt riα, x-ray, x-ray absorptiometry, x12, xanthine, xanthine oxidase, xanthine oxidase inhibition, xanthine oxidase inhibition preserves, xo inhibition, xo-mediated, xo-mediated ros, xo-mediated ros effects, year, year after discharge, year for heart, year for heart failure, year of oht, years, years after admission, years after hospitalization, years of age, years of follow-up, years old with heart, years old with heart failure, yield, yielded hazard, yielded hazard ratios, yields relaxation, york, york heart, york heart association, york heart association class, york heart association class ii, york heart association class ii to iv hf, york heart association class iii, york heart association class iii heart, york heart association class iii heart failure, york heart association classes, york heart association classification, york heart association functional class, yorkshire, yorkshire swine, young, young adult, young adult jehovah, young adults, young adults with heart, young adults with heart failure, young adults with hf, young athletes, young normal, young normal reference, young woman, younger, younger patients, younger than non-survivors, youngest, youngest age, youngest age group, youngest group, youngest patients, youngest patients with hf, zealand, zealand white, zealand white rabbits, zebrafish, zsf1, zung, zung self-rated depression, zung self-rated depression scores, ®, ® immunoassays, ® system, ® system in heart, ® system in heart failure, ® system in heart failure patients, ±, ± allopurinol, α, α-myosin, α-myosin heavy chain, α-subunit, β, β-adrenergic, β-adrenergic receptor, β-adrenergic receptor activation, β-adrenergic receptor agonist, β-adrenergic receptor blockade, β-adrenergic receptor blocker, β-adrenergic receptor blocker therapy, β-adrenergic receptor stimulation, β-adrenoceptor, β-adrenoceptor blockade, β-adrenoceptor blockade with esmolol, β-ar, β-ar drive, β-ar responsiveness, β-ar stimulation, β-ar stimulation via catecholamine, β-ar stimulation via catecholamine infusions, β-blockade, β-blocker, β-blocker dose, β-blocker dose changes, β-blocker dose increase, β-blocker metoprolol, β-blocker uptitration, β-blocker uptitrations, β-blocker uptitrations in patients, β-blocker-induced, β-blocker-induced enhancement, β-blockers, β-blockers therapy, β-myosin, β-myosin heavy chain, β1-adrenergic, β1ar, β2-adrenergic, β2-receptor, δ, μg, μmol, ≈30, ≤, ≤30, ≤35, ≤75, ≤90, ≥, ≥10, ≥15, ≥160, ≥18, ≥2, ≥35, ≥40, ≥50, ≥55, ≥60, ≥65, ≥70
